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                                                                         ABSTRACT 
      Protein translocation is essential for bacterial survival and the most important translocation mecha-
nism in bacteria is the secretion (Sec) pathway. Thus targeting Sec pathway is a promising strategy for 
developing novel antibacterial therapeutics. We report the design, syntheses, mechanistic studies and 
structure-activity relationship analyses using HQSAR and 3-D QSAR Topomer CoMFA analyses of 4-
oxo-5-cyano thiouracil derivatives. In summary, introduction of polar group such as –N3 and linker 
groups such as –CH2-O- enhanced the potency as well as logP and logS several fold.   
      We also report the discovery, optimization and structure-activity relationship study of 1,2,4-triazole 
containing pyrimidines as novel, highly potent antimicrobial agents. A number of inhibitors have been 
found to inhibit microbial growth at high nanomolar concentrations. 
 
INDEX WORDS: SecA inhibitors, Sec pathway inhibition, Thiouracil, 1, 2,4-Triazole, Novel antibacteri-
al therapeutics, Protein translocation inhibition 
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1.      DESIGN, SYNTHESES AND MECHANISTIC STUDIES OF 4-OXO-5-CYANO THIOURACIL  
DERIVATIVES AS SECA INHIBITORS 
         
Abstract: Protein translocation is essential for bacterial survival and the most important transloca-
tion mechanism in bacteria is the secretion (Sec) pathway. Thus targeting Sec pathway is a promising 
strategy for developing novel antibacterial therapeutics. In this chapter, we report the syntheses, evalua-
tion and structure-activity relationship studies using HQSAR and 3-D QSAR Topomer CoMFA analyses. 
We designed and analyzed over 60 analogs of 4-oxo-5-cyano thiouracil derivatives based upon our previ-
ously reported core structure. In summary, introduction of polar group such as –N3 and linker groups such 
as –CH2-O- enhanced the potency as well as logP and logS several fold. Apart from being potential anti-
bacterial agents, SecA inhibitors can be indispensable tools for biologists to probe the mechanism of pro-
tein translocation via the SecA machinery in bacteria. 
1.1 Introduction 
1.1.1 Why do we need NOVEL antibacterial agents? 
Ever since antibiotics were invented and referred to as ‘wonder-drugs’, they earned the reputation 
of a key defense mechanism for human survival against disease causing bacteria. However, the thriving 
occurrence of antibiotic resistance threatens a fit survival of human race and warns of impending epidem-
ics. Looking into the chronology of resistance events, in the 1950’s Staphylococcus aureus resistant to 
last-line drugs tetracyclines and chloramphenicol appeared, and remained widespread throughout the 
world until the semi-synthetic penicillins and cephalosporins regained control of situation in the 1960’s. 
Introduced in early 1970’s, gentamicin and other aminoglycosides restrained the resistant bacteria until 
the late 1970’s when pathogens encoding aminoglycosides inactivating enzymes surfaced. In the early 
1980’s three novel classes of antibiotics including carbapenems, fluoroquinolones and third generation 
cephalosporins exhibited an effective control against nearly all Gram-negative bacteria. In the last few 
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decades, the global emergence of extensively-drug resistant and pan-drug resistant bacterial strains has 
raised severe healthcare concerns.
1
 The US Center for Disease Control and Prevention (CDC) has classi-
fied “High Priority Antibiotic Resistant Bacteria” that include MRSA, Clostridium difficile, Streptococcus 
pneumonia, Mycobacterium tuberculosis (MDR, XDR), Klebsiella species, Acinetobacter, Neisseria gon-
orrhoeae and Campylobacter and Salmonella. Recently in the US, the dissemination of carbapenem-
resistant Enterobacteriaceae (CRE) and its subtypes such as New Delhi metallo-β-lactamase resistant 
strains have raised added concerns due to the high mortality rates of these new strains.
2
 
           As one can imagine, the widespread emergence of multi drug-resistant bacteria or superbugs has 
become a major public health concern in recent years. The urgent need for antimicrobial agents cannot be 
overstated and developing drugs with novel mechanism of action or new targets is more imperative than 
ever before.
3
  However, any new antimicrobials effective against drug resistant strains will not be used as 
the first line of treatment options (for good reasons).  This means that there is not much money to be 
made. Therefore, pharmaceutical industry is essentially staying away or at least not focusing on new an-
timicrobials.
3b
 Last three decades have seen only three entirely new classes of antibiotics (linezolid,
4
 dap-
tomycin
5
 and platensimycin
6
) other than improved analogs of pre-existing antibiotic agents. 
The focus in the field is on the search for antimicrobials with new mechanisms of action and/or new tar-
gets instead of analog design along the lines of existing drugs. 
1.1.2 Is SecA an ideal target? 
           SecA is an integral membrane protein, an ATPase and a protein-conducting channel across bacteria. 
It is the central driving force of the Sec machinery, is essential for bacterial viability and virulence, has no 
human counterparts and is highly conserved in sequence. In addition, the structure and function of the Sec 
machinery in bacteria have been extensively studied
7
 and a great deal of information about SecA is 
known through X-ray crystallography,
7c, 8
 NMR spectroscopy,
9
 cryo-EM,
7c, 10
 and other techniques.
11
 This 
makes SecA an ideal target for design and development of inhibitors. 
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1.1.3 Insights into Form, Function and utility of SecA as an ideal target 
1.1.3.1  Structure of SecA 
              In order to achieve a good level of understanding for inhibitor design, it is important that we 
come to an adequate appreciation of the structural features of this protein such as various forms, confor-
mational changes, and subunit complexation. SecA is the central component of the Sec machinery and is 
conserved in nearly all bacteria. It functions as an ATPase, assisting in the transport and folding of pro-
teins
12
 and interacting with nearly all other components of the Sec machinery. In each E. coli cell, there is 
relatively high concentration of SecA (8 µM),
13
 which corresponds to around 13,000 copies per cell if 
assuming a cellular volume of 2.75 µm
3
.
14
 SecA is a soluble protein and it localizes both to the cytosol 
and the cytoplasmic membrane.
15
 It is believed that most soluble SecA forms homo-dimers in the cyto-
sol.
13, 16
 This dimerization process is dynamic, and the dissociation constant is estimated at low µM range 
(Kd ~ 0.1 µM) previously.
16a
 A more accurate binding constant is determined to be 0.76 nM using an equi-
librium technique and dual-color fluorescence-burst analysis (DCFBA).
17
 However, the sensitive nature 
of the dimerization process influenced by many factors such as salt, detergents or temperature has provid-
ed debatable results amongst a series of studies.
18
 Although there is a long-lasting debate about oligomer-
ization of SecA in solution, it is the consensus that each protomer contains several sub-structural domains 
(Fig. 1.1). The nucleotide binding domain (NBD) and the intramolecular regulator of ATPase activity 2 
domain (IRA2) forms the “DEAD” motor, the main catalytic moiety of SecA. The ATP binding site of 
SecA is located at the interface of the NBD and the IRA2 domains. SecA is a member of the superfamily 
II (SF2) DExH/D proteins, the majority of which are helicases.
19
 Other than helicases, to achieve the 
unique functions of SecA, the preprotein binding domain (PBD) and the C-terminal domain are two key 
domains that contribute to SecA substrate specificity. The PBD is composed of two sub-domains: an anti-
parallel β strand (stem) connects PBD and NBD, and a bilobate globular domain (bulb).20 The C-terminal 
domain is composed of four substructures: the wing domain (WD), the α-helical scaffold domain (SD), 
the intramolecular regulator of ATP activity 1 domain (IRA1), and a C-terminal linker (CTL). 
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                                        Figure 1.1. Three-dimensional structure of the E. coli SecA monomer 
 
Table 1.1. List of X-ray crystallography structures of SecA 
 
Organism PDB entry Ligand Additional structures 
M. tuberculosis 1NL38b  1NKT (ADP, Mg2+) 
B. subtilis 2IBM8d ADP  
T. thermophiles 2IPC8c   
E. coli 2FSF21  2FSG (ATP), 2FSH (AMP-PNP), 2FSI (ADP) 
B. subtilis 1M6N22  1M74 (ADP, Mg2+,SO4
2- ) 
B. subtilis 3JV223 ADP, Mg2+, peptide  
B. subtilis 3DL824   
B. subtilis 1TF525  1TF2 (ADP, Mg2+) 
T. maritima 3JUX23 ADP, Mg2+  
T. maritima 3DIN24 ADP, Mg2+, BEF  
E. coli 3BXZ26 ADP, Mg2+, spermidine  
   
                                              
         The structure of SecA has been studied using X-ray crystallography (Table 1.1), tNMR spectrosco-
py,
9a
 cryo-EM,
27
 atomic force microscopy,
27a
 small angle X-ray scattering
11b
 and small angle neutron scat-
tering (SANS).
11a
 Most of these studies revealed a dimeric structure for SecA with one exception.
28
 Inter-
estingly, in each of the SecA structures, the protomer structures are very similar. However, the orientation 
of each protomer relative to one another is quite different in every dimeric structure. In most dimers, their 
5 
 
C-domains face opposite directions creating anti-parallel structures (Fig. 1.2A), while one has a parallel 
orientation (Fig. 1.2B).  
 
            
Organism NBE (NBFI, NBD1) PBD (PPXD) IRA2 (NBFII, NBD2) C-domain 
E. coli 1-221, 376-416 222-375 417-621 622-836 
M. tuberculosis 1-220, 356-397 221-355 398-608 608-835 
B. subtilis 1-219, 356-396 219-355 397-567 568-780 
T. thermophilus 1-221, 370-410 222-370 411-723 724-939 
T. maritima 1-264, 401-441 265-400 442-613 614-816 
 
Figure 1.2. Space filling models of SecA dimers are shown. Dimeric SecA proteins were structurally 
aligned on one of their protomers (the nucleotide binding domain NBD, red; the intramolecular regulator 
of ATPase 2 IRA2, dark blue; the protein binding domain PBD, yellow and the C-domain, purple) so as 
to demonstrate the variable position that the second (grey) protomer occupies; arrows indicate C-terminus. 
The figure was created using the UCSF Chimera package.
29,30
 The structures used are: Escherichia coli 
(ecSecA 1; 2FSF),
8a
 Thermus thermophilus (ttSecA; 2IPC).
8c
 Bottom: Residue boundaries of SecA do-
mains of different organisms 
1.2 SecA functioning 
          The Sec pathway is the major pre-protein translocation machinery in bacteria (Fig. 1.3). It includes 
a Sec YEG translocon, an association complex of three embedded proteins Sec Y, Sec E and Sec G, serv-
ttSecA 1 ecSecA 1 
A B 
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ing as molecular receptor for an energy powering ATPase, termed SecA. This SecA in complexation with 
the preprotein’s signal sequence and SecB chaperone binds to the SecYEG, becomes activated for ATP 
hydrolysis and powers the preprotein movement through the translocon to the periplasm.
20a, 31
 Details of 
the SecA-mediated secretion process have been discussed elsewhere.
21, 32
 Briefly, the prevailing view of 
transport process has the following events (Fig. 1.3)
33
 (1) SecB binds the preprotein and then SecA;
9
 (2) 
the pre-protein bound SecA sees and binds to the lateral gate SecY
25
 of the SecYEG hetero-trimeric com-
plex; (3) electrostatic gate opening
34
 occurs due to allosteric regulation; (4) ADP is released from the Se-
cA motor domains
9b, 34-35
 and SecA C-terminal domain mediated suppression relieves; (5) SecA acquires 
the translocation ATPase activity,
36
 and (6) SecYEG channel  loosens
37
 and gets ready for pre-protein to 
be pushed in by the intramolecular regulator of ATPase activity 1 domain (IRA1) helix-loop-helix ele-
ment in SecA. As the final step of the secretion, the signal peptide is cleaved by signal peptidase leading 
to the release of the mature protein, which gets folded later.  
 
 
 
 
                                       Figure 1.3.  Protein translocation machinery in bacteria 
 
             Despite the fact that several structural and biochemical studies have been done over the last two 
decades, the exact mechanism of SecA-mediated protein translocation is unknown. Some studies have 
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concluded that SecA functions as a dimer
16b, 38
 while other studies propose that monomeric SecA is the 
key component in protein translocation.
24, 39
 Meanwhile, both monomeric
24, 39a, 40
 and dimeric
38a, 38c, 40-41
 
SecA was found to bind SecYEG. Therefore, another attempt to reveal the function of SecA in protein 
translocation took place. In 2011, a reciprocating piston model (Fig. 1.4) was proposed by Driessen and 
co-workers
18
 as another SecA-dependent translocation pathway model. It divides the whole translocation 
process into two parts. The initiation of protein translocation includes steps 1-4 and the translocation cy-
cle is illustrated in steps 5-9. First, a SecA homodimer binds to the Sec-YEG channel (Step 1)
38a, 38c
 initi-
ating the ATPase activity by changing the conformation of SecA (Step 2).
34, 36b
 Within the dimer, one Se-
cA is anchored to SecYEG and the PBD of this protomer showing a clamp-like structure caused by a 
dramatic conformational change.
24
 The other protomer, in the meantime, only interacts with SecYEG 
bound SecA.
17
 In the cytosol, homotetrameric chaperone protein SecB binds to the mature region of new-
ly synthesized preproteins keeping them partially unfolded and transfers them to SecA. SecB interacts 
with both C-terminal of the SecA dimer separately (step 3).
42
 Following, ATP binds with SecA and trig-
gers SecB release, and the signal sequence and the adjacent mature region of the preprotein are pushed 
into the SecYEG channel forming a hairpin-linke structure (Step 4).
43
 Now the initiation part of protein 
translocation is complete. The second part of the SecA mediated protein translocation starts from Step 5.  
           During this step, one of the dimeric SecA protomer powered by ATP hydrolysis dissociates from 
the preprotein and the one SecYEG bound SecA. The remaining SecA prevents backsliding of the poly-
peptide chain in the SecYEG channel. In addition, an assumed de-insertion step (Step 6), which is accel-
erated by the proton motive force (PMF),
44
 is led by the conformational change of SecYEG bound SecA 
during ATP hydrolysis. SecA from the soluble SecA pool in cytosol re-binds to the preprotein (Step 7) 
and to the remaining SecA protomer. This re-binding of preprotein segment and subsequent SecYEG 
bound SecA causes compression of the polypeptide chain and forces it into the channel.
7b, 45
 This ATP-
independent translocation is responsible for the insertion of a 2 to 2.5 kDa peptide segment (Step 8).
46
 
Then, ATP binding, insertion of SecA into SecYEG and translocation of another 2 to 2.5 kDa peptide 
8 
 
 
segment occurred (Step 9).
24, 33a, 33b
 Repeating Steps 5-9 leads translocation of 4-5 kDa or 25-30 amino 
acids in each cycle
77, 46
 until the preprotein is fully transported. 
 
 
     
 
 
Figure 1.4. A schematic model of the preprotein secretion pathway in bacteria. Modified from Segers et al 
Chem. Biol., 2011, 18, 685-698 with copyright permission from Elsevier
47
 
1.2.1.1 SecA functions as a protein-conducting channel in the membrane 
              SecA exists in 2 forms: a soluble and a membrane form. The membrane SecA interacts with 
phospholipids and integrates into membranes. The previously mentioned model for protein translocation 
views SecYEG as the core of the protein conducting channel in the membrane with SecA as a motor to 
transport proteins across membranes (Fig. 1.4, Wickner’s Model).33a However in a major breakthrough 
that suggests an alternative model, it has been found that SecA alone in liposomes can function as a pro-
tein-conducting channel to promote protein translocation and ionic-channel activity
48
 (Fig. 1.5, Tai mod-
el). This is strongly supported by earlier findings that SecA can integrate into the membranes in two 
forms, SecAM and SecAS
49
 (Fig. 1.6), and can form ring-like pores structures in lipids
27a, 27c, 50
 that provide 
the physical basis for the protein-conducting channel. The finding that SecA functions as a protein-
conducting channel as well as ATPases in the membrane strongly supports the notion that SecA is acces-
sible from the extracellular matrix by inhibitors.  
9 
 
 
              Figure 1.5. Working models of SecA in the membranes     
The Tai model: SecA dimer
27b, 50-51
 alone as the protein conducting-channel to promote protein transloca-
tion and ion-channel activity.
48, 52
 There exist two forms of integral SecA in the membranes,
49a, 49b
  SecAS 
has the same conformation as in soluble form, and SecAM is specific for lipids.
27a, 27c, 53
 
1.2.1.2 The ATPase activity of SecA is regulated by the NBD and the IRA2 domains 
              The opening and closing of the nucleotide-binding cleft, which is located in the gap between the 
NBD and IRA2 domains, play the key role in SecATPase activity regulation.
36b, 54
 The complex confor-
mational changes upon binding the DEAD motor and C-terminal domain of SecA to SecYEG complex 
control the interactions between NBD and IRA2. Before binding to SecYEG, cytoplasmic SecA has high 
affinity for ADP. Therefore this ADP-bound SecA shows low intrinsic ATPase activity and low affinity 
for the SecYEG complex.
22, 35
 Binding with SecYEG in the membrane weakens the interactions between 
the NBD and IRA2 domains and stimulates the ATPase activity. The SecA form with elevated ATPase 
activity is named “membrane ATPase.” Besides, binding of the DEAD motor and C-terminal domain of 
SecA to the SecYEG complex triggers conformational changes at the interface among the IRA1, PBD, 
and CTL domains. These allosteric changes increase the SecA affinity for signal peptides as well. Conse-
quently, binding of the signal peptide near the stem region of PBD-NBD interface causes a large rotation 
of the bulb domain, which drives trapping of the first amino-terminal segment of mature pre-protein do-
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mains.
9b, 23, 55
 This binding further increases the ATPase activity of SecA and converts it into a transloca-
tion ATPase. At this stage, the C-terminal domain inhibition effect is totally relieved and the Gate 1 salt 
bridge is open at the base of the DEAD motor.
34
 Next, the DEAD motor ADP affinity is lost while the 
IRA2 detaches from the NBD and becomes disordered.
34, 56
 ADP released from the DEAD motor induces 
the PBD (with the trapped preprotein) conformational changes
20b, 56-57
 and the dissociation of SecB.
42a
  
             Later ATP binds to the empty nucleotide-binding cleft, and brings subsequent conformational 
changes that cause insertion of SecA along with bound pre-protein into the SecYEG channel. Finally, 
ATP hydrolysis drives a small segment of the pre-protein release from SecA into the SecYEG channel.
25
 
The SecA returns to the NBD-IRA2 tight interaction state that forces SecA to exit the SecYEG channel 
while the PBD moves further along the pre-protein chain
33a, 33b
 and re-attaches onto the following pre-
protein segment, which causes ADP release and allows a new round of ATP binding and hydrolysis.
58
  In 
order for the whole pre-protein to cross the channel, the co-insertion of pre-protein through the channel in 
segments is approximately 30 residues at a time.
43b, 46a
 
1.2.1.3 Assays for testing SecA inhibition 
            Developing assaying strategies that are robust, reliable and accurate to the physiological target is 
crucial to the discovery of novel inhibitors. For the 104 kDa, dimeric-membrane protein SecA, the task is 
even more challenging due to the existence of multiple forms of physiological SecA functional within the 
bacteria. As discussed above, SecA exists in a regulated form (with regulatory C-terminal), which be-
comes unregulated (C-domain truncated) upon membrane integration. The unregulated form serves as the 
transporter while bound to SecYEG translocon. Also, SecA functions as an ATPase in either solution or 
membrane-bound form. It becomes important to emphasize that because of the involvement of different 
SecA forms operating inside the cell to bring about protein translocation, inhibition studies need to in-
volve different assay techniques in order to achieve a thorough understanding of the inhibition. Under-
standably, it is highly likely that different inhibitors may exhibit varying affinities for the different forms 
of SecA.  
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           Presently, there are several ways to test SecA inhibitory activities. First, the ATPase activity can be 
examined using different forms of SecA in solution, such as intrinsic SecA (regulated ATPase), truncated 
SecA without the C-terminal inhibitory sequence in solution (e.g., EcN68, unregulated ATPase), SecA in 
membrane (membrane ATPase), and SecA complexed with SecYEG in membrane (translocation 
ATPase).
[64]
 Assaying inhibition of each form of SecA provides a partial understanding of the targeted 
SecA form, however these assays when combined together, can be used to obtain a reliable and more ac-
curate understanding of the actual form/stage of protein translocation inhibited. Finally, the antimicrobial 
growth assay is used to correlate the enzyme inhibitory activity to bacterial growth inhibition. It is im-
portant to emphasize that SecA inhibition studies do need to involve all different methods in order to 
achieve a thorough understanding of the ability for these inhibitors to inhibit SecA ATPase. The follow-
ing section provides a detailed discussion of these assays. 
1.2.1.3.1 ATPase assay 
            All ATPase assays rely on the determination of free inorganic phosphate formed as a result of 
ATP hydrolysis. In doing so, the malachite green colorimetric method is most commonly used.
59
 In 
screening for potential inhibitors, the most obvious one is the use of the whole SecA in determining how 
an inhibitor modifies the ATPase activity. However, whole SecA is in a regulated and closed-state largely 
controlled by its regulatory C-terminal (C34) domain. Therefore this is a minimally active state of SecA. 
Thus results generated using the whole SecA do not truly reflect the ability for the inhibitor to inhibit the 
fully active ATPase, which is the case when SecA is in membrane and in live bacteria. Another assay 
method uses truncated SecA with only the catalytic domain (N68) in solution (e.g., EcSecA-N68, unregu-
lated ATPase, Figure 1.6). Because of the lack of the inhibitory C-terminal domain, this assay is very sen-
sitive. It has also been demonstrated that results from assays using the truncated form parallels that of 
membrane SecA assays.
60
 Another way of avoiding the intrinsic inhibition effect of the C-terminal do-
main is by using a mutant with elevated intrinsic activities. For example, in EcSecA residue W775 is im-
portant for the C34 regulation,
61
 which is located at the interface of the SD and the IRA1 domains (Fig. 
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1.1). Replacing the bulky tryptophan with a small hydrophobic alanine weakens the interaction of the SD 
and the IRA1 domains and elevates the intrinsic ATPase activity by 5-fold compared to the wild-type 
EcSecA.
56, 61
 Therefore, using this mutated W775A EcSecA allows the benefit of the full-length enzyme 
without the intrinsic inhibition effect of the C-terminal domain.
32b
 
 
                                       Figure 1.6.  Two separable soluble domains and lipid-specific domain of SecA 
There exist two forms of SecA in the membrane: SecAS, which is similar to the soluble form with 2 sepa-
rable domains: N68 and C34, and the other SecAM with the N36 and M48 domains spanning the lipid 
membrane.
[55]
 Top: X-ray ribbon structure of EcSecA with N68 (Yellow) and C34 (Green). 
1.2.1.3.2 Protein-channel activity 
             The protein/ion channel activity assay developed in Tai lab
48, 62
 is a semi-physiological assay for 
electrophysiological measurement of protein-channel activity in the oocytes. It truly mimics the physio-
logical conditions, is easy to use, requires nanogram amounts of materials and studies the translocation by 
exogenous SecA through membrane vesicles/liposomes embedded in individual oocytes. Due to their 
large size, oocytes can easily accommodate various manipulations and electrode penetration and the re-
cording noise is very low due to the large number of channels measured in such experiments (calculated 
to be 200-1,000,000 channels).
62
 The procedure involves using E. coli total lipids (dried, re-suspended in 
150 mM KCl, and sonicated in ice water bath, 3-5 mins), liposomes and oocytes (obtained from live frog 
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Xenopus laevis, Xenopus Express, Inc.). The sample mixture is injected into dark pole site of oocytes us-
ing Nanoject II injector and the ion current is recorded three hours after the injection. The amount for 
each component is 120 ng liposomes, 120 ng SecA, 14 ng proOmpA, 2 mM ATP, and 1 mM Mg
++
 com-
ponent in the oocytes, based upon the average volume of 500 nl for each oocyte. It is important to empha-
size that the results from the truncated SecA assay and the electrophysiology oocyte assays seem to paral-
lel that of antimicrobial results, which adds further support to its near physiological nature. 
1.2.2   Reported SecA inhibitors and screening strategies 
            The suitability of SecATPase as an ideal target for the development of antibacterial agents has 
been increasingly recognized
63
 and thus there have been efforts in developing SecA inhibitors. Table 1.2 
provides a comparative summary of the various inhibitors that have been reported and the screening strat-
egies employed therein. Prior to the recent efforts, inorganic azide (1) (Table 1.2, Entry 1) was the only 
known SecA inhibitor and was reported to possess antibacterial activity in 1891.
64
 Decades later, its anti-
bacterial activity was attributed to inhibition of SecA mediated protein translocation both in vitro and in 
vivo.
65
 Sodium azide resistance in E. coli and B. subtilis has been mapped on the SecA gene
66
  and it is 
also known to inhibit the translocase form of SecA in E. coli, albeit with a high IC50 of 5 mM. Although, 
no effect on the intrinsic or membrane-bound SecA functioning has been observed. The SecA binding 
mechanism of sodium azide has been extensively probed,
33b, 46b, 67
 which point towards a possible inhibi-
tion mechanism involving the stabilization of membrane-inserted, ADP bound form of SecA during pro-
tein translocation. Nevertheless, sodium azide is least likely to hold strong grounds as a promising SecA 
inhibitor given its human toxicity and non-specificity for a diverse array of other enzymes, which includes 
mitochondrial ATPase,
68
 cytochrome c oxidase,
69
 superoxide dismutase,
70
 alcohol dehydrogenase,
71
 and 
ceruloplasmin.
72
 
          Later on, through virtual screening, random screening, and natural product isolation, inhibitors of 
various structural classes have been identified. A random screening of natural and synthetic compound 
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libraries using a SecA-LacZ reporter assay
73
 was conducted in 2000. SecA is known to autogenously reg-
ulate its expression under normal protein secretion by binding to its own mRNA, blocking the translation 
active site and inhibiting its expression. On the other hand, inhibition of secretion dissociates the SecA-
mRNA complex and causes an up-regulation of SecA. The strategy was to identify compounds that en-
hance SecA expression through inhibition of protein secretion caused due to SecA inhibition.  An imino-
containing lipophilic compound (2) (Table 1.2, Entry 2) shows the lowest IC50 value of 6.2 μM for S. au-
reus RN 8081. A key disadvantage associated with the mentioned class of compounds is their deleterious 
effects on the cell membrane and the resulting high cell toxicity, which seems to have led to discontinued 
efforts.  
            CJ-21058 (3) (Table 1.2, Entry 3) a natural product isolated from CL47745 (unidentified fungus) 
was found to inhibit translocation SecATPase with IC50 of 38.4 μM and showed growth inhibition of mul-
ti-drug resistant S. aureus and Enterococcus faecalis with MIC50 value of 12.9 μM.
74
 The screening strat-
egy was to monitor the effect of inhibitors on the SecA catalyzed translocation of proOmpA through 
membrane vesicles bearing SecYEG. Malachite green was used to quantify the ATP consumption by en-
ergy-motor SecA during the translocation process. However, no effect of these compounds was observed 
on the inhibition of S. pyogenes and E. coli growth.  
          Another report of a natural product SecA inhibitor employed an antisense-based screening method. 
The strategy involved using an antisense mRNA to bind selectively to mRNA regions encoding SecA, 
thereby blocking its translation. This decreased translation caused a subsequent bacterial sensitization to-
wards SecA inhibitors. A two-plate agar based differential sensitivity assay including the antisense se-
quence RNA (AS-RNA) sensitized strain and the wild type controls were used to compare the growth 
inhibition. Pannomycin (4) (Table 1.2, Entry 4) obtained from the extract of a leaf-litter fungus Geomyces 
Pannorum was shown to possess antibacterial activity
75
 against B. subtilis (IC50 = 0.4 mM), S. aureus 
(IC50 = 1.4 mM), E. faecalis (IC50 = 1.4 mM), although no in vitro SecA inhibition was reported.   
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         Our initial efforts led to the discovery of the first ever SecA inhibitors. An in silico screening of 
small molecule ligand libraries (~115,000 compounds) was carried out using structure-based virtual 
screening methods against the E. coli SecATPase. The top ranked compounds were further tested for in 
vitro inhibition of ATPase activity against E. coli N68. Two modest inhibitors that were obtained 
(Scheme 1, 11 and 12) showed IC50s in the range of 100 µM.
63a
 For a rationally guided design, the two 
hits obtained were docked into the enzyme active site and binding interactions were examined to aid in 
structure optimization for analog syntheses. A further round of structure optimization of the isoxazolecar-
boxamide series 11 was carried out with the focus laid on the aryl group attached to the amide. In the sec-
ond series 12, we started by testing different aryl structures flanking the central ring followed by 5-cyano-
6-aryl-2-thiouracils derivatives 5 and 6 (Scheme 1 and Table 1.2, Entry 5). A simplified ‘monomer” series 
of compounds was also prepared to understand the core structural need for inhibition. The compounds 
were tested in vitro using EcN68 SecA and the whole EcSecA.
63b
 Bacterial growth inhibition studies were 
done with a leaky mutant NR698 and wild type E. coli strain MC4100. The result showed that dimer se-
ries compound 5 shows low micromolar inhibition (IC50 = 2 µM), which is 50-fold more potent than the 
hit compound 11 (IC50 = 100 µM). For growth inhibition, the ‘monomer’ compound 6 exhibited the most 
potent inhibition against NR698 (IC50 = 20 µM), whereas ‘dimer’ compound 5 did not exhibit significant-
ly antimicrobial activities. However, neither 5 nor 6 showed inhibition effects against wild type E. coli 
strain MC4100. Such results suggested that the permeability of 5 against NR698 and 6 against MC4100 
might be a key factor.
76
 Currently, low molecular weight inhibitors are being explored to aid better mem-
brane permeability and improved antibacterial growth inhibition. 
         Since our publication, another report of a series of thiazolo [4, 5-d] pyrimidine derivatives (7) (Ta-
ble 1.2, Entry 6) as SecA inhibitors has been reported.
63c
 Their screening strategy involved using an in 
vitro malachite green method employing recombinant E. coli or S. aureus SecA. The compounds were 
also tested for inhibition of protein translocation using E. coli preprotein AlkProPhoA(Cys-)3 transloca-
tion through SecYEG overexpressed in membrane vesicles. Compound 7 was reported to have an IC50 
value of 135 µM against EcSecA intrinsic ATPase and 200 µM for translocation SecATPase.  
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         As discussed above, the question of which forms of reported SecA structures are truly physiological 
and functionally dominant still remains to be answered. From a drug discovery perspective, designing 
inhibitors targeting specific SecA forms can be efficiently pursued if we could link the oligomerization 
states such as monomer-dimer equilibria to protein secretion events. The issue of oligomerization of SecA 
during catalysis and in assembly with the translocase remains crucial for medicinal chemists to design 
selective inhibitors. For a rational drug design, this raises several issues, such as how do different SecA 
forms respond to inhibitors? Which could be the best SecA form to target? In our recent report,
77
 we 
(Wang and Tai labs) approached this issue by using assay techniques to individually assess inhibition for 
different SecA forms.  
          A diverse array of assaying techniques were designed and optimized to assess the inhibition abili-
ties of Rose Bengal (RB) (8) and erythrosine B (EB) (9) (Table 1.2, Entry 7). The inhibition assays in-
volved truncated/unregulated SecA, regulated SecA (intrinsic, membrane-bound and translocase), SecA-
mediated protein translocation and the antimicrobial growth inhibition using leaky mutant EcN68 and 
wild type strains.
77
 As seen there are large differences in the sensitivity shown by different forms of Sec-
ATPases towards inhibitors, which could largely be due to the effect of conformational changes affecting 
the accessibility of the inhibitors. The intrinsic SecA which is the native and regulated form shows higher 
IC50 values for RB (25 µM) and EB (21 µM). The membrane-bound form shows IC50 of 5 µM for RB and 
12 µM for EB. The translocation ATPase shows IC50 of 0.9 µM and 10 µM for RB and EB inhibition, 
respectively. 
           The effect of inhibitors on SecA-dependent protein translocation of precursor proOMpA into the 
membrane vesicles was also studied. Both RB and EB were found to inhibit its translocation with IC50 
values of 0.25 µM and 4 µM respectively. We know that Sec dependent protein translocation maintains 
normal physiology and is crucial for viability; therefore the effect of inhibitors on bacterial growth was 
studied. The MIC values observed for Gram-negative bacteria (E. coli > 1 mM) are much higher than 
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gram positive (B. subtilis, 3.1 µM) and the leaky mutant (E. Coli NR698, 3.1 µM), suggesting that cellu-
lar membrane acts as a barrier to inhibitor permeability.  
          In a recent study, SecA inhibitors were reported for a citrus plant bacterium Candidatus Liberibac-
ter asiaticus (Las) responsible for causing Huanglongbing citrus disease (Table 1.2, Entry 8).
63d
 SecA 
homology model of Las SecA was derived from E. coli SecA and used for virtual screening studies. The 
20 hits obtained were tested for SecA ATPase activity inhibition using malachite green spectrophotomet-
ric method and antimicrobial growth inhibition was studied for A. tumefaciens. The most potent SecA 
inhibitor obtained was 10 with IC50 of 0.25 µM. This is the first example of inhibitors targeting Sec-
ATPase of a plant infecting bacteria and its potential for SecATPase inhibition of animal infecting bacte-
ria is worth exploring. 
                        Table 1.2.  A comparative account of various SecA inhibitors and the assays 
 
Entry        Structure and ID      Inhibition constants (IC50s) and assay used 
1  
            
          NaN3 (1)  
     Inorganic azide
65
 (1990) 
      
Translocation EcSecA: 5 mM 
Intrinsic and Membrane-bound SecATPase: No effect 
2 
   
 
Imino-containing molecule (2)
73
   
Source: Synthetic (2000) 
 
Antibacterial: 6.2 μM (S. aureus RN 8081) 
Assay: SecA-lacZ reporter fusion to identify compounds that enhance 
SecA expression through inhibition of protein secretion 
3 
 
  
          CJ-21058 (3)
74
  
 Source: CL47745 (unidentified 
fungus) (2002)    
 
 
 
Translocation SecATPase: 38.4 μM 
Antibacterial: 12.0 μM (MRSA, Enterococcus  faecalis) 
Assay: Monitoring ATP hydrolysis using the SecA mediated transloca-
tion of proOmpA through the inner membrane vesicles bearing the het-
erotrimeric SecYEG complex  
18 
 
 4 
 
 Pannomycin (4)
75
 
Source: Geomyces Pannorum 
 (Fungus) (2009) 
 
   Antibacterial: 
 B. subtilis: 0.4 mM 
 S. aureus: 1.4 mM 
E. faecalis: 1.4 mM 
Assay: Antisense-based screening strategy 
5 
 
 
 
 
 
 
                        
                           (5) Dimer                                                                                   (6) Monomer  
 
5-cyano-6-aryl-2-thiouracils derivatives
63b
 
Source: Synthetic (2010) 
 
Intrinsic SecATPase (EcN68): 2 µM (5) 
Antibacterial (EcNR698): 20 µM (6) 
                                                 Assay:  ATPase Malachite green assay 
 
6 
 
Thiazolo [4,5-d] pyrimidine deriv-
atives (7) 
63c
 
Source: Synthetic (2011) 
 
Intrinsic SecATPase: 135 µM 
Translocation SecATPase: 200 µM 
E. coli or S. aureus SecA 
 
Assay:  
1. ATPase Malachite green assay 
2. Protein translocation using membrane vesicles containing overex-
pressed SecYEG and the E. coli preprotein  AlkProPhoA(Cys-) 
19 
 
 
 
 
 
 
 
 
7 
 
 
 
 
 
        
    
      RB analog (8) 
  
  
      EB analog (9)
77
  (2012) 
        SecA type  8 9 
In vitro 
(IC50/μM) 
Unregulated/truncated 
N68 
0.5   2 
Intrinsic ATPase 25   21 
 
Membrane bound 
ATPase 
5   12 
Translocation ATPase 0.9   10 
 
SecA mediated trans-
location 
0.25   4 
In vivo 
(MIC95) 
E. coli NR698 (leaky 
mutant) 
3.1 250-
500 
B. subtilis168 3.1 250-
500 
E. coli  (Wild type)  >1000 >1000 
 
 
 
 
 
 
8 
 
 
 Indole derivative (10)
63d
 
 Source: Synthetic (2012) 
 
 
Intrinsic SecATPase inhibition: 0.25 µM (Candidatus Liberibacter asi-
aticus)  
Antibacterial: 0.76 mM (A. tumefaciens) 
 
 
Assay: ATPase Malachite green assay 
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Scheme 1.1. A graphic representation to show the various steps for hit optimization 
 
       We have continued our structural optimization efforts on the core scaffold, to further explore the 
structural requirements for strong and selective SecA inhibition and enhanced drug-likeness. Our struc-
ture optimization has successfully achieved an overall increase of 50-fold in enzymatic inhibition and 
nearly 10-fold in antimicrobial inhibition with improvement in calculated physicochemical properties 
such as logP and logS. 
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1.3 Our Rationale  
          To begin with, we reasoned that the two most potent compounds we obtained previously (5 and 6, 
Scheme 1.1 and Table 1.2) were highly hydrophobic, poorly water soluble and showed low membrane 
permeability. As the core scaffold (optimized hit) was promisingly potent, we set out to design com-
pounds with modifications around the core structure. Our design was guided using experimental assess-
ment of potency along with medicinal chemistry intuition for improving pharmaceutical properties. Our 
focus remained on enhancing potency, membrane permeability (logP) and solubility (logS) possibly with 
low MW compounds. Keeping this in mind, 65 novel compounds were synthesized by introducing func-
tional groups such as PEG and triazole linkers, charged polar groups (COOH, B(OH)2, NH2, OH,) and 
uncharged polar groups (N3, COOR, OR, NHR, NHOH). 
1.4 Chemistry 
1.4.1 Syntheses of inhibitors for enzyme and bacterial growth inhibition studies 
          The synthetic procedures are summarized in Schemes 1.2 and 1.3. The methods for obtaining the 
core structure have been reported previously.
63b
 Briefly, 5-cyano-6-aryl-2-thiouracils (14a-d and 20a-c) 
were prepared by condensation of an appropriate aldehyde with ethyl cyanoacetate and thiourea in the 
presence of piperidine. This was followed by the benzylation/alkylation in the presence of potassium car-
bonate in acetonitrile or NaOH/THF to obtain compounds 15a-p (Scheme 1.2) and 21a-o (Scheme 1.3).  
Compound 16 was obtained from 15a using POCl3 to introduce a -Cl group, which was then subjected to 
various amines/nucleophiles to obtain series 17a-j. The compounds containing azido moiety were further 
subjected to click coupling (Scheme 1.3) with different alkynes in order to obtain a new series having 1, 2, 
3 triazole linkers (18a-g). The syntheses were carried out using the standard Cu-catalyzed click reactions. 
Also, in order to study the amide bond interactions, N and O-alkylations were done on 15a using the cor-
responding alkyl/aryl halides under basic conditions to obtain 19a-c (Scheme 1.3).  
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        Scheme 1.2.  Syntheses of series 2 and 4 with various functional group modifications (R1-R7) 
          
Scheme 1.3. Syntheses of series 5, 6, 7 and 8 with various functional group modifications (R8-R11) 
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1.4.2 Syntheses of probes for preliminary mechanistic studies and target validation  
        
                 Figure 1.7. Structure of pyrimidine analogs conjugated to biotin or immobilized on beads 
  
1.4.2.1 Synthesis of biotinylated probe 24 
             
Scheme 1.4. Synthesis of compound 24 
Reagents and conditions: a) NHS, EDCI, DMF, rt,16 h; b) 15o, TEA, DMF, rt, 8h, 75% 
 
           Scheme 1.4 depicts the synthesis of compound 24 in two steps. First, compound 23 (NHS-
activated biotin) was obtained by reacting biotin with EDCI and NHS in DMF. The crude product thus 
obtained (23) was further reacted with 15o, in the presence of triethylamine in DMF, to obtain 24 in good 
yields. Compounds 25 and 26 were synthesized by reacting 15o and 17g with agarose beads as described 
in experimental section. 
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1.5 Biological Evaluation 
1.5.1.1 Enzyme and bacterial growth inhibition assays 
          The enzyme inhibition studies were done using EcN68SecA, a truncated form lacking the C-
terminal inhibitory domain. The literature colorimetric malachite green ATPase assay was used to meas-
ure the release of free inorganic phosphate.
63b
 The growth inhibition activities of the compounds were 
assessed against a leaky mutant NR698 of E. coli by determining the minimum inhibition concentrations 
(MIC).  
 
1.6 Results and Discussion 
          For initial screening, compounds were evaluated at a concentration of 25 µM. Those showing more 
than 50% inhibitions were further screened at 5 µM for EcN68SecA. A total of 23 compounds show IC50 
values below 5 µM as shown in Figure 1.8. 
 
Figure 1.8. Compounds screened at a concentration of 5 µM for EcN68SecA inhibition 
 
         In series 15, effect of modifications on rings A and D was studied (Scheme 1.2).  The enzymatic 
inhibition results for 15a-15p show that modifications on ring D with groups such as –N3 (15a, IC50 = 3.8 
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µM; 15h, IC50 = 3.5 µM), -COOMe (15e, IC50 = 6.0 µM) and –COOEt (15i, IC50 = 8.5 µM) enhance the 
inhibition activity as compared to the lead (IC50 = 12 µM). On the other hand, introduction of polar, high-
ly ionizable groups such as –COOH (15d, IC50 = 30 µM), -B(OH)2 (2c, IC50 = 60 µM) and –NH2 (15b, 
IC50 > 25 µM) at the p-position causes the inhibition potency to drop by several fold. Of all the modifica-
tions done in series 15, the one showing the most potent enzyme inhibition is the p-azido substituted 
compound (IC50 = 3.8 µM). This led us to explore the significance of –N3 position, resulting in synthesis 
of the m- N3 substituted analog 15j. A comparison of the IC50 values of 15a (IC50 = 3.8 µM) and m-N3 
substituted 15j (IC50 > 200 µM) shows a drastic decrease in inhibition potency. It seems that p-
substitution of at least the azido moiety is crucial for enzyme inhibition activity.  
 
Figure 1.9. IC50 values for compounds 21a, 21j and 21k against EcSecA N68 
        In the same series, some early modifications done at ring A with functional groups such as –OMe, -
Me,-OH, and -NHBoc (Scheme 1.2) did not show any improved inhibition over 15a. This observation 
was in agreement with our previously published results
63b
 where we established that biphenyl moiety 
works the best by itself over several other modifications such as introduction of halogens and various al-
kyl groups on the phenyl ring. Our general observation from modifications on ring A is that polar groups 
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are not very well tolerated and so far the biphenyl rings works best by itself, perhaps providing just the 
right combination of bulkiness and hydrophobicity. 
         Next, we wanted to obtain an understanding of 4-oxo-5-cyano thiouracil ring role in inhibition, 
mainly the importance of the amide bond. Therefore, in series 17, first carbonyl oxygen was replaced with 
different amines with or without the –N3 group at the R6 position (17a-j). Because of a good understand-
ing of the –N3 modification at p-position on ring D showing better potency than other functional groups, 
our further modifications were concentrated on keeping the –N3 moiety intact at this position. Amongst 
series 17, compound 17a and 17d show IC50 values of 4.7 µM and 3.5 µM respectively. However, 17a 
with –NHOH group shows a better MIC value of 20.5 µM as compared to 17d, which shows MIC >250 
µM. The modifications done in compounds 17h (-NHCH2CH2COOH), 17i (-NHNH2), and 17j (-
NHCH2CHCH) caused significant drops in the potency. Also, PEG linkers were introduced in 4e, 4f and 
17g to enhance water solubility. Analog 17g (MIC = 12.5 µM) having a PEG linker with a free amine 
shows an MIC value, which is the same as that of 15a, although the enzyme inhibition potency for 17g 
(IC50, 17g = 25 µM) is lower than that of 15a. A comparison of 17g with 17e and 17f (MIC > 250 µM) 
reveals that a terminal free –NH2 group equipped with a PEG linker contribute to improved antimicrobial 
inhibition. 
         In series 18, 1, 2, 3-triazoles having various functional groups were introduced on ring D (Scheme 
1.3). The idea was to enhance the water solubility and drug-likeness by introducing a polar, nitrogen rich 
triazole moiety equipped with -H bond donors and acceptors. The results reveal that compounds 18a (IC50 
= 2.5 µM) and 18b (IC50 = 3.0 µM), having a phenyl and p-NH2-phenyl respectively at position R8 on the 
triazole moiety show better enzyme inhibition potency than 15a. Other modifications such as –COOH, -
CH2OCOCH3, -CH2CH2COOH, -CH2COOH, -CH2OH in 18c-g respectively, contribute moderately (IC50s, 
18c = 6.5 µM, 18d = 7.5 µM, 18e = 8.0 µM, 18f = 10 µM, 18g = 8.0 µM) to enzymatic inhibition. How-
ever, there was a general trend throughout series 18, having marked decreases in antimicrobial inhibition 
with MICs > 100 µM. This led us to conclude that introduction of a triazole moiety with various func-
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tional groups drastically diminishes the antimicrobial potency, despite 18a and 18b showing slightly im-
proved enzymatic inhibition over 15a. Following such observations, we discontinued this series because 
adding bulk on ring D was adversely affecting the antimicrobial potency.  
           To further study the role of amide bond in the enzyme inhibition, N- and O-modifications were 
achieved in 19a-c. In 19a, methylation at the N-position led to a large drop in potency with an IC50  value 
of 60 µM as compared to 19a (IC50 = 3.8 µM). It is possible that the N-H bond could be contributing as 
H-bond donor to the enzyme binding site and thus its absence causes decreased activity. A structural 
comparison of 19b to 17d reveals the only difference being –OMe (IC50 = 5 µM) and -NHMe (IC50 = 3.8 
µM) respectively in place of a carbonyl group in 15a (IC50 = 3.8 µM). Despite the amide modifications 
being well-tolerated for enzymatic inhibition, they all were accompanied by loss of antimicrobial potency 
(MIC > 250 µM). Hence, amide bond was retained as such in further modifications, in order to preserve 
the balance of enzymatic and bacterial growth inhibition of our compounds. 
         At this point, compound 15a was our best candidate for further modifications. With the p-N3 modi-
fication being beneficial on ring D, enhancing the potency and permeability several fold, next we focused 
our attention on the rigid biphenyl structure (rings A and B). Our initial modifications indicated less toler-
ance for polar moieties and introduction of –OMe, COOMe, OH groups dropped the potency several fold. 
So, we thought to ease out its rigidity in order to make it sufficiently flexible for a better fit and also in-
troduce groups that would help the solubility. The introduction of linkers such as –CH2O, -O-, -C C-
would give us a clear understanding of the ring’s preference to stay rigid (biphenyl), Linear (alkyne), re-
stricted (-O-) or a relatively free rotation (-CH2O). The results obtained were remarkable in understanding 
the biphenyl preference. Table 1.3 shows a comparison of the effect of linkers and various R10 substitu-
ents on enzyme and growth inhibition. The IC50 values of compounds 21a (-CH2O-), 21i (-O-) and 21l (-C
C-) are 2.4 µM, 2.2 µM, and 1.4 µM respectively. When compared to 15a, these modifications show 
slight increase in enzyme inhibition; however growth inhibition remains particularly interesting for these 
compounds. Compounds 21a and 21i show good antimicrobial inhibition with MICs of 12.5 µM and 18.2 
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µM respectively, however compound 21l does not show any antimicrobial inhibition up to 250 µM. 
Compound 21l has poor aqueous solubility (logS = -4.07), which is much lower even when compared to 
the 6 (logS = -3.31) or 21a and 21i (Table 1.3). Compound 21a and 21e show significantly improved logP 
(0.60 and 1.78 respectively) and logS (-2.08 and -2.59 respectively) over 15a (1.28, -2.91 respectively) 
and compound 6. Figure 1.10 shows a summary of the structure-activity relationship study of 4-oxo-5-
cyano-thiouracil analogs. 
Table 1.3.  A comparison to show the effect of different linkers on enzymatic and bacterial growth inhibi-
tion for series 21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ID  R10 -Y- 
EcSecAN68 
IC50 (μM) 
E. coli NR698, 
MIC (μM) 
21a -p-N3-Bn -CH2O- 2.4 12.5 
21b -p-COOMe-Bn -CH2O- 2.0 >250 
21c -p-OMe-Bn -CH2O- >25 >250 
21d -p-Br-Bn -CH2O- 2.8 12.5 
21e -o-Br-Bn -CH2O- 2.5 8.8 
21f -Cychexyl -CH2O- 4.6 16.7 
21g -(3,5-OMe-Bn) -CH2O- 2.0 >250 
21h -(3,5-Me-Bn) -CH2O- 5.0 18.8 
21i -p-N3-Bn -O- 2.2 18.2 
 21j -p-COOMe-Bn -O- 2.8 8.0 
21k -p-OMe-Bn -O- 3.8 12.5 
 21l -p-N3-Bn -C≡C- 1.4 >250 
 2m -p-COOMe-Bn -C≡C- 2.0 >250 
21n -p-OMe-Bn -C≡C- 1.8 >250 
21o -(3,5-OMe-Bn) -C≡C-           5.0 >250 
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Table 1.4. A comparison of logP and logS 
 
 
 
 
Table 1.5. Comparison of top ranked inhibitors for enzyme and growth inhibition with compound 6 
 
                                                          
 
                                                                        
 
                                                                                            
 
 
 
 
 
 
 
 
 
 
 
            
 
 
              Figure 1.10.  A summary of structure-activity relationship of 4-oxo-5-cyano-thiouracil analogs 
 
 
 
                                     
 
 
  
   
    
-Spacers enhance antimicrobial potency 
-Increased length or flexibility better 
-Rigidity not good 
 
-Phenyl at p-position works best 
-Overall hydrophobicity preferred 
-Polar groups not tolerated 
 
-Polar ionizable well tolerated 
-Carbonyl not crucial 
-H-bond donors/acceptors good 
-NH crucial for activity 
 
-Polar (un-ionizable) > non- polar > polar (ionizable) 
-Triazole modifications good for enzymatic inhibition, poor  
  for antimicrobial growth 
 
-p-position very crucial for -N3 group 
- No activity for m-N
3 
analog 
 
ID logP logS 
6 2.33 -3.31 
15a 1.28 -2.91 
21a 0.60 -2.08 
21e 1.78 -2.59 
21i 0.68 -2.43 
21l 1.88 -4.07 
ID 
       EcSecAN68 
       IC50 (M) 
          E. coli NR698 
       MIC (M) 
6 12.1 59.7 
15a 3.8 12.5 
17a 4.7 20.5 
21a 2.4 12.5 
21d 2.8 12.5 
21e 2.5 8.8 
21f 4.6 16.7 
21h <5 18.8 
21i 2.2 18.2 
21j 2.8 8.0 
21k 3.8 12.5 
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1.7 Preliminary mechanistic and target validation studies:  
We used 15a as a representative inhibitor of 4-oxo-5-cyano thiouracil class to evaluate 1) ion- 
channel inhibition, 2) bactericidal and bacteriostatic inhibition against multi-drug resistant (MRSA and B. 
anthracis) bacterial strains, 3) response of efflux pumps, 4) effect on the virulence factors (bacterial tox-
ins) production, and 5) SecA binding. We also conducted preliminary target evaluation using probes 24, 
25 and 26 to perform 6) whole cell pull-down assays. In summary, results indicate that 15a inhibits secre-
tion of virulence factors, remains largely unaffected by multi-drug resistance causing efflux pumps and 
pulls out SecA from the whole-cell lysates. These studies validate SecA as the target, and establish that 
15a inhibits the production of virulence factors in bacteria. 
 
1.7.1 Inhibition of S. aureus and B. anthracis SecA 
            SecA1 and SecA2 are the two SecA homologues identified in S. aureus
78
 and B. anthracis.
79
 Se-
cA1 is important for housekeeping while SecA2 is required for virulence factor secretion such as adhe-
sion-SraP
78
 in S. aureus and two S-layer proteins secretion in B. anthracis. The ATPase inhibition activity 
of 15a was analyzed against SecA1 and SecA2 for both S. aureus and B. anthracis, as shown in Table 
1.6.  
Table 1.6. 15a induced inhibition of SecA homologues 
 
   Assays Proteins IC50 (μM) 
   ATPase  
   activity 
  BaSecA2   20 
  SaSecA2   13 
  Ion-channel      
   activity 
SaSecA1   2.0 
BaSecA1   2.8 
                                
                                             
        Next, SecA-liposomes ion-channel activity assays (in oocytes) was done to evaluate the effect of 15a 
on membrane embedded SecA1, for both SaSecA1 and BaSecA1. This assay is a sensitive semi-
31 
 
physiological assay developed in Tai lab.
80
 As shown in Table 1.6, 15a shows potent inhibition against 
ion-channel activity of SaSecA1-liposomes (IC50 = 2 M) and BaSecA1-liposomes (IC50 = 2.8 M) in the 
oocytes. These results obtained from enzyme inhibition and ion-channel activity assays indicate that 15a 
inhibits the protein translocation through SecA inhibition.  
1.7.2 Antimicrobial activities for MRSA strains and B. anthracis Sterne 
          We tested the bacteriostatic inhibition effects of 15a and 17a on microbial growth (Table 1.7) of 
MRSA strains (N315 and Mu50), a clinically isolated S. aureus ATCC 6538, and B. anthracis Sterne. 
Both inhibitors show promising bacteriostatic effects, B. anthracis sterne is more sensitive with MIC95 (4-
5 M) and S. aureus strains with MIC95 10-25 μM. In addition, bactericidal effects of 15a and 17a were 
also studied for S. aureus 6538, S. aureus Mu50 and B. anthracis sterne.  As shown in Figure 1.11, 15a at 
10 μM kills two log numbers of B. anthracis sterne in one hour, while 25 μM kills three log numbers of 
the other strains.  
 
 
 
 
Table 1.7. Bacteriostatic effects of 15a and 17a for S. aureus and B. anthracis 
 
                        Bacteriostatic effects (M) 
Strains  
        15a       17a 
MIC50  MIC95  MIC50  MIC95  
B. anthracis Sterne 4 5 3 4 
S. aureus 6538 12 15 9 10 
S. aureus Mu50 23 25 9 10 
S. aureus N315 9 25 9 18 
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                  Figure 1.11. Bactericidal effects of 15a for S. aureus and B. anthracis 
1.7.3 Effect of efflux pumps on antimicrobial potency 
           EcSecA is known to exist in both membrane and soluble forms,
81
 and constitutes ring-like struc-
tures upon interaction with anionic phospholipids.
10a, 82
 It has also been demonstrated to export prOmpA 
across liposomes
83
 which suggests that SecA could very well be involved in forming a protein conducting 
channel spanning the entire membrane. Thus, SecA inhibitors may be able to access SecA through extra-
cellular matrix, exerting their inhibitory effects without entering cellular membrane. This could bypass 
the effect of efflux transporters, thereby overcoming the drug resistance issue. Drug efflux pumps are a 
major cause of multi-drug resistance in bacteria, therefore in Gram-positive bacteria, targeting SecA 
might be able to bypass the effect of efflux pumps. NorA and MepA are two major efflux pumps in S. 
aureus. In this study (Table 1.8), we investigated the effect of overexpression (NorA
+++ 
and
 
MepA
+++
) or 
deletion (NorA
-
 and MepA
-
) of these efflux pumps, implicated in drug resistance, on bacteriostatic and/or 
bactericidal properties of inhibitors. Both, 15a and 17a were used as representative inhibitors. Table 1.8 
shows the bacteriostatic effects of 15a and 17a on the S. aureus mutants. Deletion or overexpression of 
NorA or MepA has not resulted in significant changes in the potency of inhibitors.  
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               Bacteriostatic effects against S. aureus efflux strains 
                 Strains 
  ID                    
WT 
8325-4 
NorA
-
 
K1758 
NorA
+++
 
K2361 
MepA
-
 
K2908 
MepA
+++
 
K2068 
15a 
MIC50 (μM) 22 25 23 30 19 
MIC95 (μM) 64 50 40 75 50 
17a   
MIC50 (μM) 27 33 21 32 19 
MIC95 (μM) 50* >50 50* >50 50* 
 
Table 1.8. Bacteriostatic effects of 15a and 17a against S. aureus efflux strains 
 
          One would expect to see a drastic decrease in antimicrobial potency of 15a, if efflux pumps 
pumped out the inhibitors and vice versa. Neither deletion nor overexpression of NorA and MepA has 
significantly affected the bacteriostatic properties of 15a and 17a. There are only small changes, NorA
- 
and MepA
-
 slightly lowered bactericidal effects, compared to wild type, while over-expression shows 
slight increase in bactericidal properties. Thus, there is no marked influence of efflux pumps, on the bac-
tericidal properties of our compounds. This evidence further supports our hypothesis, that 4-oxo-5-cyano 
thiouracil inhibitors may be able to access the transmembrane SecA from the periplasm.  
1.7.3.1 Inhibition on secretion of B. anthracis toxins 
            15a inhibits the secretion of lethal factor, edema factor, and protective antigen toxins in B. anthra-
cis as shown in Figure 1.12, at a much lower concentration than that required for S. aureus.     
 
Figure 1.12. Inhibition on the secretion of specific toxins of B. anthracis Sterne 
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15a was added to the mid-log phase of B. anthracis sterne at OD600 ≈ 3.2 ml culture was collected after 1, 3 and 5 
hrs. Then the supernatant and cell pellet were separated. 200 μl supernatant was added to 50 μl of 5X sample buffer 
and 40 μl was loaded into each lane. Specific antibodies were used to detect LF, EF, and PA.  
            These results establish that 15a is able to significantly reduce the bacterial virulence, most likely 
by inhibiting the in vivo functions of SecA1 in S. aureus and B. anthracis. Thus, it appears that SecA tar-
geting inhibitors function by bringing down the bacterial virulence, caused by inhibiting the maturation of 
virulence causing proteins. 
1.7.4 Trypsin digestion of SecA: 15a alters the digestion pattern 
In order to further validate SecA as the target of our inhibitors, we investigated the SecA-inhibitor 
binding interactions by monitoring the difference in trypsin digestion. Ligands bound to proteins are 
known to cause protein stabilization, leading to conformational changes and subsequently affecting the 
protease digestion. Figure 1.13 (left panel) shows the effect of 15a (80 µM) on EcSecAN68 digestion pat-
tern. First, separate additions of ATP and 15a lead to different digestion patterns; when the two are added 
together, the digestion is similar in pattern to only 15a. No significant effects of UV induced azido-
protein cross-linking were seen. Besides, 15a also changes the trypsin digestion of SecA homologs SaSe-
cA1 and SaSecA2 (Fig. 1.13, right panel). These results indicate that SecA is indeed the biological target 
of 15a. 
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Figure 1.13. 15a binds with EcSecA N68 (Left panel), and SaSecA1 and SaSecA2 (Right panel) 
10 μg of SaSecA1 and SaSecA2, respectively, was incubated at 25°C for 10 min with or without 15a. 
Then 1.2 μg of trypsin was added and the mixture was incubated on ice for 25 min. 15% SDS-PAGE 
were run. 
1.7.5 Pull down assay 
           We performed pull-down assays to further validate SecA as the target. For this purpose, a PEG 
linker was used to attach 15a to biotin (24) and agarose beads (25 and 26). Western blots analysis was 
done and EcSecA antibodies were used to probe for SecA. Results shown in in Figure 1.14, clearly 
demonstrate the presence of SecA in E.coli and S. aureus lysate pull-downs respectively, with the corre-
sponding negative controls showing no detection of SecA protein. These results further validate that 4-
oxo-5-cyano thiouracil derivatives target SecA in bacteria, as shown by the studies done using the repre-
sentative compound 15a. 
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Figure 1.14. Pull down results from E. coli MC4100 whole-cell lysate (top panel). Pull down results from 
S. aureus whole-cell lysate (bottom panel) 
                                      
1.8  Computational studies 
1.8.1.1 Molecular docking 
            To get an insight into the binding modes of our inhibitors, we used molecular docking to analyze 
the possible binding pocket of our top 20 active ligands using Surflex-docking method in Sybyl-X 2.0. 
Our previously published results show the core structure binds to the ATPase binding pocket of SecA. 
Figure 1.15 shows the top 20 active ligands in the ATP binding pocket. 
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                      Figure 1.15. Top 20 active compounds docked in the active site of SecATPase 
 
 
 
Figure 1.16. Compound 21a is shown in the binding pocket of SecA. Enzyme residues are color coded, 
blue: hydrophilic, brown: hydrophobic. 21a is colored by atom type and ATP is seen to the bottom right 
         We investigated the binding modes of our compounds and Figure 1.16 depicts one of the most po-
tent compound 21a, in the ATPase binding pocket of SecA interacting with residues at the interface of 
chain A and B. The azido group is seen at a distance of 6.5 Å from A/ATP900 and points towards hydro-
philic residues including A/ASP512, A/ARG509, A/GLY510 and A/THR511. The change in torsion an-
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gle caused by the –O atom between the two phenyl groups allows the phenoxy group to rest in a pocket, 
away from B/THR511, B/GLY510 and B/GLU487 residues. 
1.8.1.2 HQSAR (2D-QSAR) and Topomer CoMFA (3D-QSAR) models 
           HQSAR or molecular fingerprinting is a method that represents any particular molecule into a 
unique string of numbers called bins. The bins are mathematical representations of unique fragments 
within a particular molecule that are allocated by a cyclic redundancy algorithm. For 2D-QSAR studies, 
we used the Hologram representation package in Sybyl-X 2.0. The training (n = 45) and test set (n = 5) 
molecules were fragmented in size range of four to seven atoms and various hologram lengths consisting 
of 97, 151, 199, 257, 307, 353, 401 bins were used. The best model was obtained from 97-bin length and 
was selected based upon the least standard error value (r
2 
= 0.781, q
2
 = 0.539, std. error = 0.289). 
         Figure 1.16 shows the individual atomic contributions for compound 21a in the training set. The 
yellow and green represent positive contributions to the activity and white are intermediate, mainly due to 
being invariant in the training set. Colors at the red end of the spectrum (red, red-orange, orange) reflect 
poor contributions and are not seen in 21a. 
 
Figure 1.17. HQSAR generated individual atomic contributions for 21a. Green and yellow represent fa-
vorable contribution. (Contributions: white: -0.042854667 to 0.047735, yellow: 0.047735 to 0.0716025, 
green: 0.1193375 and above). 
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           We used HQSAR and Topomer CoMFA to derive a global QSAR analysis using the enzyme inhi-
bition values as dependent variables. Topomer CoMFA methodology is used as a tool to visualize steric 
and electrostatic interactions of the ligands and can also be used for R-group virtual screening to help 
guide the design of new compounds. A training set of 45 inhibitors was used for deriving the two QSAR 
models and an external validation using a test set of five compounds was done to analyze the predictive 
power of both models. Our test set compounds represented different structural properties that are incorpo-
rated within our training set compounds. The q
2
 value is considered a good measure of internal inconsist-
encies in the model and CoMFA models have been suggested to have q
2
 > 0.3,
84
 although a high q
2
 values 
does not necessarily indicate good predictability.
85
 External validation, as described above, is an effective 
method for testing the predictability of model because the compounds are not presented to the program in 
the training set. 
 
Figure 1.18. Topomer representations of compound 15a. Thiouracil biphenyl fragment on the left and az-
ido benzyl on the right with overlaid steric and electrostatic contours from the Topomer CoMFA model of 
EcSecAN68 inhibition. (Green and yellow contours indicate the favored and disfavored steric interactions. 
Red and Blue contours represent the favored negative and positive electrostatic environment respectively) 
         Figure 1.17 shows CoMFA PLS contour maps for the steric and electrostatic fields of compound 
15a. Green and yellow contours represent favorable and unfavorable steric tolerance respectively, where-
as red and blue represents a preference for electronegative and electropositive groups respectively. Our 
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model shows an overall good correlation with topomer CoMFA training set (r
2 
= 0.789, q
2 
= 0.428) and 
HQSAR (r
2
 = 0.781, q
2 
= 0.539). Figures 1.18 and 1.19 show the graphic results for experimental vs pre-
dicted PIC50 values for HQSAR and Topomer CoMFA respectively. Also, Table 1.9 shows the test set 
compounds with predictions using HQSAR and CoMFA models; in close correlation with each other and 
the experimental values. Compound 21n shows higher residual values than expected. The reason for this 
could be structural dissimilarity of 21n due to relatively small dataset. Nevertheless, the overall correla-
tion of r
2
 and q
2
 values in both HQSAR and Topomer CoMFA models is good and the contour plots are in 
agreement with the experimental observations. 
          A structural interpretation of the contour for thiouracil biphenyl topomer indicates major steric con-
tributions to the activity with a bulky phenyl at p-position (green contour). Yellow contour represents un-
favorable steric clashes on the phenyl moiety as indicated by experimental results with groups such as –
NHBoc (15k), -COOMe (15m and 15n) with IC50s > 25 µM. The electronegative -CN and amide -NH 
bond contribute favorably to the activity with the red contour showing a preference for the negative 
charge. The potency drastically goes down upon methylation of –NH to –NMe (19a, IC50 = 60 µM), 
which is clearly demonstrated by the yellow and red contours at –NH showing its preference for non-
bulky and negatively charged substituents. Favorable modifications at carbonyl group of amide with –
NHMe (17d, IC50 = 3.5 µM and –OMe (19b, IC50 < 5 µM) are shown in blue contour for electropositive 
groups well-tolerated. For the benzyl azido topomer, a preference is clearly indicated for the bulky groups 
at p-position, which stands true to our observation of triazole substituted groups showing improved en-
zymatic inhibition over 15a (5a and 5b, IC50 = 2.5 and 3 µM respectively). We know from experimental 
observation that –COOH and –B(OH)2 (15c, IC50 = 30 µM; 15d, IC50 = 60 µM) substitutions bring down 
the activity drastically and the blue contour map in the region show a preference for electropositive 
groups. Yellow contours represent steric bulk is not good at the 3-position (15j, IC50 >100 µM, m-
substituted azido group) and a preference for electronegative group at position 2 (21e, IC50 = 2.5 µM). 
Topomer CoMFA models built from available structure and activities for 45 molecules in the training set 
41 
 
are in good coherence with experimental results (Figure 1.20, Table 1.10) coupled with statistically good 
q
2
 values and good predictability for the test set compounds (Table 1.9). 
Table 1.9. External cross-validation to test HQSAR and Topomer CoMFA models’ predictability (n = 5) 
 
 
                 
 
                     
          
 
 
Figure. 1.19. Graphic plots for experimental vs predicted PIC50 values for the training (cyan) and test set 
(red) for HQSAR model 
 
 
No. 
 
ID 
Exp.        
PIC50s 
 CoMFA     
Predictions 
 
HQSAR 
Predictions 
  
1 15i 5.07   5.02 5.02 
2 18c 5.18   5.28 5.41 
3 18d 5.12   5.29 5.24 
4 21h 5.30   5.67 5.44 
5 21n 5.69   5.11 5.21 
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Figure 1.20.  Graphic plots for experimental vs predicted PIC50 values for the training (cyan) and test set 
(red) for Topomer CoMFA 3D-QSAR model 
1.9 Conclusions 
          Scheme 1.5 summarizes the structure optimization efforts and the sites of modifications on the op-
timized hit (as depicted by arrows) are also shown. Structure optimization of this novel class of SecA in-
hibitors has led to nearly 50-fold improvement in enzyme inhibition over the hit and 10-fold improvement 
in antimicrobial potency. Besides, improvement in calculated physicochemical properties such as logP 
and aqueous solubility (logS), have added more drug-like character to these inhibitors. The computational 
tools such as molecular docking, 2D and 3D-QSAR analyses allowed for a deeper understanding and val-
uable insights into structure-activity relationship of 4-oxo-5-cyano thiouracil inhibitors.  
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Scheme 1.5. A schematic summary of hit optimization 
 
             The mechanistic studies establish that 15a shows promising inhibition effect on ATPase activities 
of SecA homologues, as well as bacteriostatic and bactericidal effects on B. anthracis sterne and drug-
resistant S. aureus strains. It also inhibits the secretion of virulence causing toxins in B. anthracis and 
thus shows the potential of reducing virulence dramatically. Virulence-targeting therapies are not suffi-
cient to combat infection, but targeting SecA homologues does not only reduce virulence, it also decreas-
es bacterial viability. This dual ability depicted by 4-oxo-5-cyano thiouracil inhibitors, significantly in-
creases the chances of controlling infection and reducing the occurrence of drug resistance.  
Partial trypsin digestion studies establish that SecA binding causes changes in cleavage patterns of SecA 
digestion. This is due to altered trypsin accessibility of SecA cleavage sites, which could be due to con-
formational changes induced upon inhibitor binding.   
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Figure 1.21. A schematic summary of 15a evaluation 
 
 
           Figure 1.21 shows a schematic summary of 15a evaluation. Pull-down studies indicate SecA as a 
major target for 15a. However, other proteins were also pulled down including D-ribosomal binding pro-
tein, tryptophanase, trp repressor binding protein, glutamate dehydrogenase, acyl-CoA carboxylase, acyl-
CoA dehydrogenase, and enoyl-(acyl-carrier protein) reductase. Although, having multiple targets inside 
bacteria can be a possibility, but when we analyze pull down assay results, we have to consider the limita-
tions involved in affinity chromatography. Small-molecule binding to targets is defined by its structural 
attributes; here we have modified our small molecules with long PEG linkers conjugated to beads or bio-
tin. Understandably, this influences the binding ability, selectivity and bioactivity of these molecules, re-
sulting in possible nonspecific binding with non-target proteins. Therefore, further studies are needed to 
evaluate whether inhibition on those proteins could result in the antimicrobial phenotype of those inhibi-
tors.  
        Also, the proteins identified from pull down assay might not be essential for bacteria, except for the 
known SecA and enoyl-(acyl-carrier protein) reductase. Besides, enoyl-(acyl-carrier protein) reductase is 
an attractive target for developing antimicrobials as it is a key enzyme of the type II fatty acid synthesis 
pathway. 
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        We need to further investigate whether 4-oxo-5-cyano thiouracil inhibitors could inhibit enoyl-(acyl-
carrier protein) reductase activity.  It would be an exciting discovery if a single small molecule could tar-
get two essential and specific bacterial proteins. Currently, our efforts are focused on further improvement 
of selectivity and potency for these inhibitors.  
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1.11 Experimental 
The following section discusses the various experimental details. 
1.12 Material and Methods 
1.12.1 Bacterial strains and culture condition 
          S. aureus strains ATCC 35556 and ATCC 6538 were obtained from the American Type Culture 
Collection. Various S. aureus strains Mu50, Mu3, and N315 were generously provided by Dr. Chung-Dar 
Lu laboratory at Georgia State University. S. aureus strains 8325-4,
86
 K1758 (NorA
-
),
87
 K2361 (NorA
++
), 
K2908 (MepA
-
), K2068 (MepA
++
)
86, 88
 were kindly provided by Dr. GW Kaatz at Wayne State University 
School of Medicine. All strains were grown on (LB) agar plates or broth at 37°C. 
1.12.2 SecA-lipsomes ion-channel activity assays in the oocytes  
           The procedure for preparation of liposomes has been described.
89
 E. coli lipids (Avanti) were dried 
and re-suspended in 150 mM KCl, and then sonicated in ice water bath for 3-5 min, till the solution was 
clear. Liposomes were stored at -80 °C and thawed just before use. The oocytes were obtained from live 
frog Xenopus laevis (Xenopus Express, Inc) and injected with sample mixtures as described previously. 
Nanoject II injector (Drummond Scientific Co., Broomall, PA) was used to inject 50 nl sample into dark 
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pole site of oocytes. The amount for each component is 120 ng liposomes, 120 ng SecA, 14 ng proOmpA, 
2 mM ATP, and 1 mM Mg
++
. The effective concentration of component in the oocytes was based on the 
average volume of oocytes of 500 nl. The ion current was recorded three hours after injection. Figure 2.3 
shows a schematic procedure of the ion-channel activity assay. 
1.12.3 Bacterial growth inhibition assay 
            For each experiment, a 12 ml culture tube was used to inoculate a single colony of bacteria in 3 ml 
of LB medium. The colony was grown at 37°C to an OD600 of ~ 0.5. This was followed by dilution of 300 
μl of the culture into 3 ml LB medium.  Then, 97.5 μl of the cell culture was aliquoted and transferred to 
1.5 ml eppendorf tube. To this tube was added 2.5 μl of SecA inhibitor at different concentrations and 
was left to incubate for 14 hr at 37°C in a thermo-mixer at (1000 rpm). Finally, OD600 was measured to 
determine the inhibition effect. 
1.12.4 Bactericidal effect determination 
           For each experiment, a 12 ml culture tube was used to inoculate a single colony of bacteria in 3 ml 
of LB medium. The colony was grown at 37 °C to an OD600 of about 0.5, then 97.5 μl of the cell culture 
was aliquoted and transferred to 1.5 ml eppendorf tube. To this tube was added 2.5 μl of SecA inhibitor at 
different concentrations and was left to incubate for 1-2 hr, (1000 rpm) at 37°C. Finally, it was diluted 
with deuterated H2O and 150 μl of the culture was spread on to LB plates. 
1.12.5 Virulence factor secretion 
           The inhibitors were added to the culture of S. aureus Mu50 or B. anthracis sterne at the mid-log 
phase of growth. OD600 was used to monitor the bacteria growth and the culture was collected after treat-
ment with inhibitors at different time points. For the S. aureus culture, the supernatant and cell pellet were 
separated using both centrifugation and syringe disk filter (0.45 μm) purchased from Fisher scientific. 
However, the supernatant of B. anthracis was separated from pellet using only the disk filter (0.45 μm).  
The toxins were detected using toxin-specific antibodies in western blot assay. The antibodies were pur-
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chased from Abcam (S. aureus enterotoxin B, B. anthracis lethal factor (LF), B. anthracis edema factor 
(EF), and B. anthracis protective antigen (PA), Acris-antibodies (S. aureus toxin shock syndrome toxin-1 
(TSST-1)) and Sigma-Aldrich (S. aureus α-hemolysin). 
1.12.6 Pull down assay 
           E. coli MC4100 and S. aureus Mu50 were grown in LB medium overnight at 37°C. Bacterial cells 
were harvested using centrifugation and then washed with binding buffer (0.1 M K3PO4, pH 7.2). Cell 
pellets thus obtained were re-suspended in binding buffer, containing a cocktail of protease inhibitors. 
Cell pellets were run through french press at 10,000 psi and the unbroken cells were separated by centrif-
ugation at 5,000 rpm. Agarose beads (purchased from invitrogen) and pierce streptavidin agarose resins 
(purchased from Thermo-scientific) were used for pull down. For pull-down with agarose beads, the 
whole cell lysates were mixed with beads, and was left on a circular shaker at 4°C for 1 h, in the pres-
ence/absence of inhibitors, followed by rolling in shaker  at rt for 10 hr. For streptavidin beads, the whole 
cell lysates were pretreated with beads at 4°C for 1 hr and then centrifuged for 2 min at 500 rpm.  The 
supernatant was treated as above. Both agarose beads and streptavidin beads were separated from cell 
lysates by centrifugation at 500 rpm for 2 min. Then, beads were washed with binding buffer for 5 times. 
After washing, beads were mixed with binding buffer and SDS sample buffer, and then boiled for 30 min.  
1.12.7 Computational studies 
        The QikProp module in Maestro v9.3.518 (Schrodinger) software was used for physicochemical 
property (logP, logS) calculations. 
        The computational studies including molecular docking, HQSAR, Topomer CoMFA was done using 
SYBYL-X 2.0 by following the standard procedures provided in the manual. HQSAR was run from 
SYBYL using default parameters: hologram lengths (97, 151, 199, 257, 307, 353 and 401), fragment at-
om count (4-7 atoms) were used. The best model was selected on the basis of the least standard error. For 
Topomer CoMFA, the two-piece fragmentation was done followed by automated PLS analysis, fragment 
alignment and activity predictions. SYBYL generated statistical parameters such as q
2
, r
2
, number of 
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components. Standard errors of prediction were recorded for both sets and steric and electrostatic contour 
maps were generated. A training set (n = 45) and test set (n = 5) were used for model building and cross-
validation respectively for both HQSAR and Topomer CoMFA 3-D models. Table shows the structures 
and Test and training set predictions. 
         For molecular docking, surflex-dock method was used to dock top 20 active ligands into SecA crys-
tal structure (PDB ID: 2FSG) using automatic docking. Standard parameters given in SYBYL X 2.0 were 
used for energy minimization of SecA crystal structure. Protein preparation was done using AMBER7 
FF99 force field and the default paramaters in surflex-Dock (SFXC). A maximum of 20 docking poses for 
each molecule were generated. 
 
Table 1.10. A comparison of experimental and predicted PIC50 values using Topomer CoMFA and 
HQSAR for the training set 
                                                 
Training set compounds (n = 45) 
 
No.                             Structure Exp. 
PIC50 
Topomer 
CoMFA 
Predictions 
  HQSAR 
Predictions 
 
 
1 
             
 
 
 
5.4 
 
 
 
4.95 
 
 
 
5.02 
 
 
 
2 
                  
 
 
4.52 
 
 
4.68 
 
 
4.92 
 
 
 
3 
           
 
 
 
4.00 
 
 
 
3.94 
 
 
 
4.13 
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4 
           
 
 
 
4.00 
 
 
 
4.10 
 
 
 
4.05 
 
 
 
5 
                   
 
 
 
4.22 
 
 
 
4.61 
 
 
 
4.38 
 
 
 
6 
                  
 
 
 
4.69 
 
 
 
4.55 
 
 
 
4.67 
 
 
 
7 
             
 
 
 
5.45 
 
 
 
5.59 
 
 
 
5.41 
 
 
 
8 
                 
 
 
4.82 
 
 
4.74 
 
 
4.86 
 
 
9 
            
 
 
4.74 
 
 
4.60 
 
 
4.59 
 
 
 
10 
           
 
 
 
3.69 
 
 
 
3.92 
 
 
 
4.30 
50 
 
 
 
 
 
 
11 
               
 
 
 
 
4.30 
 
 
 
 
5.13 
 
 
 
 
4.82 
 
 
 
12 
             
 
 
 
4.91 
 
 
 
4.65 
 
 
 
4.64 
 
 
 
 
13 
              
 
 
 
5.62 
 
 
 
5.73 
 
 
 
5.86 
 
 
 
14 
          
 
 
 
5.69 
 
 
 
5.77 
 
 
 
5.81 
 
 
 
15 
            
 
 
 
5.65 
 
 
 
5.68 
 
 
 
5.75 
 
 
 
16 
               
 
 
 
5.55 
 
 
 
5.22 
 
 
 
5.16 
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17 
       
 
 
 
5.60 
 
 
 
5.67 
 
 
 
5.65 
 
 
 
18 
          
 
 
 
5.42 
 
 
 
5.52 
 
 
 
5.64 
 
 
 
 
19 
 
 
 
 
5.60 
 
 
 
5.41 
 
 
 
5.24 
 
 
 
20 
 
 
 
 
5.52 
 
 
 
  5.53 
 
 
 
5.49 
 
 
 
 
21 
        
 
 
 
5.33 
 
 
 
 5.40 
 
 
 
5.38 
 
 
 
 
22 
         
 
 
 
 
5.55 
 
 
 
 
 5.43 
 
 
 
 
5.60 
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23 
          
 
 
 
5.85 
 
 
 
 5.63 
 
 
 
5.83 
 
 
 
24 
 
 
 
 
5.30 
 
 
 
 5.57 
 
 
 
5.59 
 
 
 
25 
          
 
 
 
5.74 
 
 
 
 5.11 
 
 
 
5.21 
 
 
 
26 
    
 
 
 
5.12 
 
 
 
 5.17 
 
 
 
5.25 
 
 
 
 
27 
          
 
 
 
5.00 
 
 
 
 5.03 
 
 
 
5.17 
 
 
 
 
28 
       
 
 
 
 
5.09 
 
 
 
 
 5.11 
 
 
 
 
5.18 
53 
 
 
 
 
 
29 
                     
 
 
 
 
4.43 
 
 
 
 
 4.29 
 
 
 
 
4.31 
 
 
 
30 
 
 
 
 
5.22 
 
 
 
4.99 
 
 
 
4.97 
 
 
 
31 
             
 
 
 
4.52 
 
 
 
4.63 
 
 
 
4.51 
 
 
 
32 
              
 
 
 
4.52 
 
 
 
4.59 
 
 
 
4.47 
 
 
 
33 
             
 
 
 
4.22 
 
 
 
4.31 
 
 
 
4.06 
 
 
 
34 
               
 
 
 
4.52 
 
 
 
4.24 
 
 
 
4.36 
 
 
 
35 
     
 
 
 
4.60 
 
 
 
4.30 
 
 
 
4.50 
54 
 
 
 
 
36 
      
 
 
 
4.69 
 
 
 
4.54 
 
 
 
4.52 
 
 
37 
                   
 
 
4.82 
 
 
4.69 
 
 
4.63 
 
 
 
38 
             
 
 
3.69 
 
 
4.43 
 
 
4.37 
 
 
 
39 
               
 
 
 
5.22 
 
 
 
5.45 
 
 
 
5.29 
 
 
 
40 
             
 
 
 
5.60 
 
 
 
5.27 
 
 
 
4.91 
 
 
 
41 
             
 
 
 
5.09 
 
 
 
  4.83 
 
 
 
4.79 
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42 
                
 
 
 
4.60 
 
 
 
  4.91 
 
 
 
4.78 
 
 
 
43 
              
 
 
 
5.45 
 
 
 
 
 
 
   5.37 
 
 
 
5.28 
 
 
 
44 
             
 
 
 
4.60 
 
 
 
 4.75 
 
 
 
4.90 
 
 
 
45 
      
 
 
5.69 
 
 
 5.66 
 
 
5.61 
 
 
Table 1.11. A comparison of experimental and predicted PIC50 values using Topomer CoMFA and 
HQSAR for the test set 
 Test set compounds (n = 5) 
No.                          Structure Exp. 
PIC50                            
  Topomer 
CoMFA
 Predictions 
HQSAR 
predictions 
1 
  
 
 
 
5.69 
 
 
 
  5.11 
 
 
 
5.21 
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2 
       
 
 
 
5.3 
 
 
 
  5.67 
 
 
 
5.44 
3 
  
 
 
 
5.18 
 
 
 
5.28 
 
 
 
5.41 
4 
 
 
 
 
5.12 
 
 
 
5.29 
 
 
 
5.24 
5 
 
 
 
5.07 
 
 
5.02 
 
 
5.02 
 
1.12.8 General chemical methods:  
           All chemical reagents and solvents used were reagent grade or purified using standard methods. 
TLC analyses were conducted on silica gel plates (Sorbent Silica G UV254).Column chromatography was 
carried out on flash silica gel (Sorbent 230–400 mesh). NMR spectra were recorded at 1H (400 MHz) and 
13
C (100 MHz) on a Bruker instrument. Coupling constants (J) and chemical shifts (δ) are given in hertz 
and ppm respectively, using TMS (
1
H NMR) and solvents (
13
C NMR) as internal standards. 
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General synthetic procedure for 14a-d:  A previously published
63b
 procedure was followed. Briefly, to 
a solution of ethanol (50 mL) and appropriate aldehyde (RCHO, 5 mmol) was added ethyl cyanoacetate 
(0.5 mL, 5 mmol), thiourea (0.38 g, 5 mmol) and piperidine (1.0 mL, 10 mmol). The mixture was heated 
under reflux for overnight and then cooled to room temperature. The precipitate was dissolved in 0.5 M 
NaOH (20 mL) and washed with ethyl acetate (15 ml  3). Then the aqueous solution was acidified to pH 
~ 2 by slow addition of 1 M HCl. This caused the product to precipitate, which was then filtered using 
vacuum filtration. Yield: 60-65%. 
General synthetic procedure for 15a-b and 15e-p:  To a solution of 6-([1, 1'-biphenyl]-4-yl)-4-oxo-2 
thioxo-1, 2, 3, 4-tetrahydropyrimidine-5-carbonitrile derivatives (1.37 mmol) in CH3CN (8 ml), K2CO3 
(6.85 mmol) was added and the resulting mixture was stirred for 10-15 min. To this was added the appro-
priate (bromomethyl)benzene derivatives (1.23 mmol) and the reaction was stirred at room temperature 
for 16-18 h. Upon completion, the reaction mixture was cooled to ambient temperature and the solvent 
removed in vacuo. The dried residue was washed by H2O (pH = 9-10, 20 mL  2) and brine (15 ml  2) 
followed by product extraction in ethyl acetate (20 ml). The solvent was evaporated in vacuo to obtain 
crude product, which was purified using silica gel column chromatography. Yields: 65-80% 
4-([1,1'-Biphenyl]-4-yl)-2-((4-azidobenzyl)thio)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (15a): 
Yield: 72%; 
1
H NMR (DMSO-d6) δ 8.07 (d, J = 8.0 Hz, 2H), 7.90 (d, J = 8.0 Hz, 2H), 7.79 (d, J = 8.0Hz, 
2H), 7.49 (m, 5H), 7.09 (d, J = 8.0 Hz, 2H), 4.56 (s, 2H); 
13
C NMR (DMSO-d6) δ 170.2, 167.1, 166.0, 
161.6, 143.8, 139.3, 139.1, 134.5, 133.9, 131.1, 129.9, 129.5, 128.8, 127.4, 119.7, 116.4, 93.4, 34.1. 
HRMS (ESI-TOF): Calc’d for C24H17N6OS [MH
+
]: 437.1179; found: 437.1183. 
4-([1, 1'-Biphenyl]-4-yl)-2-((4-aminobenzyl)thio)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (15b): 
Yield: 65%; 
1
H NMR (DMSO-d6): δ 7.62 (d, J = 8.0 Hz, 2H), 7.54 (d, J = 8.0 Hz, 2H), 7.48-7.52 (m, 5H), 
6.94 (d, J = 8.0 Hz, 2H), 6.59 (d, J = 8.0 Hz, 2H); 
13
C NMR (DMSO-d6) δ 166.0, 163.4, 160.2, 149.7, 
139.8, 135.9, 130.0, 129.9, 129.1, 129.0, 128.2, 128.1, 127.0, 114.9, 112.6, 93.4, 36.9. HRMS-ESI (+): 
Calc. for C24H18N4OS [MH
+
]: 411.1280; found: 411.1276. 
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(4-(((6-Cyano-5-oxo-4, 5-dihydro-[1, 1':4', 1''-terphenyl]-3yl) thio) methyl) phenyl) boronic acid 
(15c): Yield 72%; 
1
H NMR (DMSO-d6): δ 8.05 (t, J = 8.0 Hz, 3H), 7.89 (d, J = 8.0 Hz, 2H), 7.79 (s, J = 
8.0 Hz, 2H), 7.74 (d, J = 8.0 Hz, 2H), 7.52 (t,  J = 8.0 Hz, 2H), 7.45 (d, J = 8.0 Hz, 2H), 7.40 (d, J = 8.0 
Hz, 2H), 4.56 (s, 2H); 
13
C NMR (DMSO-d6): δ 167.1, 166.2, 163.2, 143.7, 139.3, 138.7, 134.8, 134.7, 
130.0, 129.6, 128.8, 128.5, 127.4, 127.3, 116.6, 93.2, 34.7. HRMS (ESI-TOF): Calc’d for 
C24H18BN3NaO3S
 
[MNa
+
]: 462.1054; found: 462.1055. 
4-(((6-Cyano-5-oxo-4, 5-dihydro-[1, 1', 4', 1''-terphenyl]-3-yl) thio)methyl) benzoic acid (15d):  
Yield 62%; 
1
H NMR (DMSO-d6): δ 8.03 (d, J = 8.0 Hz, 2H), 7.91 (t, J = 8.0 Hz, 4H), 7.79 (d, J = 8.0 Hz, 
2H), 7.54 (m, 4H), 7.44 (t, J = 8.0 Hz, 1H), 4.63 (s, 2H);  
13
C NMR (DMSO-d6): δ 167.4, 167.1, 165.9, 
161.8, 143.7, 142.4, 139.3, 134.5, 130.3, 129.9, 129.9, 129.6, 129.5, 128.7, 127.4, 127.2, 116.4, 93.4, 
34.2. HRMS (ESI-TOF): Calc’d for C25H16N3O3S [MH
-
]: 438.0918; found: 438.0914. 
Methyl 4-(((4-([1, 1'-biphenyl]-4-yl)-5-cyano-6-oxo-1,6-dihydropyrimidin-2 yl)thio)methyl) benzoate 
(15e): Yield 83%; 
1
H NMR (DMSO-d6) δ 7.98 (d, J = 8.0 Hz, 2H), 7.90 (d, J = 8.0Hz, 2H), 7.83 (d, J = 
8.0 Hz, 2H), 7.76 (d, J = 8.0 Hz, 2H), 7.58 (d, J = 8.0 Hz, 2H), 7.51 (t, J = 8.0 Hz, 2H), 4.57 (s, 2H), 7.42 
(t, J = 4.0 Hz, 1H), 4.55 (s, 2H), 3.84 (s, 3H); 
13
C NMR (DMSO-d6) δ 167.0, 166.4, 143.9, 143.1, 139.5, 
135.4, 132.0, 129.9, 129.7, 129.7, 129.6, 129.5, 128.9, 128.6, 127.3, 127.0, 117.8, 92.0, 52.5, 34.0. 
HRMS (ESI-TOF): Calc’d for C26H19N3NaO3S [MNa
+
]: 476.1039; found: 476.1039 
4-([1, 1'-Biphenyl]-4-yl)-2-(methylthio)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (15f): Yield 68%                                                                     
1
H NMR (DMSO-d6): δ 7.92 (d, J = 8.0 Hz, 2H), 7.86 (d, J = 8.0 Hz, 2H), 7.74 (d, J = 8.0 Hz, 2H), 7.40 
(t, J = 8.0 Hz, 2H), 7.23 (t, J = 8.0 Hz, 1H), 4.05 (s, 3H), 2.64 (s, 3H); 
13
C NMR (DMSO-d6): δ 173.2, 
170.1, 166.4, 139.8, 135.4, 129.6, 127.3, 127.1, 114.3, 85.4, 53.5, 14.5.  HRMS (ESI-TOF): Calc’d for 
C19H16N3OS [MH
+
]: 334.1014; found: 334.1019
 
 
4-([1, 1'-Biphenyl]-4-yl)-6-oxo-2-(prop-2-yn-1-ylthio)-1, 6-dihydropyrimidine-5-carbonitrile (15g): 
Yield 72%; 
1
H NMR (DMSO-d6): δ 8.09 (d, J = 8.0 Hz, 2H), 7.86 (d, J = 8.0 Hz, 2H), 7.78 (d, J = 8.0 Hz, 
2H), 7.521 (t, J = 8.0 Hz, 2H), 7.44 (t, J = 8.0 Hz, 1H), 4.06 (s, 2H), 3.23 (s, 1H); 
13
C NMR (DMSO-d6): 
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δ 166.9, 143.4, 139.4, 135.1, 129.8, 129.5, 128.6, 127.3, 127.1, 74.2, 19.3. HRMS (ESI-TOF): Calc’d for 
C20H14N3OS [MH
+
]: 344.0852; found: 344.0845.
 
 
4-([1, 1'-Biphenyl]-4-yl)-2-((2-(4-azidophenyl)-2-oxoethyl) thio)-6-oxo-1,6  dihydropyrimidine-5-
carbonitrile (15h): Yield 74%; 
1
H NMR (DMSO-d6) δ: 8.07 (d, J = 8.0 Hz, 2H), 7.74 (d,  J = 8.0 Hz, 
2H), 7.68 (d, J = 8.0 Hz, 2H), 7.60 (d, J = 8.0 Hz, 2H), 7.50 (t, J = 8.0 Hz, 2H), 7.42 (t, J = 8.0 Hz, 1H), 
7.27 (d, J = 8.0 Hz, 2Hz), 4.84 (s, 2H); 
13
C NMR (DMSO-d6) δ: 192.3, 166.9, 145.1, 143.2, 139.3, 133.0, 
130.9, 129.5, 129.5, 128.7, 127.2, 126.7, 119.7, 115.0. HRMS (ESI-TOF): Calc’d for C25H17N6O2S 
[MH
+
]: 465.1128; found: 465.1207. 
Ethyl 4-(((4-([1, 1'-biphenyl]-4-yl)-5-cyano-6-oxo-1,6-dihydropyrimidin-2 -yl)thio)methyl)benzoate 
(15i): Yield 82%; 
1
H NMR (DMSO-d6): δ 7.96 (d,  J = 8.0 Hz, 2H),7.85 (m, J = 8.0Hz, 4H), 7.74 (d, J = 
8.0 Hz, 2H), 7.55 (d, J = 8.0 Hz, 2H) , 7.47 (t, J = 8.0 Hz, 4H), 7.39 (t, J = 8.0 Hz, 1H), 4.57 (s, 2H), 4.24 
(q, 2H), 1.25 (t, J = 8.0 Hz, 3H); 
13
C NMR (DMSO-d6): δ 167.2, 166.5, 165.9, 143.6, 143.1, 139.3, 134.8, 
129.8, 129.7, 129.7, 129.5, 129.3, 128.7, 127.3, 127.1, 116.8, 93.4, 61.1, 34.2, 14.5. HRMS (ESI-TOF): 
Calc’d for C27H21N3NaO3S [MNa
+
]: 490.1196; found: 490.1204.  
4-([1,1'-Biphenyl]-4-yl)-2-((3-azidobenzyl)thio)-6-oxo-1, 6-dihydropyrimidine-5-carbonitrile (15j): 
Yield 80%; 
1
H NMR (DMSO-d6): δ 8.06 (d, J = 8.0 Hz, 2H), 7.89 (d, J = 8.0 Hz, 2H), 7.78 (d, J = 8.0 Hz, 
2H) , 7.52 (t, J = 8.0 Hz, 2H), 7.44 (t, J = 8.0 Hz, 1H), 7.38 (t, J = 8.0 Hz, 1H), 7.27 (d, J = 8.0 Hz, 1H), 
7.22 (s, 1H), 7.02 (m, J = 4.0 Hz, 1H), 4.57 (s, 2H); 
13
C NMR (DMSO-d6): δ 167.1, 166.0, 143.8, 139.9, 
139.6, 139.3, 130.6, 129.9, 129.5, 128.8, 127.4, 127.2, 126.3, 120.0, 118.7, 116.4, 93.4, 34.1. HRMS 
(ESI-TOF): Calc’d for C24H17N6OS [MH
+
]: 437.1179; found: 437.1183. 
Tert-butyl (4'-(2-(benzylthio)-5-cyano-6-oxo-1, 6-dihydropyrimidin-4-yl)-[1,1'-biphenyl]-3-
yl)carbamate (15k): Yield 75%; 
1
H NMR (DMSO-d6) δ 9.49 (s, 1H), 8.10 (d, J = 8.0 Hz, 2H), 7.46 (d, J 
= 8.0 Hz, 2H), 7.39 (s, 1H), 7.00 (s, 1H), 4.62 (s, 2H), 3.87-3.83 (m, 9H,), 3.59 (s, 3H); 
13
C NMR 
(DMSO-d6) δ: 167.8, 167.3, 166.4, 151.5, 148.3, 144.8, 143.1, 135.4, 134.2, 129.8, 129.1, 128.8, 122.1, 
166.7, 114.1, 113.2, 93.1, 56.3, 56.2, 52.6, 52.1, 34.2. HRMS (ESI-TOF): Calc’d for C29H26N4O3S [MH
-
]: 
509.1647; found: 509.1644  
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2-(Benzylthio)-4-(3'-hydroxy-[1,1'-biphenyl]-4-yl)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (15l): 
Yield 80%; 
1
H NMR (DMSO-d6): δ 9.75 (br, 1H), 8.00 (d, J = 8.0 Hz, 2H), 7.77 (d, J = 8.0 Hz, 2H), 7.62 
(d, J = 8.0 Hz, 2H),7.43 (d, J = 8.0 Hz, 2H), 7.30 (m, 3H), 6.89 (d, J = 8.0 Hz, 2H), 4.52 (s, 2H); 
13
C 
NMR (DMSO-d6) δ: 167.0, 166.7, 158.4, 143.6, 140.8, 137.2, 133.6, 130.5, 129.9, 129.8, 129.4, 128.9, 
128.5, 127.8, 127.0, 126.1, 118.1, 117.0, 116.3, 115.7, 114.1, 92.3, 34.6. HRMS (ESI-TOF): Calc’d for 
C24H16N3O2S [MH
-
]: 412.1120; found: 412.1112. 
Methyl 4'-(2-((4-azidobenzyl)thio)-5-cyano-6-oxo-1,6-dihydropyrimidin-4-yl)-4,5-dimethoxy-[1,1'-
biphenyl]-2-carboxylate (15m): Yield 81%; 
1
H NMR (DMSO-d6): δ 7.99 (d, J = 8.0 Hz, 2H), 7.47 (d, J 
= 8.0 Hz, 4H), 7.39 (s, 1H), 7.07 (d, J = 8.0 Hz, 2H), 6.99 (s, 1H), 4.55 (s, 3H), 3.86 (s, 3H), 3.85 (s, 3H), 
3.58 (s, 3H); 
13
C NMR (DMSO-d6): δ 167.7, 167.3, 166.0, 161.7, 151.6, 148.4, 144.9, 139.0, 135.4, 
134.0, 133.9, 131.1, 129.1, 128.8, 122.1, 119.6, 116.4, 114.2, 113.3, 93.3, 56.3, 56.2, 52.1, 34.1. HRMS 
(ESI-TOF): Calc’d for C28H21N6 O5S [MH
-
]: 553.1300; found: 553.1306. 
Methyl 4'-(5-cyano-2-((4-(methoxycarbonyl)benzyl)thio)-6-oxo-1,6-dihydropyrimidin-4-yl)-4,5-
dimethoxy-[1,1'-biphenyl]-2-carboxylate (15n): Yield 72%; 
1
H NMR (DMSO-d6): δ 7.92 (d, J = 8.0 Hz, 
4H), 7.59 (d, J = 8.0 Hz, 2H), 7.46 (d, J = 8.0 Hz, 2H) ,7.39 (s, 1H), 7.00 (s, 1H), 4.62 (s, 2H), 3.87 (s, 
3H), 3.86 (s, 3H), 3.83 (s, 3H),  3.59 (s, 3H); 
13
C NMR (DMSO-d6): δ 167.8, 167.3, 166.4, 151.5, 148.3, 
144.8, 143.1, 135.4, 134.2, 129.8, 129.1, 128.8, 122.1, 166.7, 114.1, 113.2, 93.1, 56.3, 56.2, 52.6, 52.1, 
34.2. HRMS (ESI-TOF): Calc’d for C30H25N3NaO7S [MNa
+
]: 594.1305; found: 594.1324. 
 
4-(((4-([1,1'-Biphenyl]-4-yl)-5-cyano-6-oxo-1,6-dihydropyrimidin-2-yl)thio)methyl)-N-(3-(2-(2-(3-
aminopropoxy)ethoxy)ethoxy)propyl)benzamide (15o): Yield 68%; 
1
H NMR (MeOD): δ 8.02 (d, J = 
8.0 Hz, 2H), 7.75 (m, J = 8.0 Hz, 4H), 7.66 (d, J = 8.0 Hz, 4H), 7.46 (t, J = 8.0 Hz, 2H), 7.39 (t, J = 8.0 
Hz, 1H), 4.55 (s, 2H), 3.58 (m, 12H), 3.46 (t, J = 8.0 Hz, 4H), 3.07 (t,  J = 8.0 Hz, 2H), 1.99 (m, 4H). 
13
C 
NMR (MeOD): δ 168.0, 167.9, 167.46, 143.7, 141.0, 139.3, 134.2, 132.9, 128.9, 128.6, 128.3, 127.5, 
126.8, 126.4, 126.3, 116.2, 91.3, 69.7, 69.3, 69.2, 68.6, 68.5, 38.4, 37.0, 33.8, 28.6, 26.3. HRMS (ESI-
TOF): Calc’d for C35H40N5O5S
 
[MH
+
]: 642.2745; found: 642.2742.  
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Tert-butyl(1-(4-(((4-([1,1'-biphenyl]-4-yl)-5-cyano-6-oxo-1,6-dihydropyrimidin-2 yl) thio )methyl) 
phenyl)-1-oxo-6,9,12-trioxa-2-azapentadecan-15-yl)carbamate (15p): 
1
H NMR (DMSO-d6): δ 8.06 (d, 
J = 8.0 Hz, 2H), 7.89 (d, J = 8.0 Hz, 2H), 7.79 (d, J = 8.0 Hz, 2H), 7.48 (m, 6H), 7.09 (d, J = 8.0Hz, 2H), 
4.55 (s, 2H), 2.09 (s, 1H); 
13
C NMR (DMSO-d6): δ 173.8, 173.4, 166.6, 162.0, 143.1, 139.5, 138.3, 135.4, 
130.9, 129.6, 129.5, 127.3, 127.1, 119.6, 115.2, 83.5, 34.5. HRMS (ESI-TOF): Calc’d for C24H17N7OS 
[MH
-
]
 
450.1137; found: 450.1132. 
General synthetic procedure for 15c-d: To a solution of 6-([1, 1'-biphenyl]-4-yl)-4-oxo-2-thioxo-1, 2, 
3, 4-tetrahydropyrimidine-5-carbonitrile derivatives (0.32 mmol) in THF: H2O (3:1, 4 ml) was added 
NaOH (0.35 mmol) and the resulting solution was stirred for 10-15 min. To this mixture, appropriate 
(bromomethyl) benzene derivatives (0.29 mmol) were added and the reaction was stirred at room temper-
ature for 8 h. On completion, the reaction mixture was cooled to ambient temperature and the solvent re-
moved in vacuo. The dried residue was washed with acidified water (pH = 4-5, 20 mL  2), brine (15 ml 
 2) and the product was extracted in ethyl acetate (20 ml). The solvent was evaporated under vacuum to 
obtain crude residue, which was purified using silica gel column chromatography. Yields: 75-80% 
(4-(((6-Cyano-5-oxo-4, 5-dihydro-[1, 1':4', 1''-terphenyl]-3yl) thio) methyl) phenyl) boronic acid 
(15c): Yield 72%; 
1
H NMR (DMSO-d6): δ 8.05 (t, J = 8.0 Hz, 3H), 7.89 (d, J = 8.0 Hz, 2H), 7.79 (s, J = 
8.0 Hz, 2H), 7.74 (d, J = 8.0 Hz, 2H), 7.52 (t,  J = 8.0 Hz, 2H), 7.45 (d, J = 8.0 Hz, 2H), 7.40 (d, J = 8.0 
Hz, 2H), 4.56 (s, 2H); 
13
C NMR (DMSO-d6): δ 167.1, 166.2, 163.2, 143.7, 139.3, 138.7, 134.8, 134.7, 
130.0, 129.6, 128.8, 128.5, 127.4, 127.3, 116.6, 93.2, 34.7. HRMS (ESI-TOF): Calc’d for 
C24H18BN3NaO3S
 
[MNa
+
]: 462.1054; found: 462.1055. 
4-(((6-Cyano-5-oxo-4, 5-dihydro-[1, 1', 4', 1''-terphenyl]-3-yl) thio)methyl) benzoic acid (15d). 
Yield 62%; 
1
H NMR (DMSO-d6): δ 8.03 (d, J = 8.0 Hz, 2H), 7.91 (t, J = 8.0 Hz, 4H), 7.79 (d, J = 8.0 Hz, 
2H), 7.54 (m, 4H), 7.44 (t, J = 8.0 Hz, 1H), 4.63 (s, 2H); 
13
C NMR (DMSO-d6) δ: 167.4, 167.1, 165.9, 
161.8, 143.7, 142.4, 139.3, 134.5, 130.3, 129.9, 129.9, 129.6, 129.5, 128.7, 127.4, 127.2, 116.4, 93.4, 34.2 
HRMS (ESI-TOF): Calc’d for C25H16N3O3S [MH
-
]: 438.0918; found: 438.0914. 
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General synthetic procedure for 17a-j: To a solution of 3 (0.109 mmol) in 2 ml of CH3CN: DMF (3:1) 
was added R-NH2/R-OH (0.164 mmol) and the reaction was allowed to stir at room temperature over-
night. Alternatively the reaction was monitored by TLC and on disappearance of the starting material the 
reaction solvent was dried in vacuo. The dried residue product was dissolved in ethyl acetate (20 ml) and 
washed with H2O (5 ml  3) and brine (5 ml  3). The solvent was evaporated under vacuum to obtain 
crude residue, which was purified using silica gel column chromatography. Yields: 65-85% 
4-([1,1'-Biphenyl]-4-yl)-2-((4-azidobenzyl)thio)-6-(hydroxyamino)pyrimidine-5-carbonitrile (17a): 
Yield 65 %; 
1
H NMR (DMSO-d6): δ 8.06 (d, J = 8.0 Hz, 2H), 7.89 (d, J = 8.0 Hz, 2H), 7.79 (d, J = 8.0 Hz, 
2H), 7.48 (m, 6H), 7.09 (d, J = 8.0 Hz, 2H), 4.55 (s, 2H), 2.09 (s, 1H). 
13
C NMR (DMSO-d6): δ 173.8, 
173.4, 166.6, 162.0, 143.1, 139.5, 138.3, 135.4, 130.9, 129.6, 129.5, 127.3, 127.1, 119.6, 116.6, 93.2, 34.1. 
HRMS (ESI-TOF): Calc’d for C24H17N7OS [MH
-
]
 
450.1137; found: 450.1132. 
4-([1,1'-Biphenyl]-4-yl)-2-(benzylthio)-6-((2-hydroxyethyl)amino)pyrimidine-5-carbonitrile (17b): 
Yield 62%; 
1
H NMR (DMSO-d6): δ 7.94 (t, J = 8.0 Hz, 3H), 7.85 (d, J = 8.0 Hz, 2H), 7. 76 (d, J = 8.0 Hz, 
2H), 7.51 (t, J = 8.0 Hz, 2H), 7.44 (d, J = 8.0 Hz, 2H), 7.33 (t, J = 8.0 Hz, 2H), 7.26 (d, J = 8.0 Hz, 1H), 
4.83 (s, 1H), 4.44 (s, 2H), 3.57 (s, 4H); 
13
C NMR (DMSO-d6): δ 173.2, 166.6, 161.5, 142.8, 139.1, 137.9, 
134.9, 129.3, 129.2, 128.9, 128.6, 128.3, 127.2, 127.0, 126.8, 116.4, 83.4, 59.1, 43.5, 34.4. HRMS (ESI-
TOF): Calc’d for C26H23N4OS
 
[MH
+
]:439.1587; found: 439.1588. 
4-([1,1'-Biphenyl]-4-yl)-2-(benzylthio)-6-methoxypyrimidine-5-carbonitrile (17c): Yield 88%; 
1
H NMR (CDCl3): δ 8.13 (d, J = 8.0 Hz, 2H), 7.74 (d, J = 8.0 Hz, 2H), 7.65 (d, J = 8.0 Hz, 2H), 7.46 (m, 
6H), 7.31 (m, 3H), 4.51 (s, 2H), 4.13 (s, 3H); 
13
C NMR (CDCl3): δ 174.7, 170.0, 168.0, 144.6, 139.9, 
136.7, 133.8, 129.5, 128.9, 128.6, 128.1, 127.5, 127.3, 127.2, 114.9, 87.8, 55.5, 35.8. HRMS (ESI-TOF): 
Calc’d for C25H20N3OS [MH
+
]: 410.1322; found: 410.1343.  
4-([1,1'-Biphenyl]-4-yl)-2-((4-azidobenzyl)thio)-6-(methylamino)pyrimidine-5-carbonitrile (17d): 
Yield  88%; 
1
H NMR (DMSO-d6): δ 7.94 (d, J = 8.0 Hz, 2H), 7.85 (d, J = 8.0 Hz, 2H), 7.74 (d, J = 8.0 Hz, 
2H), 7.50 (q, J = 8.0 Hz, 4H), 7.43 (d, J = 8.0 Hz, 1H), 7.08 (d, J = 8.0 Hz, 2H), 4.45 (s, 2H), 2.95 (s, 3H). 
13
C NMR (DMSO-d6): δ 173.4, 166.6, 162.0, 143.1, 139.5, 138.6, 135.4, 130.9, 129.6, 129.5, 127.3, 
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127.1, 119.6, 116.7, 83.7, 34.2, 28.7.  HRMS (ESI-TOF): Calc’d for C25H20N7S
 
[MH+]: 450.1495; found: 
450.1491. 
Tert-butyl(3-(2-(2-(3-((6-([1,1'-biphenyl]-4-yl)-2-((4-azidobenzyl)thio)-5-cyanopyrimidin-4-
yl)amino)propoxy)ethoxy)ethoxy)propyl)carbamate  (17e): Yield 75%;  
1
H NMR (CDCl3): δ 8.05 (d, J 
= 8.0 Hz, 2H), 7.72 (d, J = 8.0 Hz, 2H), 7.64 (d, J = 8.0 Hz, 2H), 7.463 (m, 5H), 6.97 (d, J = 8.0 Hz, 2H), 
5.05 (br, 1H), 4.42 (s, 2H), 3.51-3.74 (m, 14H), 3.32 (d, 2H), 1.94 (t, J = 8.0 Hz, 2H), 1.76 (m, 2H), 1.44 
(s, 10H); 
13
C NMR (CDCl3): δ 173.9, 166.2, 161.7, 156.0, 143.98, 140.0, 138.9, 134.8, 134.4, 130.3, 
129.1, 128.93, 127.9, 127.2, 127.2, 119.1, 116.7, 83.6, 70.7, 70.6, 70.6, 70.4, 70.2, 70.2, 69.5, 40.7, 38.5, 
34.8, 29.6, 28.5, 28.4. HRMS (ESI-TOF): Calc’d for C39H47N8O5S
 
[MH
+
]: 739.3385; found: 739.3367. 
Tert-butyl(3-(2-(2-(3-((6-([1,1'-biphenyl]-4-yl)-2-(benzylthio)-5-cyanopyrimidin-4-
yl)amino)propoxy)ethoxy)ethoxy)propyl)carbamate (17f): Yield 75%; 
1
H NMR (DMSO-d6): δ 8.08 (t, 
1H), 7.94 (d, J = 8.0 Hz, 2H), 7.82 (d, J = 8.0 Hz, 2H), 7.74 (d, J = 8.0 Hz, 2H)  7.45 (m, 5H), 7.32 (t, J = 
8.0 Hz, 2H), 7.26 (t, J = 6.0 Hz, 1H), 4.44 (s, 2H), 3.44 (m, 16H), 2.97 (d, J = 8.0 Hz, 2H), 1.82 (t, J = 6.0 
Hz, 2H), 1.59 (t, J = 8.0 Hz, 2H). 
13
C NMR (DMSO-d6): δ 174.0, 167.8, 166.3, 161.5, 143.5, 139.6, 
137.6, 134.7, 132.1, 130.9, 129.0, 128.6, 128.6, 128.2, 127.7, 126.8, 126.7, 126.5, 116.1, 83.1, 79.4, 70.0, 
70.0, 69.7, 69.3, 68.9, 39.3, 38.65, 34.9, 31.4, 29.4, 28.5. HRMS (ESI-TOF): Calc’d for C39H48N5O5S
 
[MH
+
]: 698.3371; found: 698.3381.  
4-([1,1'-Biphenyl]-4-yl)-6-((3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)amino)-2-(benzylthio)-
1,6-dihydropyrimidine-5-carbonitrile (17g): Yield 82%; 
1
H NMR (MeOD): δ 7.90 (d, J = 8.0 Hz, 2H), 
7.63 (d, J = 8.0 Hz, 2H), 7.58 (d, J = 8.0 Hz, 2H), 7.38 (t, J = 8.0 Hz, 4H), 7.30 (d, J = 8.0 Hz, 1H), 7.26 
(t, J = 8.0 Hz, 2H), 7.21 (d, 1H), 4.38 (s, 2H), 3.53 (m, 15H), 2.70 (br, 2H), 1.81 (t, J = 8.0 Hz, 2H), 1.67 
(t, J = 8.0 Hz, 2H). 
13
C NMR (MeOD): δ 174.0, 167.8, 166.3, 161.5, 143.5, 139.6, 137.6, 134.1, 132.1, 
130.9, 129.0, 128.6, 128.6, 128.2, 127.7, 126.8, 126.7, 126.5, 116.1, 83.1, 70.0, 70.0, 69.7, 69.3, 68.9, 
39.3, 38.6, 34.9, 31.4, 29.4, 28.6. HRMS (ESI-TOF): Calc’d for C34H40N5O3S
 
[MH
+
]: 598.2846; found: 
598.2866. 
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4-([1,1'-Biphenyl]-4-yl)-2-((4-azidobenzyl)thio)-6-((2-hydroxyethyl)amino)-1,6-dihydropyrimidine-
5-carbonitrile (17h): Yield 65%; 
1
H NMR (DMSO-d6) δ: 7.94 (d, J = 8.0 Hz, 2H), 7.85 (d, J = 8.0 Hz, 
2H), 7.76 (d, J = 8.0 Hz, 2H), 7.50 (q, J = 8.0 Hz, 4H), 7.42 (t, J = 8.0 Hz, 1H), 7.08 (d, J = 8.0 Hz, 2H), 
4.83 (s, 1H), 4.43 (s, 2H), 3.56 (s, 4H); 
13
C NMR (DMSO-d6) δ: 173.4, 166.9, 161.8, 143.1, 139.5, 138.6, 
135.3, 135.2, 130.9, 129.6, 128.6, 127.3, 127.0, 119.6, 116.7, 83.8, 59.4, 43.9, 34.2. HRMS (ESI-TOF): 
Calc’d for C26H22OS
 
[MH
+
]: 480.1601; found: 480.1606. 
4-([1,1'-Biphenyl]-4-yl)-2-((4-azidobenzyl)thio)-6-hydrazinyl-1,6-dihydropyrimidine-5-carbonitrile 
(17i): Yield 60%; 
1
H NMR (DMSO-d6): δ 7.91 (d, J = 8.0 Hz, 2H), 7.84 (d, J = 8.0 Hz, 2H), 7.77 (t, J = 
8.0 Hz, 2H), 7.52 (m, J = 8.0 Hz, 4H), 7.50 (d, J = 8.0 Hz, 1H), 7.06 (d, J = 8.0 Hz, 2H), 4.43 (s, 2H), 
1.97 (d, J = 4.0 Hz, 2H); 
13
C NMR (DMSO-d6): δ 174.0, 167.8, 166.3, 161.5, 143.5, 139.6, 137.6, 134.7, 
132.1, 130.9, 129.0, 128.6, 128.6, 128.2, 127.7, 126.8, 126.7, 126.5, 116.1, 83.1, 70.1, 70.0, 69.7, 69.3, 
68.9, 39.3, 38.6, 34.9, 31.4, 29.4, 28.6. HRMS-ESI (+): Calc. for C24H20N8S [M-H]
-
: 451.1453; found: 
451.1444. 
4-([1,1'-Biphenyl]-4-yl)-2-((4-azidobenzyl)thio)-6-(prop-2-yn-1-ylamino) pyrimidine-5-carbonitrile 
(17j): Yield 72%; 
1
H NMR (DMSO-d6): 7.95 (d, J = 8.0 Hz, 2H), 7.85 (d, J = 8.0 Hz, 2H), 7.76 (d, J = 
8.0 Hz, 2H), 7.50 (m, J = 8.0 Hz, 4H), 7.43 (t, J = 8.0 Hz, 1H), 7.07 (d, J = 8.0 Hz, 2H), 4.48 (s, 2H), 4.22 
(d, J = 4.0 Hz, 2H), 3.20 (s, 1H); 
13
C NMR (DMSO-d6): δ 173.5, 167.1, 161.4, 143.2, 139.4, 138.6, 135.4, 
135.0, 130.9, 129.7, 129.5, 128.6, 127.3, 127.20, 119.6, 116.4, 84.1, 81.2, 73.6, 34.2, 30.9. HRMS (ESI-
TOF): Calc’d for C27H20N7S
 
[MH
+
]: 474.1495; found: 474.1490. 
General synthetic procedure for 18a-g: A solution of 4-([1, 1'-biphenyl]-4-yl)-2-((4-azidobenzyl) thio)-
6-oxo-1, 6-dihydropyrimidine-5-carbonitrile 2 (30 mg, 0.068 mmol) was prepared in 0.3 ml of DMF in a 
4 ml glass vial. To this solution were added appropriate alkynes (0.103 mmol) and the resulting mixture 
was dissolved by stirring.  To this mixture was added 0.015 ml of 1M CuSO4.5H2O in H2O and sodium 
ascorbate (6.81 mg, 0.0344 mmol). The reaction is left to stir overnight at room temperature. On comple-
tion, the reaction solvent is evaporated under vacuum and the dried residue in dissolved in ethyl acetate. 
The resulting solution is washed with acidified water (pH = 4-5, 10 ml  3) and brine (5 ml  2). The sol-
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vent was evaporated under vacuum to obtain crude residue, which was purified using silica gel column 
chromatography. Yields: 65-80% 
4-([1,1'-Biphenyl]-4-yl)-6-oxo-2-((4-(4-phenyl-1H-1,2,3-triazol-1-yl)benzyl)thio)-1, 6-dihydro pyrim-
idine-5-carbonitrile (18a):  Yield 85%; 
1
H NMR (DMSO-d6): δ 9.25 (s, 1H), 8.07 (d, J = 8.0 Hz, 2H), 
7.91 (m, 6H), 7.79 (d, J = 8.0 Hz, 2H), 7.70 (d, J = 8.0 Hz, 2H), 7.50 (m, 4H), 7.43 (m, 2H), 4.65 (s, 2H);
 
13
C NMR (DMSO-d6): δ 167.1, 166.4, 147.7, 143.7, 139.3, 138.1, 136.2, 134.7, 131.1, 130.9, 130.6, 
129.8, 129.5, 129.4, 128.7, 128.7, 127.8, 127.4, 127.2, 125.8, 120.5, 119.7, 116.6, 93.2, 36.2. HRMS 
(ESI-TOF): Calc’d for C32H23N6OS [MH
+
]: 539.1649; found: 539.1656. 
4-([1,1'-Biphenyl]-4-yl)-2-((4-(4-(4-aminophenyl)-1H-1,2,3-triazol-1-yl)benzyl)thio)-6-oxo-1,6-
dihydropyrimidine-5-carbonitrile (18b): Yield 75%; 
1
H NMR (DMSO-d6) δ: 8.90 (s, 1H), 7.89 (d, J = 
8.0 Hz, 2H), 7.84 (d, J = 8.0 Hz, 2H), 7.75 (m, J = 8.0 Hz, 5H), 7.64 (d, J = 8.0 Hz, 2H), 7.57 (t, J = 8.0 
Hz, 2H), 7.49 (t, J = 8.0 Hz, 2H), 7.39 (t, J = 8.0 Hz, 1H), 6.63 (t, J = 8.0 Hz, 2H), 4.39 (s, 2H). 
13
C NMR 
(DMSO-d6): δ 174.0, 167.8, 166.3, 161.5, 143.5, 139.6, 137.6, 134.7, 132.1, 130.9, 129.0, 128.7, 128.6, 
128.2, 127.7, 126.8, 126.7, 126.5, 115.7, 116.1, 93.5, 36.1. HRMS (ESI-TOF): Calc’d for C32H24N7OS 
[MH
+
]: 554.1758; found: 554.1759. 
1-(4-(((4-([1,1'-Biphenyl]-4-yl)-5-cyano-6-oxo-1,6-dihydropyrimidin-2yl)thio)methyl)phenyl)-1H-
1,2,3-triazole-4-carboxylic acid  (18c): Yield 80%; 
1
H NMR (DMSO-d6): δ 9.38 (s, 1H), 8.07 (d, J = 8.0 
Hz, 2H), 7.93 (m, 4H), 7.80 (d, J = 8.0 Hz, 2H), 7.68 (d, 2H), 7.53 (t, J = 6.0 Hz, 2H), 7.44 (d, J = 8.0 Hz, 
1H), 4.65 (s, 2H); 
13
C NMR (DMSO-d6): δ 171.4, 169.2, 166.5, 161.4, 143.2, 139.4, 138.6, 135.4, 135.0, 
130.9, 129.7, 129.5, 128.6, 127.3, 127.2, 119.6, 113.5, 93.4, 36.4. HRMS (ESI-TOF): Calc’d for 
C27H19N6O3S [MH
+
]: 507.1234; found: 507.1246. 
 (1-(4-(((4-([1,1'-Biphenyl]-4-yl)-5-cyano-6-oxo-1,6-dihydropyrimidin-2-yl)thio)methyl)phenyl)-1H-
1,2,3-triazol-4-yl)methyl acetate (18d): Yield 92%; 
1
H NMR (DMSO-d6): δ 8.83 (s, 1H), 8.05 (d, J = 
8.0 Hz, 2H), 7.88 (t, J = 8.0 Hz, 4H), 7.79 (d, J = 8.0 Hz, 2H), 7.70 (s, 1H), 7.52 (t, J = 8.0 Hz, 2H), 7.43 
(d, J = 8.0 Hz, 1H), 5.20 (s, 2H), 4.68 (s, 2H), 2.05 (s, 3H); 
13
C NMR (DMSO-d6): δ 170.6, 142.5, 139.6, 
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135.9, 131.1, 129.5, 129.2, 128.4, 127.3, 127.1, 123.5, 120.8, 75.2, 57.3, 56.4, 52.0, 21.0, 18.9. HRMS 
(ESI-TOF): Calc’d for C29H23N6O3S [MH
+
]: 535.1547; found: 535.1552. 
3-(1-(4-(((4-([1,1'-Biphenyl]-4-yl)-5-cyano-6-oxo-1,6-dihydropyrimidin-2-yl)thio)methyl)phenyl)-
1H-1,2,3-triazol-4-yl)propanoic acid  (18e): Yield 66%; 
1
H NMR (DMSO-d6): δ 12.21 (s, 1H), 8.54 (s, 
1H),  8.05 (d, J = 8.0 Hz, 2H), 7.89 (d, J = 8.0 Hz, 2H), 7.80 (q, J = 8.0 Hz, 4H), 7.64 (d, J = 12.0 Hz, 
2H), 7.51 (t, J = 8.0 Hz, 2H), 7.41 (d, 1H), 4.62 (s, 2H), 2.91 (t, J = 8.0 Hz, 2H), 2.64 (t, J = 4.0 Hz, 2H); 
13
C NMR (DMSO-d6): δ 173.9, 167.3, 166.0, 161.7, 147.4, 143.7, 139.3, 137.6, 136.3, 134.5, 130.9, 
129.9, 129.5, 128.8, 127.4, 127.2, 120.7, 120.3, 116.4, 93.4, 34.0, 33.3, 21.1. HRMS (ESI-TOF): Calc’d 
for C29H23N6O3S
 
[MH
+
]: 535.1547; found: 535.1559. 
2-(1-(4-(((4-([1,1'-biphenyl]-4-yl)-5-cyano-6-oxo-1,6-dihydropyrimidin-2-yl)thio)methyl)phenyl)-1H-
1,2,3-triazol-4-yl)acetic acid (18f): Yield 65%; 
1
H NMR (DMSO-d6): δ 8.12 (d, J = 8.0 Hz, 2H), 7.83 (d, 
J = 8.0 Hz, 4H), 7.74 (d, J = 8.0 Hz, 2H), 7.69 (d, J = 8.0 Hz, 2H), 7.50 (t, J = 8.0 Hz, 2H), 7.42 (t, J = 
8.0 Hz, 2H), 4.70 (s, 2H), 3.01 (s, 1H), 2.87 (s, 1H); 
13
C NMR (DMSO-d6): δ 173.9, 167.3, 166.0, 161.7, 
147.4, 143.7, 139.3, 137.6, 136.3, 134.5, 130.9, 129.9, 129.5, 128.8, 127.4, 127.2, 120.7, 120.3, 116.4, 
93.4, 34.0, 33.3, 21.1. HRMS (ESI-TOF): Calc’d for C28H19N3O3S
 
[MH
-
]: 519.1239; found: 519.1250. 
4-([1,1'-Biphenyl]-4-yl)-2-((4-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)benzyl)thio)-6-oxo-1,6-
dihydropyrimidine-5-carbonitrile (18g): Yield 70%; 
1
H NMR (DMSO-d6): δ 8.64 (s, 1H), 7.96 (d, J = 
8.0 Hz, 2H), 7.835 (q, 4H) ), 7.76 (d, J = 8.0 Hz, 2H), 7.63 (d, 2H), 7.50 (d, J = 8.0 Hz, 2H), 7.41 (t, J = 
8.0 Hz, 1H), 4.59 (s, 2H), 4.50 (s, 2H); 
13
C NMR (DMSO-d6): δ 170.4, 166.2, 160.5, 144.2, 140.2, 139.6, 
136.0, 134.7, 129.8, 129.2, 128.5, 127.3, 127.0, 121.4, 120.4, 114.5, 93.6, 55.4, 33.8. HRMS (ESI-TOF): 
Calc’d for C27H19N6O2S [MH
+
]: 491.1296; found: 491.1292.  
General synthetic procedure for 19a-c: To a solution of 2a (0.109 mmol) in 2 ml of CH3CN: DMF 
(3:1) was added R-X (0.164 mmol) and the reaction was monitored by TLC. Upon disappearance of the 
starting material, the reaction solvent is dried in vacuo, followed by washing with H2O (5 ml  3) and 
brine (5 ml  3). The product is extracted in ethyl acetate (10 ml) and the solvent was evaporated under 
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vacuum to obtain crude residue, which was purified using silica gel column chromatography. Yields: 70-
80% 
4-([1,1'-Biphenyl]-4-yl)-2-((4-azidobenzyl)thio)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-
carbonitrile (19a): Yield 25%; 
1
H NMR (DMSO-d6): δ 8.03 (d, J = 8.0 Hz, 2H), 7.95 (d, J = 8.0 Hz, 2H), 
7.86 (d, J = 8.0 Hz, 2H), 7.61 (m, 5H), 7.18 (d, J = 8.0 Hz, 2H), 4.54 (s, 2H), 3.05 (s, 3H); 
13
C NMR 
(DMSO-d6): δ 166.8, 164.9, 160.3, 143.9, 139.3, 134.3, 133.1, 131.3, 129.9, 129.58, 128.8, 127.4, 127.3, 
119.7, 116.4, 92.2, 36.0, 31.3. HRMS (ESI-TOF): Calc’d for C25H18N6NaOS [MNa
+
]
 
451.1341; found: 
473.1150. 
4-([1, 1'-Biphenyl]-4-yl)-2-((4-azidobenzyl)thio)-6-methoxypyrimidine-5-carbonitrile (19b): Yield 
45%; 
1
H NMR (DMSO-d6): δ 8.09 (d, J = 8.0 Hz, 2H), 7.90 (d, J = 8.0 Hz, 2H), 7.79 (d, J = 8.0 Hz, 2H), 
7.50 (m, 6H), 7.10 (d, J = 8.0 Hz, 2H), 4.66 (s, 2H), 3.48 (s, 3H); 
13
C NMR (DMSO-d6): δ 167.4, 165.1, 
161.5, 159.3, 155.3, 131.3, 130.3, 130.1, 128.9, 126.7, 124.7, 120.3, 117.4, 115.4, 114.2, 92.2, 55.3, 35.3. 
HRMS (ESI-TOF): Calc’d for C25H18N6NaOS [MNa
+
]
 
473.1160; found: 473.1161.
 
 
4-([1,1'-Biphenyl]-4-yl)-6-((4-azidobenzyl)oxy)-2-((4-azidobenzyl)thio)pyrimidine-5-carbonitrile 
(19c): Yield 72%; 
1
H NMR (DMSO-d6): δ 8.12 (d, J = 8.0 Hz, 2H), 7.90 (d, J = 8.0 Hz, 2H), 7.78 (d, J = 
8.0 Hz, 2H), 7.44 (m, 8H), 7.08 (m, 4H), 5.26 (s, 2H), 4.62 (s, 2H); 
13
C NMR (DMSO-d6: δ 166.5, 160.6, 
144.0, 139.4, 139.3, 139.2, 134.1, 132.8, 131.3, 131.2, 130.9, 130.4, 130.0, 129.5, 129.5, 128.8, 127.4, 
127.3, 119.8, 119.7, 119.6, 116.3, 92.9, 47.7, 36.3. HRMS (ESI-TOF): Calc’d for C31H22N9OS [MH
+
]
 
567.1663; found: 568.1689. 
General synthetic procedure for 20a-c:  Same as used for 14a. Yields: 70-75% 
4-(4-(benzyloxy)phenyl)-2-mercapto-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (20a). Yield 65%; 
1
H NMR (DMSO-d6) δ: 7.65 (d, J = 8.0 Hz, 2H), 7.38 (m, 5H), 7.19 (t, J = 8.0 Hz, 2H), 5.22 (s, 2H); 
13
C 
NMR (DMSO-d6) δ: 176.6, 167.9, 161.8, 160.8, 159.1, 157.9, 136.9, 133.2, 131.7, 130.6, 128.9, 128.3, 
121.6, 118.1, 116.1, 115.5, 90.2, 69.9. HRMS (ESI-TOF): Calc’d for C18H13N6O2S
 
[MH
-
]: 334.0650; 
found: 334.0644. 
2-mercapto-6-oxo-4-(4-phenoxyphenyl)-1,6-dihydropyrimidine-5-carbonitrile (20b): Yield 65%     
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1
H NMR (DMSO-d6): δ 7.73 (d, J = 8.0 Hz, 2H), 7.46 (t, 3H), 7.25 (d, J = 8.0 Hz, 1H), 7.11 (t, J = 8.0 Hz, 
4H), 1.62 (s, 1H); 
13
C NMR (DMSO-d6): δ 177.8, 161.7, 160.5, 159.7, 155.5, 131.5, 130.8, 125.5, 125.1, 
120.3, 117.6, 116.1, 93.5. HRMS (ESI-TOF): Calc’d for C25H18N6O2S
 
[MH
+
]: 320.0494; found: 320.0500. 
2-Mercapto-6-oxo-4-(4-(phenylethynyl)phenyl)-1,6-dihydropyrimidine-5-carbonitrile (20c): Yield 
72%; 
1
H NMR (CDCl3): δ 10.03 (s, 1H), 7.87 (d, J = 8.0 Hz, 2H), 7.69 (d, J = 8.0 Hz, 2H), 7.57 (t, J = 8.0 
Hz, 2H), 7.39 (t, J = 8.0 Hz, 2H); 
13
C NMR (CDCl3): δ 171.4, 135.4, 132.1, 131.8, 129.6, 129.0, 128.5, 
122.5, 93.4, 88.5. HRMS (ESI-TOF): Calc’d for C19H10N3OS
 
[MH
-
]: 328.0545; found: 328.0541. 
General synthetic procedure for 21a-o:  Same as used for 15a. Yields: 65-70% 
2-((4-Azidobenzyl)thio)-4-(4-(benzyloxy)phenyl)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (21a): 
Yield 68%; 
1
H NMR (CDCl3): δ 7.99 (d, J = 8.0 Hz, 2H), 7.40 (m, 7H), 7.19 (d, J = 8.0 Hz, 2H), 7.05 (d, 
J = 8.0 Hz, 2H), 5.21 (s, 2H), 4.52 (s, 2H); 
13
C NMR (CDCl3): δ 166.7, 165.6, 162.0, 161.7, 139.0, 136.9, 
134.0, 131.2, 131.1, 128.9, 128.5, 128.3, 127.9, 119.6, 116.8, 115.3, 91.9, 70.0, 34.0. HRMS (ESI-TOF): 
Calc’d for C25H18N6O2S
 
[MH
+
]: 465.1139; found: 465.1127. 
Methyl4-(((4-(4-(benzyloxy)phenyl)-5-cyano-6-oxo-1,6-dihydropyrimidin-2-yl)thio)methyl)benzoate 
(21b): Yield 75%; 
1
H NMR (DMSO-d6): δ 7.90 (m, J = 8.0 Hz, 4H), 7.55 (d,  J = 8.0 Hz, 2H), 7.47 (d, J 
= 8.0 Hz, 2H), 7.40 (t, J = 8.0 Hz, 2H), 7.34 (d, 1H), 7.16 (d, J = 8.0 Hz, 2H), 5.20 (s, 2H), 4.56 (s, 2H), 
3.82 (s, 3H); 
13
CNMR (DMSO-d6): δ 166.7, 166.4, 166.1, 161.5, 143.2, 136.9, 131.1, 129.7, 129.7, 129.0, 
128.9, 128.4, 128.2, 128.1, 117.2, 115.2, 114.3, 91.6, 69.9, 52.5, 34.1. HRMS (ESI-TOF): Calc’d for 
C27H21N3O4S
 
[MH
-
]: 482.1180; found: 482.1165. 
4-(4-(Benzyloxy)phenyl)-2-((4-methoxybenzyl)thio)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile 
(21c): Yield 75%; 
1
H NMR (CDCl3): δ 8.03 (d, J = 8.0 Hz, 2H), 7.48 (d, J = 8.0 Hz, 2H), 7.37 (m, 5H), 
7.21 (d, J = 8.0 Hz, 2H), 6.87 (d, J = 8.0 Hz, 2H), 5.22 (s, 2H), 4.49 (s, 2H), 3.71 (s, 3H); 
13
C NMR 
(CDCl3): δ 166.7, 165.5, 161.8, 161.6, 159.3, 136.9, 131.3, 130.7, 128.9, 128.5, 128.41, 128.3, 127.9, 
116.7, 115.3, 114.4, 91.9, 69.9, 55.5, 34.2. HRMS (ESI-TOF): Calc’d for C26H20N3O3S
 
[MH
-
]: 454.1225; 
found: 454.1227. 
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4-(4-(Benzyloxy)phenyl)-2-((4-bromobenzyl)thio)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (21d): 
Yield 70%; 
1
H NMR (DMSO-d6): δ 7.97 (d, J = 8.0 Hz, 2H), 7.50 (t, J = 8.0 Hz, 4H), 7.39 (m, 5H), 7.20 
(d, J = 8.0 Hz, 2H), 5.22 (s, 2H), 4.51 (s, 2H); 
13
C NMR (DMSO-d6): δ 171.9, 166.9, 165.4, 161.7, 137.0, 
136.8, 131.8, 131.6, 131.2, 128.9, 128.5, 128.3, 121.0, 116.8, 115.3, 91.8, 70.0, 33.8. HRMS (ESI-TOF): 
Calc’d for C25H17BrN3O2S [MH
-
]: 503.3904; found: 504.0203. 
4-(4-(Benzyloxy)phenyl)-2-((2-bromobenzyl)thio)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (21e): 
Yield 67%; 
1
H NMR (DMSO-d6): δ 7.97 (d, J = 8.0 Hz, 2H), 7.65 (d, J = 8.0 Hz, 1H), 7.55 (d, J = 8.0 Hz, 
1H), 7.47 (d, J = 8.0 Hz, 2H), 7.26 (m, 7H), 5.21 (s, 2H), 4.61 (s, 2H); 
13
C NMR (DMSO-d6): δ 166.9, 
165.4, 162.2, 161.7, 136.8, 135.7, 133.2, 131.9, 131.3, 130.4, 129.0, 128.5, 127.7, 124.5, 116.8, 115.3, 
91.9, 69.9, 35.4.
 
HRMS (ESI-TOF): Calc’d for C25H17BrN3O2S [MH
-
]: 503.3904; found: 502.0288.
 
4-(4-(Benzyloxy)phenyl)-2-((cyclohexylmethyl)thio)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile 
(21f): Yield 68%; 
1
H NMR ((CD3)2CO): δ 8.09 (d, J = 8.0 Hz, 2H), 7.54 (d, J = 8.0 Hz, 2H), 7.36 (m, 
3H), 7.20 (d, J = 8.0 Hz, 2H), 5.27 (s, 2H), 3.27 (d, 2H), 1.26 (m, 10H); 
13
C NMR (DMSO-d6): δ 171.7, 
166.4, 161.7, 136.9, 130.8, 128.4, 128.3, 127.9, 127.7, 116.2, 114.6, 69.85, 45.5, 37.7, 37.3, 32.2, 28.3, 
26.0, 25.7. HRMS (ESI-TOF): Calc’d for C27H21N3O4S
 
[MH
-
]: 431.1667; found: 430.1605. 
4-(4-(Benzyloxy) phenyl)-2-((3, 5-dimethoxybenzyl) thio)-6-oxo-1,6  dihydropyrimidine-5-
carbonitrile (21g): Yield 68%; 
1
H NMR (DMSO-d6): δ 8.00 (d, J = 8.0 Hz, 2H), 7.33 (m, 5H), 7.17 (d, J 
= 8.0 Hz, 2H), 6.56 (s, 2H), 6.34 (s, 1H), 5.20 (s, 2H), 4.43 (s, 2H). 
13
C NMR (DMSO-d6): δ 166.7, 165.6, 
161.9, 161.7, 160.8, 139.5, 136.9, 131.3, 128.9, 128.5, 128.2, 127.9, 116.84, 115.3, 115.0, 107.4, 99.9, 
91.8, 69.9, 55.4, 34.7, 29.7. HRMS (ESI-TOF): Calc’d for C24H16N6O2S
 
[MH
-
]: 484.1331; found: 
484.1343. 
4-(4-(Benzyloxy)phenyl)-2-((3,5-dimethylbenzyl)thio)-6-oxo1,6 dihydropyrimidine-5-carbonitrile 
(21h): Yield 72%; 
1
H NMR (DMSO-d6): δ 8.00 (d, J = 8.0 Hz, 2H), 7.34 (m, 5H), 7.20 (d, J = 8.0 Hz, 
2H), 7.01 (s, 2H), 6.88 (s, 1H), 5.23 (s, 2H), 4.43 (s, 2H), 2.18 (s, 6H); 
13
C NMR (DMSO-d6): δ 171.5, 
170.3, 166.5, 142.7, 141.7, 141.3, 136.0, 134.0, 133.7, 133.2, 133.0, 132.7, 132.0, 121.5, 120.0, 96.9, 74.7, 
39.4, 25.9.  HRMS (ESI-TOF): Calc’d for C27H23N3O2S
 
[MH
-
]: 452.1433; found: 452.1435. 
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2-((4-Azidobenzyl)thio)-6-oxo-4-(4-phenoxyphenyl)-1,6-dihydropyrimidine-5-carbonitrile (21i): 
Yield 65%; 
1
H NMR (CDCl3): δ 8.10 (d, J = 8.0 Hz, 2H), 7.40 (m, 5H), 7.19 (d, J = 8.0 Hz, 2H), 7.11 (m, 
4H), 6.98 (d, 2H), 4.54 (s, 2H); 
13
C NMR (CDCl3): δ 167.4, 164.2, 163.1, 161.7, 155.2, 139.9, 131.5, 
131.3, 130.5, 130.1, 128.7, 124.8, 120.3, 119.4, 117.4, 115.1, 92.6, 35.0. HRMS (ESI-TOF): Calc’d for 
C24H16N6O2S
 
[MH
-
]: 451.0983; found: 451.0977. 
Methyl4-(((5-cyano-6-oxo-4-(4-phenoxyphenyl)-1,6-dihydropyrimidin-2-yl)thio)methyl)benzoate 
(21j): Yield 62%; 
1
H NMR (CDCl3): δ 7.91(t, J = 8.0 Hz, 4H), 7.38 (m, 4H), 7.20 (t, J = 8.0 Hz, 2H), 
7.07 (d, 2H), 6.97 (d, 2H), 4.43 (s, 2H), 4.43 (s, 2H), 3.87 (s, 3H); 
13
C NMR (CDCl3): δ 169.7, 167.1, 
166.5, 161.2, 155.3, 140.9, 131.1, 130.0, 129.9, 129.5, 129.07, 128.9, 124.6, 120.2, 117.3, 91.8, 52.1, 
35.0. HRMS (ESI-TOF): Calc’d for C26H19N3O4S
 
[MH
+
]:470.1169; found: 470.1165. 
2-((4-Methoxybenzyl)thio)-6-oxo-4-(4-phenoxyphenyl)-1,6-dihydropyrimidine-5  carbonitrile (21k): 
Yield 65%; 
1
H NMR (CDCl3): δ 8.10 (d, J = 8.0 Hz, 2H), 7.42 (t, J = 8.0 Hz, 2H), 7.29 (d, J = 8.0 Hz, 
2H), 7.22 (t, J = 8.0 Hz, 1H), 7.09 (m, 4H), 6.84 (d, 2H), 4.51 (s, 2H), 3.79 (s, 3H); 
13
C NMR (CDCl3): δ 
167.4, 165.1, 161.5, 159.3, 155.3, 131.3, 130.3, 130.1, 128.9, 126.7, 124.7, 120.3, 117.4, 115.4, 114.2, 
92.2, 55.3, 35.3. HRMS (ESI-TOF): Calc’d for C25H19N3O3S [MH
-
]: 440.1074; found: 440.1070. 
2-((4-Azidobenzyl)thio)-6-oxo-4-(4-(phenylethynyl)phenyl)-1, 6-dihydropyrimidine-5  carbonitrile 
(21l): Yield 78%; 
1
H NMR (CDCl3): δ 7.96 (d, J = 8.0 Hz, 2H), 7.73 (d, J = 8.0 Hz, 2H), 7.58 (t, 2H), 
7.43 (m, 5H), 7.05 (d, J = 8.0 Hz, 2H), 4.48 (s, 2H); 
13
C NMR (CDCl3): δ 167.0, 166.7, 141.5, 138.9, 
135.8, 134.2, 132.0, 131.9, 131.1, 129.7, 129.5, 129.3, 125.8, 122.2, 119.6, 116.7, 92.3, 89.1, 34.1. 
HRMS (ESI-TOF): Calc’d for C24H16N6O2S
 
[MH
+
]: 460.1106; found: 461.1185. 
Methyl-4-(((5-cyano-6-oxo-4-(4-(phenylethynyl)phenyl)-1,6-dihydropyrimidin-2-yl)thio)methyl) 
benzoate (21m): Yield 73%; 
1
H NMR (DMSO-d6): δ 7.91 (t, J = 8.0 Hz, 4H), 7.72 (d, J = 8.0 Hz, 2H), 
7.59 (m, 4H), 7.45 (t, 3H), 4.58 (s, 2H), 3.81 (s, 3H); 
13
C NMR (DMSO-d6): δ 174.9, 166.7, 166.4, 143.0, 
135.5, 132.0, 131.8, 129.7, 129.5, 129.3, 125.9, 122.2, 116.4, 92.4, 89.0, 52.6, 34.2. HRMS (ESI-TOF): 
Calc’d for C28H18N3O3S
 
[MH
+
]: 476.1069; found: 476.1057. 
71 
 
2-((4-Methoxybenzyl)thio)-6-oxo-4-(4-(phenylethynyl)phenyl)-1,6-dihydropyrimidine-5-carbonitrile 
(21n): Yield 71%; 
1
H NMR (DMSO-d6): δ 7.91 (t, J = 8.0 Hz, 4H), 7.72 (d, J = 8.0 Hz, 2H), 7.59 (m, 
4H), 7.45 (t, 3H), 4.58 (s, 2H), 3.81 (s, 3H); 
13
C NMR (DMSO-d6): δ 166.6, 166.5, 161.6, 159.1, 135.6, 
132.0, 131.9, 130.8, 129.7, 129.5, 129.3, 128.4, 126.0, 122.2, 116.3, 114.4, 93.6, 92.3, 89.1, 55.5, 34.4. 
HRMS (ESI-TOF): Calc’d for C27H18N3O2S
 
[MH
+
]: 448.1120; found: 448.1118. 
2-((3,5-Dimethoxybenzyl)thio)-6-oxo-4-(4-(phenylethynyl)phenyl)-1,6-dihydropyrimidine-5-
carbonitrile (21o): Yield 74%; 
1
H NMR (DMSO-d6): δ 8.02 (d, J = 8.0 Hz, 2H), 7.73 (d, J = 8.0 Hz, 2H), 
7.60 (s, 2H), 7.45 (s, 3H), 6.57 (s, 2H), 6.36 (s, 1H), 4.49 (s, 2H), 3.72 (s, 6H); 
13
C NMR (DMSO-d6): δ 
167.0, 160.8, 139.4, 135.6, 132.0, 131.9, 129.7, 129.5, 129.3, 125.9, 122.2, 116.6, 107.5, 99.8, 92.4, 89.0, 
55.6, 55.5, 34.8. HRMS (ESI-TOF): Calc’d for C24H16N6O2S
 
[MH
-
]: 478.1225; found: 478.1243  
General synthetic procedure for 24: 
Compound 24 was synthesized in two steps. For biotin-NHS activation, 200 mg (0.819 mmol) of biotin 
was dissolved in DMF, followed by addition of 95 mg (0.819 mmol) NHS and 219 mg (1 mmol) of EDCI. 
The reaction was monitored using TLC, upon completion the DMF evaporated in vacuo and the resulting 
semi-solid mixture is dissolved in cold water, causing precipitates which are filtered to obtain 23, which 
was used for next step without purification.  In a 10 ml glass vial, 34.2 mg (0.098 mmol) of 23 was dis-
solved in 5 ml anhydrous DMF and to this was added 63 mg (0.098 mmol) of 15o and 0.02 ml of TEA 
(0.196 mmol). The reaction is allowed to stir at room temperature and monitored using TLC. Upon com-
pletion, DMF is evaporated in vacuo and the resulting semi-solid mixture is dissolved in ethyl acetate (10 
ml) and washed with cold water (3 ml × 3) and brine (3 ml × 2). The resulting mixture is purified using 
silica gel chromatography and the product was eluted using ethyl acetate: hexane (2:1). 
General synthetic procedure for 25 and 26: In a 4 ml glass vial, 2 ml suspension of NHS-activated 
beads (in acetone, Pierce Prod # 20259) was taken and washed with DMF (2 ml × 5) (HPLC-grade). To it 
was added 26 mg 15o (0.040 mmol) or 25 mg (0.041 mmol) of 17g, and 0.008 ml of TEA (0.081 mmol). 
The mixture was sealed and shaken at room temperature for 24 h. Then, the reaction mixture is washed 
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with DMF (4 ml × 5) to get rid of the side products and unbound residues. Then, the beads were washed 
in PBS buffer (pH = 7.38) and stored at 4°C till use.  
4-(((4-([1,1'-Biphenyl]-4-yl)-5-cyano-6-oxo-1,6-dihydropyrimidin-2-yl)thio)methyl)-N-(15-oxo-19-
((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-4,7,10-trioxa-14 azanonadecyl) ben-
zamide (24): Yield 75%; 
1
H NMR (CDCl3): δ: 8.02 (d, J = 8.0 Hz, 2H), 7.71 (d, J = 8.0 Hz, 2H), 7.63 (d, 
J = 8.0 Hz, 2H), 7.41 (m, 5H), 6.96 (d, J = 8.0 Hz, 2H), 6.82 (t, J = 8.0 Hz, 1H), 6.69 (t, J = 8.0 Hz, 1H), 
6.58 (br, 1H), 5.88 (br, 1H), 4.52 (t, J = 8.0 Hz, 1H), 4.41 (s, 2H), 4.37 (t, J = 8.0 Hz, 1H), 3.64 (m, 11H), 
3.58 (t, J = 8.0 Hz, 2H),  3.53 (t, J = 8.0 Hz, 2H), 3.31 (d, J = 8.0 Hz, 2H), 2.89 (m, 1H), 2.83 (m, 1H), 
2.70 (m, 1H), 2.17 (t, J = 8.0 Hz, 2H), 1.92 (t, J = 8.0 Hz, 2H), 1.75 (t, J = 8.0 Hz, 2H), 1.66 (m,  3H), 
1.41 (t, J = 4.0 Hz, 2H); 
13
C NMR (CDCl3): δ173.9, 173.2, 166.4, 164.1, 161.7, 143.9, 139.9, 138.9, 134.8, 
134.3, 130.3, 129.2, 129.1, 128.9, 128.0, 127.2, 127.1, 119.1, 116.8, 83.5, 77.4, 77.1, 76.8, 69.8, 61.7, 
60.2, 55.7, 40.5, 37.6, 36.0, 34.8, 28.9, 28.5, 28.3, 28.1, 25.7. HRMS (ESI-TOF): Calc’d for 
C45H54N7O7S2
 
[MH
+
]: 868.3526; found: 868.3549. 
 
 
. 
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2 DISCOVERY OF 1, 2, 4-TRIAZOLE PYRIMIDINE ANALOGS AS NOVEL ANTIMICROBIAL AGENTS 
TARGETING SECA 
        Abstract. The following chapter reports the discovery, structure optimization and structure-activity 
relationship study of 1, 2, 4-triazole containing pyrimidine as novel, highly potent antimicrobial agents. A 
series of triazole-pyrimidine analogs were synthesized and evaluated, a number of inhibitors have been 
found to inhibit microbial growth at high nanomolar concentrations. 
2.1 Introduction 
        In earlier sections, we have discussed the need for developing novel methods for targeting multi-
drug resistance against existing antibiotics. Our continuous efforts in this direction involve screening, de-
sign, syntheses and structure-optimization to develop novel structural classes of small molecule SecA in-
hibitors having antimicrobial properties. We have discovered another class of 1, 2, 4-triazole containing 
pyrimidine compounds using similar approach. The hit (27, Scheme 2.1) obtained was evaluated for SecA 
and bacterial growth inhibition and the results obtained (IC50 = 30 µM; MIC = 3.4 µM) showed 27 to be 
good starting point for structure optimization.   
2.1.1 Rationale 
         The structural attributes of 27 make it symmetrical, hydrophobic and poorly water-soluble (logS = -
5.29). The initial medicinal chemistry intuition was to simplify the structure into half so as to enhance 
drug-likeness by reducing the MW and hydrophobicity. As shown in Scheme 2.1, the monomer com-
pound (28) obtained by halving the hit (27) showed improvement in enzyme inhibition (IC50 = 12 µM), 
increased calculated aqueous solubility (logS = -0.92) and reduced MW. In order to modify the lead struc-
ture, two different strategies were adopted; the first was to explore the functional group modifications on 
the molecule while preserving the core scaffold. The second strategy involved changing the substitution 
pattern on the pyrimidine ring, in order to change the relative positions of rings B and C with respect to A, 
while keeping the functional groups intact. We used density functional theory calculations to understand 
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the underlying changes brought upon by various structural modifications such as orbital interaction ener-
gies, bond angles, bond distances and atomic charges. Our analyses provided useful information and val-
uable insights for future design work. 
 
 
Scheme 2.1. Structure optimization of the hit compound 27           
2.2 Results and Discussion 
2.2.1 Chemistry 
          The key intermediate 32 was synthesized in two steps as shown in Scheme 2.2. First, an amidation 
of commercially available benzoyl chlorides (29a-b) with hydrazinecarboamides (30a-b) was done to 
synthesize compound 31, followed by condensation using 5% NaOH under reflux conditions. For inter-
mediate series 34, different thiols or amines were reacted with 2, 4, 6 trichloro pyrimidine under cold 
conditions to obtain 2-substituted pyrimidines (34a-q) as major product (Scheme 2.2). Series 36 (Scheme 
2.3) was obtained by reacting 32a with commercially available 35a-d and series 37 (Scheme 2.4) was 
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obtained by reacting 32b-c with 34a-q, under basic conditions in acetone at ambient temperature. Com-
pound 37b was further used to synthesize series 38 (Scheme 2.4) by replacement of –Cl using different 
amines at room temperature. Table 3.1 summarizes the different R2 and R3 groups in series 34, 37 and 38. 
In series 40 the N-4 position on the triazole was modified by reaction with various alkyl/aryl halides with 
34b in the presence of triethylamine in DMF (Scheme 2.5, Table 2.2). Synthesis of compound 42 was 
done in two steps, first by reacting 32b with Iodomethane at 0°C to obtain 41, followed by reaction with 
4,6-dichloro-2-(methylthio)pyrimidine in acetone under basic conditions (Scheme 2.6). Finally, com-
pounds 43a-b were synthesized by reacting 32a-b with 2, 4, 6-trichloropyrimidine in acetone under basic 
conditions (Scheme 2.7). 
 
 
Scheme 2.2. Synthesis of series 31, 32 and 34 
Reagents and conditions: a) Hydrazinecarbothioamide, 30a or  Hydrazinecarboximidamide, 30b, THF, 
0°C ~ rt, overnight; b) 5% NaOH, reflux, 5 h, 65-87% over two steps; c) THF, -5°C-rt, 2-8 h,70-85% 
 
 
 
76 
 
                        
 
Scheme 2.3. Synthesis of series 36 
 Reagents and conditions: a) K2CO3, acetone, rt, 2~3 h, 65%-80% 
 
 
 
 
Scheme 2.4. Synthesis of series 37 and 38 
Reagents and conditions: a) 34a-q, K2CO3, acetone, rt, 2 ~ 3 h, 70%-75%; b) R3-NH2, acetone/DMF, rt, 
5-12 h, 65%-75% 
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Table 2.1.  R2 and R3 groups for series 34, 37 and 38 
 
  
 
 
 
 
 
Scheme 2.5. Synthesis of series 40 
 
 Reagents and conditions: a) TEA, DMF, rt-40°C, 2-8 h, 70-85% 
 
Table 2.2. Various R4 groups in series 40 
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Scheme 2.6. Synthesis of compound 42 
Reagents and conditions: a) Iodomethane, 0°C, 5 h; b) TEA, 4,6-dichloro-2-(methylthio)pyrimidine,  
acetone, rt, 10 h, 85% 
 
Scheme 2.7. Synthesis of series 43 
                    Reagents and conditions: a) 2, 4, 6-trichloropyrimidine, K2CO3, acetone, 0-4°C, 10 h, 60% 
 
2.2.2 Biological Evaluation 
2.2.2.1 Enzyme and bacterial growth inhibition assays 
         The enzyme inhibition studies were done using B. subtilis168 using the literature colorimetric mala-
chite green ATPase assay to measure the release of free inorganic phosphate.
63b
 The growth inhibition 
activities of the compounds were assessed against a leaky mutant NR698 of E. coli by determining the 
minimum inhibitory concentrations (MIC). 
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2.3 Results and Discussion 
         Our optimization efforts started with the modifications of –CF3 groups on the phenyl ring. CF3 is a 
well-known functional group used in several drugs due to its unique electronic/steric properties and 
desolvation effects. We replaced this sterically hindered, strongly electron withdrawing –CF3 group with 
smaller, electron releasing methyl groups. Scheme 2.3 (36a-d) shows the methyl group (R1) bearing ana-
logs that were synthesized with modification also done to R2 and R3 positions on pyrimidine. In compari-
son to lead 28 (IC50 = 6 µM; MIC50 = 35 µM), all four show decreased inhibition potency (Scheme 2.1, 
Table 2.3). From this series, 36d with R2 = –SMe and R3 = -Cl is the most potent –CH3 containing com-
pound (IC50 = 15 µM; MIC50 = 32 µM). This point towards an important role played by –CF3 for enzyme 
inhibition, and thus in later modifications –CF3 was preserved. 
Table 2.3. Inhibition results for series 36, 38, 39 and 43 
                  
Table 2.4. Inhibition results for series 37      
   
 
           Next, the 2 and 6- pyrimidine positions (series 37a-q and 38a-h respectively) were modified with 
different functional groups as shown in Scheme 3.4 (Table 2.1). The inhibition results for series 37 and 38 
are shown in Tables 2.3 and 2.4 respectively. At position 2, various functional groups such as alkyl, cy-
clic and aromatic were used to study the preferred electronic and steric environment on the pyrimidine 
ring. The inhibition data shows this position accommodates several different functional groups and yet 
retains the potency. As shown in Figure 2.1, a variety of functional groups such as -H (37a, 0.8 µM), -
SMe (37b, 0.3 µM), -OPh (37i, 0.8 µM) and –SPh (37q, 0.5 µM) showed MIC below 1 µM (Tier-I modi-
     36a 36b 36c 36d 38a 38b 38c 38d 38e 38f 38g 38h 39a 43a 43b 
B.subtilis168  
MIC (µM) 
>100 16 >100 15 6.5 1.5 >100 >100 ND >250 9.3 12.5 >100 30 0.7 
E. coli NR698 
MIC (µM)  
>100 100 >100 32 35 6.2 >100 >100 12.5 ND 50 >250 >100 70 8.0 
     37a 37b 37c 37d 37e 37f 37g 37h 37i 37j 37k 37l 37m 37n 37o 37p 37q 
B.subtilis168  
MIC (µM) 
0.8 0.3 
 
1.5 ND >250 >250 4.6 2.0 0.8 1.5 3.1 6.2 5 1.5 25 31 0.5 
E. coli NR698 
MIC (µM)  
18 6.3 9.3 ND >250 >250 15.6 10.9 7.0 12.5 9.3 >250 >250 5.47 25 43 4.0 
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fications). Besides, modifications such as pyrimidine (37c), pyrollidine (37h), o-trifluoromethyl thio-
phenyl (37j) and 4-methy thiophenyl (37n) shows MIC values between 1-2 µM (Tier-II modifications). 
However, there is another striking trend seen in compounds having –NH linked functional groups at 2-
position. In all such compounds (37d, 37e, 37f, 37l and 37m) the antimicrobial activity is nearly abol-
ished with MIC values > 250 µM. Although, 37l (IC50 = 6.2 µM) and 37m (IC50 = 5.0 µM) show moderate 
enzyme inhibition values, but all others show a complete loss of enzyme inhibition in addition to antimi-
crobial activity. As we further continue to explore this position, so far our results indicate that 2-
pyrimidine tolerates a variety of functional groups very well. It is also evident that the -S/O/NH at 2-
position has some important role to play for inhibition. 
 
 
 
Figure 2.1. Top tier functional group modifications on pyrimidine ring in comparison to 37b 
 
           In the hit compound, the 6-position is occupied by a -Cl atom and just like –CF3, halogen atoms 
due to their electronegative properties and small size are of significance in drug design. We analyzed the 
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importance of the electronegative environment offered by the –Cl group at 4-pyrimidine position. So far, 
37b showed the best potency, so further modifications were performed using 37b as the starting point. 
Various modifications including –N3, -NHMe, -NHEt (linear), -NHiPr, (branched) and –NHCyP (cyclic) 
were done as seen in Table 2.1. A comparison of -Cl (37b, IC50 = 0.3 µM) with substitutions such as –H 
(38a, IC50 = 12 µM), -NH(Me)2 (38c, IC50  > 100 µM), -NHMe (38d, IC50 > 100 µM), –NHCyp (38f, IC50 > 
100 µM) show highly decreased (38a) or completely abolished potency. It appears the electronegative 
environment is preferred to electron releasing at this position. If we compare 37b, 38a to others in this 
series 38, the trend is, electron-withdrawing group > none > electron-donating group. This observation 
can be further supported by –N3 substitution (38b, MIC: 1.5 µM), an electron withdrawing group, alt-
hough less potent than 37b, still retains potency. Overall, the pyrimidine ring at both 2-and 6-positions is 
more sensitive to electronic effects than the steric effects. 
         Compound 39 (Scheme 2.4) was synthesized in order to study the importance of the linker between 
pyrimidine and triazole, thus -S- linkage was substituted by –NH. Intriguingly, 39 showed a complete 
elimination of activity (MIC, and IC50 > 100 µM) as compared to 37b (IC50 = 0.3 µM) with only a small 
structural modification (-S, 37b to –NH, 39). Next, we wanted to explore the importance of 1,2,4-triazole 
moiety and thus we started out with the modification on its 4-NH position (40a-f). Several functional 
group modifications (Scheme 2.5, Table 2.2) such as linear (-Me, -Et) or branched (i-Pr) alkyl, cyclobutyl 
and phenyl ring were done as shown. Interestingly, the IC50 values for all the compounds in series 40 
were > 250 µM. In effect, all these modifications have masked the ability of triazole’s -NH to H-bond, 
which seems to have led to a complete loss of activity. It appears that the H-bonding ability of triazole -
NH plays an extremely crucial role in making the compounds potent. Compound 42 (Scheme 2.6) also 
showed a complete loss of potency (IC50 > 100 µM) for both enzymatic and bacterial growth inhibition, 
pointing towards the significance of both –NH and S-triazole linkage.  
          As we mentioned, our alternate strategy for designing inhibitors was to change the substitution of 
5-(3,5-bis(trifluoromethyl)phenyl)-4H-1,2,4-triazole-3-thiol moiety on the pyrimidine ring to 2-position 
instead of 4-position. Interestingly, the two molecules synthesized in this series (43a-b) led to a deeper 
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understanding (Scheme 2.7, Table 2.3) of the structure-activity relationship. For our initial studies, we 
synthesized analogs with both –CH3 (43a) and -CF3 (43b). Here, 43b (IC50 = 0.7 µM, MIC = 8 µM) shows 
nearly as good potency as 37b (IC50 = 0.3 µM, MIC = 6.3 µM). Also, the trend of decreased potency with 
-CF3 to CH3 substitution is the same as earlier, a decrease in inhibition potency for 43a (IC50 = 30 µM, 
MIC= 70 µM).  
           Taken collectively, all the inhibition results point towards a) the importance of triazole –NH’s H-
bonding ability b) the electron withdrawing groups (-CF3) on phenyl playing crucial roles c) the signifi-
cance of electronic environment generated by pharmacophores triazole and pyrimidine taken together. To 
obtain better insights, we turned to computational analysis of these molecules to understand the effect of 
structural modifications on orbital interaction energies, bond angles, atomic charges and H-bonding abili-
ties. 
             
2.3.1.1 Energy Minimization studies using Density Functional Theory (DFT):  
           There are numerous precedents in literature indicating the effect of intramolecular H-bonding of 
inhibitors on molecular structure and properties causing huge variations in potency. Design and syntheses 
of potent inhibitors containing pseudo-rings
90
 formed by intramolecular H-bonding interactions is well-
known. When the donor and acceptors are in close proximity, equilibrium exists between closed confor-
mation (intramolecular H-bonded) forming a temporary ring system and open conformation (intermolecu-
lar H-bonded) when exposed to polar solvent.
91
 Such closed-conformations hide the polarity/charges and 
are more lipophilic thus showing enhanced membrane permeability. Such properties have been explored 
for the development of lipophilic drugs
92
 for enhanced CNS penetration. Several studies reported the im-
portance of conformational restrictions
93
 brought about by intramolecular H-bonding
94
 and their signifi-
cant effects on receptor-inhibitor binding.
95
   
         The inhibition results obtained for 1,2,4-triazole analogs showed trends similar to reported literature, 
in terms of possibility of a 6-membered H-bonded pseudo ring formation between the triazole and pyrim-
idine, effect of –CF3 substitution and H-bond donors/acceptors playing crucial role to the potency. There-
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fore, we decided to explore the effect of some crucial functional group modifications on interactions en-
ergies, bond lengths, bond angles and atomic charges. To begin with, we analyzed our most active com-
pound 37b. As shown in Figure 2.2, in silico energy minimization of open conformation 37b (1) resulted 
in closed conformation 37b (2), suggesting that the latter is favored. An evidence of H-bonding was ob-
tained from calculating the Lp (N)* (N-H) interaction energies (13.5 kcal/mol) and N---H bond dis-
tance (1.964 Å) of 37b (2). Replacing the electron withdrawing –CF3 group with an electron donating –
CH3 group 36d (2), (Figure 2.3) resulted in lower interaction energy of Lp (N)* (N-H) in 36d (2), 
(10.4 kcal/mol) as compared with 37b (2) (13.5 kcal/mol). This reduced the strength of H-bond by ~3 
kcal and increased the distance between N---H by 0.042 Å (2.006 Å). Interestingly, experimental results 
show these –CH3 analogs having remarkably reduced enzyme inhibition compared to the –CF3 substituted 
compounds. This suggests that the electron withdrawing substituents on the phenyl ring make the triazole 
ring a good H-bond donor thereby stabilizing structure 37b (2) by forming the H-bond with the triazole.  
          We also calculated the energies in water using the PCM-SCRF/B3LYP/6-311g (d,p) level, for both 
37b (1) and 37b (2), which showed nearly the same energy suggesting that the polar solvent, water, com-
pensates for their stabilization, similar to reports in literature.
96, 91
 To our understanding, the enhanced 
lipophilicty of 37b could either cause enhanced cell permeability due to masking of polarity
92
 or  in a 
relatively non-polar or hydrophobic environment, such as the enzyme binding pocket, structure 37b (2) 
with H-bonding between triazole and pyrimidine should predominate.
94, 95
 Besides, Our 6-membered 
pseudo ring hypothesis is supported by the assay inhibition results.  For example, the complete loss of 
activity seen with modifications on triazole’s –NH (40a-f) and compound 42. In series 40, NH bonding 
ability was masked using a variety of functional groups, which led to all the compounds in this series 
showing complete loss of activity. Likewise, the control compound 42, which was specifically designed 
to study the importance of pyrimidine-triazole proximity, shows a complete loss of activity. This is be-
cause there is no possibility of H-bonding between triazole and pyrimidine given the structural attributes 
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of 42. This also explains the intriguing activity seen in series 43, which instead of having a completely 
different substitution pattern on the pyrimidine, shows nearly as good activity as 37b.   
 
 
 
Figure 2.2. Computed geometry for CF3-substituted 37b (2) and its rotamer 37b (1) on B3LYP/6-311g 
(d,p) level (gas phase). Interaction energies (kcal/mol) of Lp (N)* (N-H) obtained were from second 
order perturbation analysis.
90
  
 
 
 
Figure 2.3. Computed geometry for CH3-substituted 36d (2) and its rotamer 36d (1) on B3LYP/6-311g (d, 
p) level (gas phase). Interaction energies (kcal/mol) of Lp (N)* (N-H) obtained were from second 
order perturbation analysis  
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          Apart from the electronic nature of the triazole and the pyrimidine ring, the H-bond strength is de-
pendent on the ∟C2-S4-C3 angle. In the present cases, lone pair of electrons in the 3p orbitals of sulfur 
overlaps with the adjacent triazole or the pyrimidine rings Lp (S)*(C2-N1): 28 kcal/mol 37b (2), and 
Lp (S)* (C7-N4): 22 kcal/mol 36d (2) thus preserving the angle at 106o.  Using this, we tried to ex-
plain the loss of inhibition observed for 39 (MIC50 and IC50 > 100µM) having an NH linkage instead of S-
linkage. In theory, one would imagine that substituting sulfur with the smaller hetero atoms such as oxy-
gen or nitrogen, whose 2p lone pairs can effectively overlap with the pyrimidine ring, should increase the 
electron density on the pyrimidine ring and in turn increase its ability as a H-bond acceptor.  
 
 
 
 
Figure 2.4.  B3LYP/6-311g (d,p) optimized geometry for NH- and O-analogs. Interaction energies 
(kcal/mol) of Lp (N1) * (N5-H6) & Lp (O1)* (N5-H6) obtained were from second order perturba-
tion analysis. 
 
          However, a minor change of S-atom from the most active compound 37b (IC50 = 0.3 µM, MIC = 
6.3 µM) to NH linkage in 39, lead to nearly abolished activity (MIC50, and IC50 > 100µM). The optimized 
structure for 39 (Figure 2.4) showed wider ∟C2-N3-C4 angle (128°) and longer H-bond (2.110Å) com-
pared to the sulfur analogs. The interaction energy for Lp (N1) * (N5-H6) obtained (7.4 kcal/mol) 
from the second order perturbation analysis was also smaller than the sulfur analogs. Interestingly, the 
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electron donating ability of NH as shown in structure is making the pyrimidine nitrogen more nucleo-
philic and better H-bond acceptor (NBO charge on N1: -0.592) than the sulfur analog, 37b (2) (NBO 
charge on N1: -0.575), but the same phenomenon also increases the ∟C2-N3-C4 bond angle from 106° to 
128° and thus weakens the H-bond. This observation adds further credibility to our hypothesis of a possi-
ble 6-membered ring formed between the triazole and pyrimidine, which causes the molecular geometry 
to become planar. To what we understand so far, this planarity in our inhibitors is crucial for effective 
enzyme-inhibitor interactions, possibly because the targeted pocket can only accommodate the planar 
molecule. 
2.3.2 Conclusion and future work:  
           Besides our discovery of novel 1, 2, 4 triazole pyrimidine analogs as antimicrobial agents, we have 
successfully achieved the design, syntheses and a structure-activity relationship analysis using various 
computational tools. Having done in-depth analyses of subtle electronic changes leading to large varia-
tions in potency of the molecules, we want to further test the validity of our 6-membered pseudo ring 
model by synthesizing more analogs designed and predicted on the basis of computational analysis. For 
example, we expect the oxygen analogs (Figure 3.4, right panel) to show intermediate enzyme inhibition 
activity between 37b and 36d, while the analogs with methylene linkage, due to their bent structure, 
should be inactive (Figure 2.5). This is based on the N1---H6 bond distance (2.215 Å) and the interaction 
energy of Lp (O1)* (N5-H6) (4.8 kcal/mol) which shows the weakest H-bond is predicted for the C3-
methylene-analogs.  However, in theory this bond can be strengthened by compressing ∟C2-C3-C4 us-
ing Thorpe-Ingold or gem-dimethyl effect (Figure 2.5). We also plan to design analogs to make the intra-
molecular H-bond stronger by testing a variety of different functional groups linking the triazole and py-
rimidine moieties. 
87 
 
 
 
 
 
 
 
 
 
F 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 2.5. B3LYP/6-311g (d,p) optimized geometry for the methylene analog. ∟C2-C3-C4 angle com-
pression and subsequent strengthening of H-bond could be achieved by substituting hydrogen on C3 
methylene with the bulky substituents (Thorpe-Ingold Effect). 
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2.5 Experimental 
2.5.1   Computational methods 
        All geometries were optimized using the Density Functional Theory (DFT) at B3LYP level with 6-
311G (d,p) which performed well for the organic compounds. Gaussian 03, Revision E.01, M. J. Frisch, 
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K. Raghavachari, J. B. Foresman, J. V. Ortiz, Q. Cui, A. G. Baboul, S. Clifford, J. Cioslowski, B. B. 
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Laham, C. Y. Peng, A. Nanayakkara, M. Challacombe, P. M. W. Gill, B. Johnson, W. Chen, M. W. 
Wong, C. Gonzalez, and J. A. Pople, Gaussian, Inc., Wallingford, CT, 2003. 
 
Table 2.5. Cartesian coordinates for structures  
Structure - 37b (1) 
Total Energy (gas-phase): -2705.814  
Total Energy (Water): -2706.285 
 
C  0.905   -1.840     0.061 
C  -1.072   -2.704    0.097 
N  -0.425   -1.508    0.093 
H  -0.925   -0.621    0.074 
S   -2.817   -2.990    0.148 
C  -3.575   -1.386    0.047 
N  -2.856   -0.261    0.012 
C  -4.980   -1.371    0.017 
C  -3.541    0.895   -0.057 
C  -5.555   -0.111   -0.049 
H  -5.573   -2.275    0.043 
N  -4.867    1.024   -0.089 
N  -0.223   -3.709    0.077 
N  1.033   -3.156    0.056 
S   -2.515    2.330  -0.108 
Cl  -7.297    0.028   -0.090 
C   2.008   -0.880    0.035 
C   1.785    0.500    0.089 
C   3.324   -1.359   -0.058 
C   2.860    1.387    0.045 
H   0.781    0.902    0.157 
C   4.389   -0.464   -0.100 
H   3.493   -2.428   -0.108 
Structure - 37b (2) 
Total Energy (gas-phase): -2705.802  
Total Energy (Water): -2706.285 
 
C   0.899   -0.289   -0.534 
C  -1.121   -1.091   -0.628 
N   0.151   -1.401   -0.226 
H   0.437   -2.234    0.265 
S   -2.454   -2.230   -0.425 
C  -3.836   -1.095   -0.192 
N  -3.716   -0.125    0.701 
C   -5.00    -1.34     -0.909 
C   -4.795   0.650    0.874 
C   -6.062  -0.486   -0.606 
H   -5.086  -2.128   -1.652 
N   -5.982    0.505    0.262 
N   -1.160    0.119   -1.137 
N    0.115    0.622   -1.075 
S    -4.577    1.950   2.045 
Cl  -7.597   -0.702   -1.424 
C    2.337   -0.138   -0.312 
C    3.126   -1.172    0.207 
C    2.942    1.086   -0.631 
C    4.493   -0.982    0.406 
H    2.695  -2.134    0.464 
C    4.306    1.266   -0.426 
H    2.330    1.882   -1.040 
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 C  4.167    0.913  -0.051 
 H  4.999    1.605  -0.104 
 C  5.804   -0.986  -0.149 
 C  2.612    2.870    0.156 
 F  6.324   -1.112   1.091 
 F  6.616  -0.150   -0.834 
 F  5.872   -2.197  -0.736 
 F  3.510    3.580   -0.557 
 F   1.379    3.207  -0.284 
 F   2.702    3.291   1.438 
 C -3.753    3.668   -0.191 
 H -4.390    3.656   0.693 
 H -3.177    4.594   -0.226 
 H -4.363   3.570   -1.089 
C    5.092    0.236    0.093 
H    6.154    0.382    0.251 
C    4.930    2.609   -0.714 
C    5.340   -2.126    0.902 
F    4.351    3.209   -1.773 
F    6.251    2.499   -0.974 
F    4.800    3.446    0.338 
F    6.388   -1.692    1.632 
F    4.626   -2.976    1.674 
F    5.841   -2.851   -0.122 
C  -6.220    2.743    2.019 
H  -6.995    2.040    2.325 
H  -6.158    3.566    2.734 
H  -6.448    3.130    1.026 
       Structure – 36d (1) 
Total Energy (gas-phase): -2110.386 
Total Energy (Water): -2110.665 
 
C   2.140   -1.430   -0.001 
C   0.203   -2.391    0.005 
N   0.792   -1.164    0.015 
H   0.263   -0.297    0.023 
S  -1.522   -2.78      0.025 
C  -2.385   -1.234    0.009 
N  -1.748   -0.059    0.009 
C  -3.790   -1.317    0.002 
C  -2.517    1.043   -0.000 
C  -4.455   -0.102   -0.005 
H  -4.317   -2.262    0.001 
N  -3.850    1.081   -0.006 
N   1.098   -3.352   -0.013 
N   2.329   -2.738   -0.017 
S  -1.606    2.556   -0.001 
Cl -6.204  -0.084   -0.014 
C   3.195  -0.414   -0.000 
C   2.900    0.956    0.007 
C   4.534   -0.830   -0.015 
C   3.922    1.909    0.002 
H   1.869    1.299    0.012 
C   5.572   0.102   -0.021 
H   4.747   -1.894  -0.028 
C   5.249    1.464   -0.016 
H   6.052    2.201   -0.030 
C   7.014   -0.346   -0.013 
C   3.601   3.385     0.038 
C  -2.947    3.794  -0.013 
H  -3.569   3.694    0.875 
H  -2.448    4.765   -0.014 
H  -3.560    3.687  -0.908 
H  2.596     3.586   -0.344 
H  3.645    3.775    1.063 
H  4.313    3.963   -0.558 
H  7.643    0.315   -0.616 
H  7.422   -0.342    1.005 
H  7.117   -1.362   -0.402 
         Structure – 36d (2) 
Total Energy (gas-phase): -2110.375  
Total Energy (Water): -2110.664 
 
C  -2.291   -0.321    0.387 
C  -0.288   -1.149    0.171 
N -1.56   -1.247    -0.323 
H -1.861   -1.793   -1.115 
S   1.021   -2.156   -0.456 
C   2.434   -1.064   -0.234 
N   2.349    0.190   -0.654 
C   3.600   -1.617   0.305 
C   3.452    0.936   -0.509 
C   4.681   -0.740    0.363 
H   3.655   -2.634    0.667 
N   4.634    0.521   -0.024 
N  -0.227   -0.234   1.109 
N  -1.493   0.288    1.243 
S    3.277    2.607   -1.047 
Cl   6.210   -1.315   1.002 
C   -3.723   -0.068   0.216 
C  -4.539   -0.924   -0.537 
C  -4.287    1.057    0.830 
C  -5.904   -0.667   -0.687 
H  -4.125   -1.819   -0.996 
C  -5.650    1.335    0.695 
H  -3.644    1.707    1.414 
C  -6.441    0.466   -0.065 
H  -7.504    0.674   -0.172 
C  -6.248    2.567    1.332 
C  -6.788   -1.593  -1.489 
C   4.945   3.271    -0.719 
H   5.698    2.731   -1.293 
H   4.911    4.315   -1.038 
H  5.182    3.215     0.342 
H  -6.181    3.431   0.659 
H  -7.305    2.421    1.570 
H  -5.724    2.833    2.254 
H  -7.279   -1.060   -2.312 
H  -6.217   -2.419   -1.921 
H  -7.580   -2.024   -0.867 
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Structure-39a 
Total Energy (gas-phase): -2363.004  
  
 C  0.809   -1.687    0.053 
 C -1.227   -2.406   0.078 
 N -0.501   -1.259   0.049 
 H -0.929   -0.340   0.014 
 C -3.509   -1.449   0.040 
 N -3.035   -0.194  -0.006 
 C -4.894   -1.720   0.044 
 C -3.946    0.789  -0.051 
 C -5.710   -0.606  -0.004 
 H -5.290   -2.727   0.081 
 N -5.273    0.649  -0.052 
 N -0.451   -3.470   0.102 
 N  0.841   -3.005   0.085 
 S  -3.247    2.410  -0.114 
 Cl-7.448   -0.826  -0.003 
 C  1.983   -0.817   0.025 
 C  1.877    0.578   0.058 
 C  3.257   -1.404  -0.043 
 C  3.024    1.371   0.017 
 H  0.910    1.065   0.107 
 C  4.394   -0.603  -0.083 
 H  3.336   -2.484  -0.075 
 C  4.288    0.789  -0.055 
 H  5.176    1.407  -0.105 
 C  5.762   -1.241  -0.107 
 C  2.901   2.871     0.109 
 F   6.256   -1.390   1.141 
 F   6.646   -0.488  -0.796 
 F   5.734  -2.464  -0.674 
 F   3.859   3.495   -0.606 
 F   1.703   3.304   -0.341 
 F   3.020   3.298    1.387 
 C -4.740    3.457   -0.168 
 H -5.344    3.311    0.726 
 H -4.374    4.484   -0.211 
 H -5.334    3.233   -1.054 
 N -2.609   -2.481    0.084 
 H -2.958   -3.430    0.112 
 Potential O-containing compd. 
Total Energy (gas-phase): -2382.846 
 
C   0.780   -1.661    0.052 
 C -1.255   -2.367    0.079 
 N -0.523   -1.219    0.053 
 H -0.939   -0.296    0.019 
 C  -3.462  -1.412    0.042 
 N  -3.007   -0.166  -0.009 
 C  -4.825   -1.736   0.053 
 C  -3.942    0.802  -0.056 
 C  -5.673   -0.642   0.002 
 H  -5.168  -2.760    0.096 
 N  -5.263    0.622  -0.053 
 N  -0.499   -3.434   0.096 
 N   0.798   -2.980   0.079 
 S  -3.282    2.436   -0.129 
 Cl -7.401   -0.901  0.008 
 C  1.965    -0.803   0.026 
 C  1.876    0.593    0.061 
 C  3.231  -1.407    -0.045 
 C  3.032   1.372     0.021 
 H  0.915    1.092    0.112 
 C  4.377   -0.620   -0.083 
 H  3.296   -2.488   -0.079 
 C  4.289    0.773   -0.053 
 H  5.184    1.380   -0.103 
 C  5.736   -1.274   -0.110 
 C  2.927    2.872    0.116 
 F  6.230   -1.432    1.137 
 F  6.630   -0.529  -0.798 
 F   5.694  -2.495  -0.680 
 F   3.890   3.486  -0.602 
 F  1.733    3.320  -0.331 
 F  3.052   3.296    1.393 
 C  -4.800   3.446  -0.185 
 H  -5.398   3.292   0.712 
 H  -4.458   4.481  -0.236 
 H  -5.390   3.202  -1.069 
 O  -2.610  -2.464   0.090 
Potential NH-containing compd. 
Total Energy (gas-phase): -2346.954 
 
 C  -0.752   -1.695   -0.429 
 C   1.254   -2.411   -0.847 
 N   0.505   -1.274   -0.778 
 H   0.901   -0.345   -0.867 
 C   3.562   -1.373   -0.610 
 N   3.094   -0.116   -0.651 
 C   4.806   -1.670   -0.049 
 C   3.874    0.842    -0.132 
 C   5.520   -0.582    0.449 
 H   5.193   -2.679    -0.009 
 N   5.0830   0.665   0.418 
 N   0.513    -3.464  -0.575 
 
 
 
 C   -2.968     1.350   -0.119 
 H   -0.903    1.051   -0.590 
 C   -4.262   -0.624    0.340 
 H   -3.194   -2.497    0.225 
 C   -4.185    0.765    0.221 
 H   -5.056    1.381    0.407 
 C   -5.589   -1.267    0.654 
 C   -2.877    2.843   -0.306 
 F   -6.306   -1.488   -0.471 
 F   -6.344   -0.481    1.453 
 F   -5.439   -2.456    1.271 
 F   -3.773    3.500    0.458 
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 N  -0.756   -3.011   -0.314 
 S    3.187    2.466    -0.215 
 Cl  7.09     -0.848    1.169 
 C  -1.914   -0.830   -0.219 
 C -1.837     0.562   -0.339 
 C -3.141    -1.419    0.124 
 
 F   -1.648   3.311   0.005 
 F   -3.117   3.196   -1.590 
 C   4.480   3.460    0.602 
 H   5.422   3.390   0.057 
 H   4.113   4.488   0.583 
 H   4.624   3.133    1.632 
 C   2.701   -2.450   -1.237 
 H   3.081  -3.444   -0.991 
 H   2.784  -2.339    -2.329 
 
2.5.2 General chemical methods: 
             All chemical reagents and solvents used were reagent grade or purified using standard methods. 
TLC analyses were conducted on silica gel plates (Sorbent Silica G UV254).Column chromatography was 
carried out on flash silica gel (Sorbent 230–400 mesh). NMR spectra were recorded at 1H (400 MHz) and 
13
C (100 MHz) on a Bruker instrument. Coupling constants (J) and chemical shifts (δ) are given in hertz 
and ppm respectively, using TMS (
1
H NMR) and solvents (
13
C NMR) as internal standards. 
General synthetic procedure for 31a-c: To a mixture of benzoyl chloride (5mmol, 1 equiv) in anhy-
drous tetrahydrofuran (25 mL) was slowly added hydrazinecarboamide at 0~5
°
C. Then, the reaction mix-
ture was brought to ambient temperature and stirred overnight. The reaction was quenched with saturated 
sodium carbonate solution, and mixture was extracted with ethyl acetate (15 ml  2) and washed by brine 
(10 ml  2). The solvent was evaporated in vacuo and the crude product was used directly for next step.  
General synthetic procedure for 32a-c: Crude product 31a-c (5mmol) was added in 5% sodium hydrox-
ide solution (50 mL) and the mixture was heated to reflux for 5-6 h. Then 2N Hydrochloride acid was 
added to adjust the pH of the mixture to ~5, and the precipitated white solid was filtered and washed with 
warm water for (20 ml  4). The white solid was dried under vacuum at room temperature to give pure 
32a-c (65-80% for two steps). 
5-(3, 5-Dimethylphenyl)-4H-1, 2, 4-triazole-3-thiol (32a): Yield: 65%; 
1
H NMR (DMSO-d6) δ 13.71 (s, 
1H), 13.62 (s, 1H), 7.54 (s, 2H), 7.14 (s, 1H), 2.31 (s, 6H); 
13
C NMR (DMSO-d6) δ 167.3, 150.8, 138.7, 
132.4, 125.7, 123.8, 21.2. 205.0. ESI-MS (+): Calc. for C10H11N3S [M+H]
+
: 206.0; found: 206.2. 
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5-(3, 5-Bis (trifluoromethyl) phenyl)-4H-1, 2, 4-triazole-3-thiol (32b):  Yield: 72%;  
1
H NMR (DMSO-
d6): δ 14.16 (br, 1H), 13.97 (s, 1H), 8.53 (s, 2H), 8.26 (s, 1H); 
13
C NMR (DMSO-d6): δ 168.1, 148.3, 
131.8, 131.4, 128.3, 126.5, 124.7, 124.3, 122.0. ESI-MS (+): Calc. for C10H5N3F6S [M+H]
+
: 314.0; found: 
314.4. 
5-(3, 5-Bis (trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-amine (32c):   Yield: 80%;  
1
H NMR (DMSO-
d6): δ 8.38 (s, 2H), 8.06 (s, 1H), 6.33 (s, 2H); 
13
C NMR (DMSO-d6): δ 158.6, 156.1, 135.0, 131.3, 131.0, 
125.5, 125.0, 122.3, 121.9. ESI-MS (+): Calc. for C10H6N4F6 [M+H]
+
: 297.0; found: 297.0. 
General synthetic procedure for 34a-q: To a solution of 2, 4, 6 trichloropyrimidine (1.30 mmol) in THF 
(8 ml), appropriate R-NH2/R-SH/R-OH (1.35 mmol) was slowly added at 0 to -5°C and stirred for 4-5 h. 
Then, the reaction was stirred at room temperature for 2-3 h and monitored using TLC. Upon completion, 
THF was removed in vacuo and dried residue was dissolved in ethyl acetate (20 mL), washed with water 
(15 ml  2) and brine (15 ml  2). The solvent was evaporated in vacuo to obtain crude product, which 
was purified using silica gel column chromatography. Yields: 70-85% 
4,6-Dichloro-2-(piperidin-1-yl)pyrimidine (34a):  Yield: 72%;  
1
H NMR (CDCl3): δ 6.46 (s, 1H), 3.79 
(d, J = 4.0 Hz, 4H), 1.61-1.67 (m, 6H); 
13
C NMR (CDCl3): δ 163.3, 162.0, 105.4, 55.8, 25.4, 24.6. ESI-
MS (+): Calc. for C9H11N3Cl2 [M+H]
+
: 232.0; found: 232.4. 
4,6-Dichloro-N-cyclopentylpyrimidin-2-amine (34b): Yield: 75%; 
1
H NMR (CDCl3): δ 6.51 (s, 1H), 
3.63 (d, J = 4.0 Hz, 2H), 3.33 (d, J = 4.0 Hz, 2H), 2.67 (m, 1H). 2.03 (m, 4H); 
13
C NMR (CDCl3): δ 
167.2, 162.4, 110.5, 55.2, 26.5. ESI-MS (+): Calc. for C9H11N3Cl2 [M+H]
+
: 232.0; found: 232.6. 
4,6-Dichloro-N-(prop-2-yn-1-yl)pyrimidin-2-amine (34c): Yield: 82%;  
1
H NMR (CDCl3): δ 7.10 (s, 
1H), 4.20 (br, 1H), 4.13 (d, J = 8.0 Hz, 2H), 3.33 (d, J = 4.0 Hz, 2H), 2.55 (s, 1H); 
13
C NMR (CDCl3): δ 
163.5, 161.2, 111.5, 80.2, 71.2, 35.8. ESI-MS (-): Calc. for C7H5N3Cl2 [M-H]
+
: 199.9; found: 199.8. 
[M+H]
+ 
4,6-Dichloro-N-cyclobutylpyrimidin-2-amine (34d): Yield: 70%; 
1
H NMR (CDCl3): δ 6.57 (s, 1H), 
5.63 (s, 1H), 4.45 (m, J = 8.0 Hz, 1H), 2.41 (m, 2H), 1.68-1.94 (m, 4H); 
13
C NMR (CDCl3): δ 167.4, 
162.3, 111.5, 65.5, 32.5, 15.8. ESI-MS (-): Calc. for C8H9N3Cl2 [M-H]
+
: 216.0; found: 216.2. 
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4-(4,6-Dichloropyrimidin-2-yl)morpholine (34e): Yield: 75%;  
1
H NMR (CDCl3): δ 6.54 (s, 1H), 3.79 
(t, J = 12.0 Hz, 2H), 3.72 (t, J = 12.0 Hz, 2H); 
13
C NMR (CDCl3): δ 161.7, 160.5, 108.2, 66.5, 44.3. ESI-
MS (+): Calc. for C8H9N3Cl2O [M+H]
+
: 234.0; found: 234.1. 
4,6-Dichloro-2-(pyrrolidin-1-yl)pyrimidine (34f): Yield: 68%;  
1
H NMR (CDCl3): δ 6.20 (s, 1H), 3.63 
(d, J = 4.0 Hz, 2H), 3.33(d, J = 4.0 Hz, 2H), 2.03 (m, 4H); 
13
C NMR (CDCl3): δ 167.2, 162.4, 110.5, 55.2, 
26.5. ESI-MS (+): Calc. for C8H9N3Cl2 [M+H]
+
: 217.0; found: 218.4. 
4,6-Dichloro-N-(2-(trifluoromethyl)benzyl)pyrimidin-2-amine (34g): Yield: 75%;  
1
H NMR (CDCl3): 
δ 7.69 (d, J = 8.0 Hz, 1H), 7.61 (d, J = 8.0 Hz, 1H), 7.53 (t, 1H), 7.41 (t, J = 8.0 Hz, 1H), 6.66 (s, 1H), 
5.91 (br, 1H),  4.81 (d, J = 8.0 Hz, 2H); 
13
C NMR (CDCl3): δ 163.4, 161.4, 135.0, 132.2, 130.2, 127.7, 
126.2, 126.2, 126.1, 109.6, 42.1. ESI-MS (-): Calc. for C12H8F3N3Cl2 [M-H]
+
: 320.0; found 320.0. 
4,6-Dichloro-2-((4-methoxyphenyl)thio)pyrimidine (34h): Yield: 67%; 
1
H NMR (CDCl3): δ 7.48 (d, J 
= 8.0 Hz, 2H), 7.02 (d, J = 8.0 Hz, 2H), 6.54 (s, 1H), 3.87 (s, 3H ); 
13
C NMR (CDCl3): δ 173.4, 163. 5, 
158.4, 125.8, 123.4, 118.5, 112.3, 54.4. ESI-MS (-): Calc. for C11H8N2Cl2OS [M-H]
+
: 285.9; found: 287.0.  
4,6-Dichloro-N-(2-methoxybenzyl)pyrimidin-2-amine (34i): Yield: 75%; 
1
H NMR (CDCl3): δ 7.22 (d, 
J = 8.0 Hz, 1H), 7.13 (s, 1H), 6.85 (m, 3H), 6.75 (s, 1H), 4.62 (s, 2H), 3.84 (s, 3H); 
13
C NMR (CDCl3):  δ 
163.4, 161.2, 155.2, 128.4, 118.6, 113.4, 112.4, 55.3, 45.4. ESI-MS (-): Calc. for C12H11N3Cl2O [M-H]
+
: 
282.0; found: 282.4. 
4,6-Dichloro-2-(p-tolylthio)pyrimidine (34k): Yield: 70%;  
1
H NMR (CDCl3): δ 7.47 (d, J = 8.0 Hz, 
2H), 7.33 (d, J = 8.0 Hz, 2H), 6.58 (s, 1H), 2.45 (s, 1H); 
13
C NMR (CDCl3):  δ 172.4, 163.3, 138.4, 128.4, 
128.3, 118.3, 22.3. ESI-MS (-): Calc. for C11H8N2Cl2S [M+H]
+
: 271.0; found: 271.3. 
 4,6-Dichloro-2-((1,4,5,6-tetrahydropyrimidin-2-yl)thio)pyrimidine (34l): Yield: 75% 
1
H NMR 
(CDCl3): δ 8.40 (s, 1H), 4.06 (t, 2H), 3.47 (t, 2H), 2.18-2.21 (m, 2H); 
13
C NMR (CDCl3):  δ 164.5, 159.2, 
120.4, 46.5, 42.4, 22.7. ESI-MS (-): Calc. for C8H8N4Cl2S [M+H]
+
: 262.9; found 263.0 
4-(2, 6-Dichloropyrimidin-4-yl)morpholine (34n): Yield: 68%; 
1
H NMR (CDCl3): δ 6.35 (s, 1H), 3.12-
3.68 (m, 8H); 
13
C NMR (CDCl3): δ 163.3, 160.7, 160.4, 99.8, 66.3, 44.3. ESI-MS: 234.4 [M+H]
+
 
ESI-MS (-): Calc. for C8H9N3Cl2O [M+H]
+
: 234.0; found: 234.4 
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2,4-Dichloro-6-(piperidin-1-yl)pyrimidine (34o): Yield: 70%; 
1
H NMR (CDCl3): δ 6.37 (s, 1H), 3.58 
(br, 4H), 1.60-1.68 (m, 6H); 
13
C NMR (CDCl3): δ 162.6, 160.1, 159.7, 99.5, 45.6, 25.4, 24.2. ESI-MS (-): 
Calc. for C9H12N3Cl2 [M+H]
+
: 232.0; found: 232.2.
 
General synthetic procedure for 36a-d and 37a-q: To a solution of 32a or 32b-c (1.5 mmol) in acetone 
(8 ml), were added 35 or 34a-q respectively (1.5 mmol), followed by addition of potassium carbonate (3 
mmol) and stirred at room temperature. Then, the reaction was monitored by TLC and upon completion, 
the solvent removed in vacuo. The dried residue was dissolved in ethyl acetate (20 mL) and washed with 
water (15 ml  2) and brine (15 ml  2). The solvent was evaporated in vacuo to obtain crude product, 
which was purified using silica gel column chromatography. Yields: 65-80% 
4-Chloro-6-((3-(3, 5-dimethylphenyl)-1H-1,2,4-triazol-5-yl)thio)pyrimidine  (36a): Yield: 68%; 
1
H 
NMR (DMSO-d6): δ 15.07 (br, 1H), 8.84 (s, 1H), 7.66 (s, 2H), 7.53 (s, 1H), 7.18 (s, 1H), 2.35 (s, 6H); 
13
C 
NMR (DMSO-d6): δ 160.4, 158.7, 138.8, 124.4, 118.0, 21.3. HRMS-ESI (+): Calc. for C14H12N5SCl 
[M+H]
+
: 318.0572; found: 318.0580.  
4-Chloro-6-((3-(3, 5-dimethylphenyl)-1H-1, 2, 4-triazol-5-yl)thio)-2-(phenylthio)pyrimidine (36b): 
Yield: 75%; 
1
H NMR (MeOD): δ 7.56 (m, 2H), 7.38 (m, 2H), 7.17 (m, 5H), 2.40 (s, 6H); 13C NMR 
(MeOD): δ 172.5, 170.7, 159.9, 138.7, 138.6, 134.7, 132.1, 129.1, 128.6, 127.7, 126.4, 123.9, 123.8, 
112.8, 20.0. HRMS-ESI (+): Calc. for C20H16ClN5S2 [M+H]
+
: 426.0625; found: 426.0612.  
4-((3-(3, 5-Dimethylphenyl)-1H-1, 2, 4-triazol-5-yl) thio)-2-(methylthio) pyrimidine (36c): Yield: 
78%;  
1
H NMR (DMSO-d6): δ 8.78 (d, J = 5.2 Hz, 1H), 8.60 (d, J = 5.2 Hz, 1H), 7.92 (d, 1H, J = 5.2 Hz), 
7.62 (m, 2H), 7.11 (s, 1H), 2.61 (s, 3H), 2.34 (s, 6H); 
13
C NMR (DMSO-d6): δ 166.1, 160.5, 157.9, 138.4, 
132.4, 124.4, 116.9, 21.3, 14.2, 13.9. HRMS-ESI (+): Calc. for C15H15N5S2 [M+H]
+
: 330.0847; found: 
330.0841.  
4-Chloro-6-((3-(3, 5-dimethylphenyl)-1H-1,2,4-triazol-5-yl)thio)-2-(methylthio)pyrimidine (36d): 
Yield: 80%; 
1
H NMR (DMSO-d6): δ 15.06 (br, 1H), 7.64 (s, 2H), 7.15 (s, 2H), 2.37 (s, 3H), 2.34 (s, 6H); 
13
C NMR (DMSO-d6): δ 172.5, 160.0, 138.8, 132.5, 124.3, 112.7, 60.2, 21.3, 14.0. HRMS-ESI (+): Calc. 
for C15H14N5S2Cl [M+H]
+
: 364.0457; found: 364.0457. 
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4-((5-(3,5-Bis(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-yl)thio)-6-chloropyrimidine (37a): Yield: 
72%;  
1
H NMR (DMSO-d6): δ 15.52 (br, 1H), 8.85 (s, 1H), 8.61 (s, 2H), 8.31 (s, 1H), 7.66 (s, 1H); 
13
C 
NMR (DMSO-d6): δ 160.6, 158.8, 132.1, 131.8, 131.5, 131.1, 126.8, 124.8, 124.0, 122.1, 118.3. HRMS-
ESI (+): Calc. for C14H6ClF6N5S [M+H]
+
: 426.0020; found: 426.0027. 
4-((5-(3,5-Bis(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-yl)thio)-6-chloro-2-(methylthio)pyrimidine 
(37b): Yield: 68%; 
1
H NMR (DMSO-d6): δ 15.50 (br, 1H), 8.57 (s, 2H), 8.25 (s, 1H), 7.28 (s, 1H), 2.34 
(s, 3H); 
13
C NMR (DMSO-d6): δ 172.7, 160.1, 131.8, 131.5, 131.1, 126.7, 124.8, 122.1, 113.0, 14.0. 
HRMS-ESI (+): Calc. for C15H8N5S2F6Cl [M+H]
+
: 471.9874; found: 471.9856  
4-((5-(3,5-Bis(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-yl)thio)-6-chloro-2-(piperidin-1-
yl)pyrimidine (37c): Yield: 71%;   
1
H NMR (CDCl3): δ 8.61 (s, 2H), 7.93 (s, 1H), 6.43 (s, 1H), 3.72 (br, 
4H), 1.63-1.69 (m, 6H); 
13
C NMR (CDCl3):  δ 165.4, 161.1, 160.4, 160.0, 147.7, 132.7, 132.3, 132.2, 
132.0, 131.7, 127.2, 126.5, 124.5, 123.0, 121.8, 119.1, 105.2, 45.4, 25.5, 24.3. HRMS-ESI (-): Calc. for 
C19H14ClF6N6S [M-H]
-
: 507.0593; found: 507.0596.  
 4-((5-(3,5-Bis(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-yl)thio)-6-chloro-N-cyclopentylpyrimidin-
2-amine (37d): Yield: 75%; 
1
H NMR (DMSO-d6): δ 8.57 (s, 2H), 8.27 (s, 1H), 7.89 (s, 1H), 1.48-1.85 
(m, 9H); 
13
C NMR (DMSO-d6):  δ 160.8, 160.6, 160.0, 132.1, 131.8, 131.5, 131.1, 127.5, 126.6, 124.8, 
123.8, 122.1, 119.4, 104.6, 53.0, 52.8, 32.3, 31.9, 23.7, 23.4. HRMS-ESI (+): Calc. for C19H15ClF6N6S
 
[M+H]
+
: 509.750; found: 509.0760  
4-((5-(3,5-Bis(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-yl)thio)-6-chloro-N-(prop-2-yn-1-yl) py-
rimidin-2-amine (37e): Yield: 74%;  
1
H NMR ((CD3)2CO): δ 8.64 (s, 2H), 8.07 (s, 1H), 6.70 (s, 1H), 
4.15 (d, J = 8.0 Hz, 2H), 2.53 (s, 1H); 
13
C NMR (CD3)2CO):  δ 168.6, 160.8, 158.9, 147.5, 132.4, 132.1, 
131.8, 131.4, 127.3, 126.3, 124.6, 122.8, 121.9, 119.2, 106.2, 80.0, 71.3, 70.2, 36.4. HRMS-ESI (-): Calc. 
for C17H9ClF6N6S [M-H]
-
: 477.0124; found: 477.0121 
 4-((5-(3,5-Bis(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-yl)thio)-6-chloro-N-cyclobutylpyrimidin-
2-amine (37f): Yield: 75%;  
1
H NMR (CDCl3): δ 8.61 (d, J = 8.0 Hz, 2H), 7.93 (s, 1H), 6.66 (s, 1H), 2.55 
(br, 2H), 2.00 (br, 4H).HRMS-ESI (-): Calc. for C18H13ClF6N6S[M-H]
-
: 493.0437; found: 493.0456.  
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 4-(4-((5-(3,5-Bis(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-yl)thio)-6-chloropyrimidin-2-
yl)morpholine (37g): Yield: 70%; 
1
H NMR (CDCl3): δ 8.60 (s, 2H), 7.95 (s, 1H), 6.53 (s, 1H), 3.77 (s, 
8H); 
13
C NMR (CDCl3):  δ 166.1, 161.3, 160.7, 160.2, 147.2, 132.8, 132.4, 132.1, 132.0, 131.8, 127.2, 
126.4, 124.4, 123.2, 123.1, 121.7, 119.0, 106.3, 66.4, 44.4. HRMS-ESI (-): Calc. for C18H13ClF6N6OS 
[M-H]
-
: 509.0386; found: 509.0386. 
4-((3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)thio)-6-chloro-2-(pyrrolidin-1-
yl)pyrimidine (37h): Yield: 72%;  
1
H NMR (CDCl3): δ 8.60 (s, 2H), 7.92 (s, 1H), 6.60 (s, 1H), 3.67-3.75 
(s, 4H), 2.06 - 2.17(m, 4H), 5.43 (s, 2H), 3.78 (s, 6H), 2.24 (s, 3H); 
13
C NMR (CDCl3):  δ 164.5, 160.8, 
159.9, 158.5, 148.8, 132.5, 132.3, 131.9, 126.4, 124.5, 122.9, 121.8, 105.4, 47.4, 47.1, 25.5, 25.2. HRMS-
ESI (-): Calc. for C18H13ClF6N6S [M-H]
-
: 493.0437; found: 493.0435. 
4-((3-(3, 5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)thio)-6-chloro-2-phenoxypyrimidine  
(37i): Yield: 75%;  
1
H NMR (DMSO-d6): δ 15.52 (br, 1H), 8.56 (m, 3H), 7.49 (m, 7H); 
13
C NMR 
(DMSO-d6): δ 170.4, 163.5, 161.7, 158.8, 152.2, 151.9, 131.8, 131.4, 130.4, 129.7, 126.8, 125.7, 124.8, 
124.1, 122.0, 121.7, 112.7, 107.6, 103.0. HRMS-ESI (+): Calc. for C20H10ClF6N5OS [M+H]
+
: 518.0277; 
found: 518.0289. 
4-((3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)thio)-6-chloro-2-((4methoxyphenyl)thio) 
pyrimidine (37k): Yield: 70%;  
1
H NMR ((CD3)2CO): δ 8.61 (s, 2H), 8.23 (s, 1H), 7.41 (t, J = 8.0 Hz, 
2H), 6.76 (d, J = 8.0 Hz, 2H), 6.23 (s, 1H), 3.55 (s, 3H); 
13
C NMR ((CD3)2CO:  δ 177.1, 161.5, 159.0, 
137.1, 132.2, 131.9, 131.5, 126.1, 124.7, 123.5, 122.0, 116.5, 115.6, 110.5, 54.8. HRMS-ESI (-): Calc. for 
C21H12ClF6N5OS22 [M-H]
-
: 561.9998; found: 561.9986  
4-((3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)thio)-6-chloro-N-(2-methoxybenzyl) py-
rimidin-2-amine (37l): Yield: 68%;   
1
H NMR (CDCl3): δ 8.55 (s, 2H), 7.92 (s, 1H), 7.30 (t, J = 8.0 Hz, 
3H), 6.93 (d, 2H), 6.69 (s, 1H), 4.55 (d, J = 4.0 Hz, 2H), 3.80 (s, 3H); 
13
C NMR (CDCl3):  δ 160.8, 159.9, 
159.4, 132.6, 132.3, 132.3, 131.9, 131.6, 126.4, 124.5, 122.9, 121.8, 114.5, 113.8, 107.5, 55.3, 45.4. 
HRMS-ESI (-): Calc. for C22H15ClF6N6O6S [M-H]
-
: 559.0543; found: 559.0540  
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4-((3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)thio)-6-chloro-N-cyclohexylpyrimidin-
2-amine (37m): Yield: 70%; 
1
H NMR (CDCl3): δ 8.56 (s, 2H), 7.93 (s, 1H), 6.44 (s, 1H), 4.19 (s, 1H), 
3.83 (s, 1H), 1.36-2.06 (m, 10H); 
13
C NMR (CDCl3):  δ 160.8, 160.6, 160.0, 132.1, 131.8, 131.5, 131.1, 
127.5, 124.8, 122.1, 119.4, 53.0, 33.9, 23.7, 23.4. HRMS-ESI (-): Calc. for C20H17ClF6N6S [M-H]
-
: 
521.0750; found: 521.0745.  
4-((3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)thio)-6-chloro-2-(p-tolylthio)pyrimidine  
(37n): Yield: 74%;  
1
H NMR ((CD3)2CO): δ 8.57 (s, 2H), 7.94 (s, 1H), 7.46 (d, J = 8.0 Hz, 2H), 7.30 (d, J 
= 8.0 Hz, 2H), 6.5 (s, 1H), 2.39 (s, 3H); 
13
C NMR ((CD3)2CO):  δ 176.3, 158.7, 141.0, 135.6, 132.0, 
131.6, 130.9, 127.4, 126.8, 124.8, 124.5, 122.5, 122.1, 110.7, 20.5. HRMS-ESI (-): Calc. for 
C21H12ClF6N5S2 [M-H]
-
: 546.0049; found: 546.0047.  
4-((3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)thio)-6-chloro-2-(pyrimidin-2-
ylthio)pyrimidine (37o): Yield: 70%;  
1
H NMR (CDCl3): δ 8.67 (d, J = 4.0 Hz, 2H), 8.59 (s, 2H), 8.30 
(s, 1H), 7.93 (s, 1H), 7.28 (s, 1H); 
13
C NMR (CDCl3):  δ 172.0, 169.7, 167.0, 160.2, 159.1, 158.0, 146.5, 
132.7, 132.4, 132.0, 132.0, 131.7, 127.1, 126.5, 126.4, 124.4, 123.1, 121.7, 119.5, 119.0, 116.2. HRMS-
ESI (-): Calc. for C18H8ClF6N7S2 [M-H]
-
: 533.9797; found: 533.9797. 
 
4-((3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)thio)-6-chloro-2-(phenylthio)-
pyrimidine (37q): Yield: 75%;  
1
H NMR (DMSO-d6) δ 15.34 (br, 1H), 8.58 (s, 2H), 8.29 (s, 1H), 7.44 
(m, 3H), 7.20 (m, 2H), 7.11 (m, 1H); 
13
C NMR (DMSO-d6): δ 171.8, 160.1, 135.1, 132.1, 131.8, 131.4, 
129.7, 127.7, 126.8, 124.8, 124.0, 122.1, 114.1. HRMS-ESI (+): Calc. for C20H10ClF6N5S2 [M+H]
+
: 
534.0049; found: 534.0062.  
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General synthetic procedure for 38a-h and 39: To a solution of 32b (1.5 mmol) in acetone/DMF (10 
ml), was slowly added R-NH2 (1.5 mmol) at room temperature and stirred. The reaction was monitored 
using TLC and on completion the solvent was removed in vacuo. The dried residue was dissolved in ethyl 
acetate (15-20 mL), washed with water (15 ml  2) and brine (10 ml  2). The solvent was evaporated in 
vacuo to obtain crude product, which was purified using silica gel column chromatography. Yields: 65-
75% 
4-((3-(3, 5-Bis (trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)thio)-2-(methylthio)pyrimidine (38a): 
Yield: 75%; 
1
H NMR (CDCl3): δ 13.34 (br, 1H), 8.60 (s, 2H), 8.39 (d, J = 5.6 Hz, 1H), 7.93 (s, 1H), 7.01 
(d, J = 5.6 Hz, 1H), 2.57 (s, 3H); 
13
C NMR (CDCl3): δ 173.3, 164.7, 160.1, 156.2, 132.3, 132.2, 132.0, 
126.4, 124.5, 123.0, 121.8, 114.0, 14.2. HRMS-ESI (+): Calc. for C15H10F6N5S2 [M+H]
+
: 438.0282; 
found: 438.0280. 
4-Azido-6-((3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)thio)-2-(methythio)pyrimidine 
(38b): Yield: 72%; 
1
H NMR (CDCl3): δ 8.60 (s, 2H), 7.93 (s, 1H), 6.53 (s, 1H), 2.65 (s, 3H); 
13
C NMR 
(CDCl3): δ 174.3, 165.0, 161.6, 159.9, 147.7, 132.7, 132.32, 131.9, 131.6, 126.4, 122.8, 102.5, 14.2. 
HRMS-ESI (-): Calc. for C15H8F6N8S2
 
[M-H]
-
: 477.0139; found: 477.0139.  
6-((3-(3, 5-Bis (trifluoromethyl) phenyl)-1H-1, 2, 4-triazol-5-yl) thio)-N-methyl-2-(methylthio) py-
rimidin-4-amine (38c): Yield: 74%; 
1
H NMR (CDCl3): δ 8.61 (s, 2H), 7.91 (s, 1H), 6.10 (s, 1H), 3.00 (s, 
3H), 2.59 (s, 3H); 
13
C NMR (CDCl3):  δ 171.5, 162.4, 159.4, 148.1, 132.6, 132.3, 132.2, 131.9, 131.6, 
127.2, 126.1, 126.0, 124.5, 122.7, 122.6, 122.5, 121.8, 119.1, 26.2, 12.4. HRMS-ESI (+): Calc. for 
C16H12F6N6S2 [M+H]
+
: 467.0547; found: 467.542.  
6-((3-(3, 5-Bis (trifluoromethyl) phenyl)-1H-1, 2, 4-triazol-5-yl) thio)-N,N-dimethyl-2-(methylthio) 
pyrimidin-4-amine (38d): Yield: 68%; 
1
H NMR (CDCl3): δ 8.60 (s, 2H), 7.90 (s, 1H), 6.15 (s, 1H), 3.13 
(br, 6H), 2.57 (s, 3H); 
13
C NMR (CDCl3):  δ 171.1, 160.8, 16.5, 159.5, 149.7, 132.8, 132.2, 131.8, 126.8, 
126.3, 122.6, 122.5, 94.7, 37.1, 14.1, 13.8. HRMS-ESI (+): Calc. for C17H14F6N6S2 [M+H]
+
: 481.0704; 
found: 481.0700.  
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6-((3-(3, 5-Bis (trifluoromethyl) phenyl)-1H-1, 2, 4-triazol-5-yl) thio)-N-isopropyl-2-(methylthio) 
pyrimidin-4-amine (38e): Yield: 75%; 
1
H NMR (CDCl3): δ 8.60 (s, 2H), 7.14 (s, 1H), 6.06 (s, 1H), 2.57 
(s, 3H), 1.28 (t, 6H, 12 Hz); 
13
CNMR (CDCl3): δ 160.2, 159.6, 149.4, 132.8, 132.5, 132.2, 131.9, 131.5, 
127.3, 124.6, 121.9, 119.1, 43.3, 22.6, 14.1. HRMS-ESI (+): Calc. for C18H16F6N6S2 [M+H]
+
: 495.0860; 
found: 495.0874.  
6-((3-(3, 5-Bis (trifluoromethyl) phenyl)-1H-1, 2, 4-triazol-5-yl) thio)-N-cyclopropyl-2-(methylthio) 
pyrimidin-4-amine (38f): Yield: 72%;  
1
H NMR (CDCl3): δ 8.61 (s, 2H), 7.91 (s, 1H), 6.43 (s, 1H), 5.56 
(s, 1H), 2.54 (s, 3H), 0.90 (t, J = 6.0 Hz, 4H).
13
C NMR (CDCl3):  δ 171.7, 162.7, 159.7, 149.3, 132.8, 
132.6, 132.2, 131.9, 131.6, 124.6, 121.9, 119.19, 95.2, 23.3, 14.0, 7.6. HRMS-ESI (-): Calc. for 
C18H14F6N6S2 [M-H]
-
: 491.0547; found: 491.0553.  
4-((3-(3,5-Bis(trifloromethyl)phenyl)-1H-1,2,4-triazol-5-yl)thio)-2-(methylthio)-6-(piperidin-1-
yl)pyrimidine (38g): Yield: 77%;  
1
H NMR (CDCl3): δ 8.60 (s, 2H), 7.90 (s, 1H), 6.23 (s, 1H), 3.65 (br, 
3H), 2.57 (s, 3H), 1.65-1.73 (m, 6H); 
13
C NMR (CDCl3): δ 171.4, 160.9, 159.7, 159.5, 149.8, 132.8, 
132.5, 132.2, 131.8, 131.5, 127.3, 126.4, 126.3, 124.6, 122.6, 122.6, 122.6, 122.5, 121.9, 119.2, 113.1, 
94.9, 45.3, 25.5, 24.4, 14.2. HRMS-ESI (-): Calc. for C20H18F6N6S2 [M-H]
-
: 519.0860; found: 519.0853.  
4-(6-((3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)thio)-2-(methylthio)pyrimidin-4-
yl)morpholine (38h): Yield: 72%;  
1
H NMR (CDCl3): δ 8.59 (s, 2H), 7.90 (s, 1H), 6.21 (s, 1H), 3.78 (t, J 
= 8.0 Hz, 4H), 3.65 (s, 4H), 2.53 (s, 3H); 
13
C NMR (CDCl3):  δ 171.7, 161.7, 160.2, 159.6, 149.2, 132.7, 
132.5, 132.2, 131.8, 131.5, 128.6, 127.3, 126.4, 126.3, 124.5, 122.7, 121.8, 119.1, 94.9, 66.2, 44.2, 14.1. 
HRMS-ESI (-): Calc. for C19H15F6N6OS2
-
: 521.0653; found: 521.0656 [M-H]
-
 
N-(3-(3, 5-Bis (trifluoromethyl) phenyl)-1H-1,2,4-triazol-5-yl)-6-chloro-2-(methylthio)pyrimidin-4-
amine (39a): Yield: 71%; 
1
H NMR (DMSO-d6) δ 8.51 (m, 2H), 8.22 (m, 1H), 7.91 (m, 2H), 7.70 (m, 
1H), 2.59 (s, 1H), 2.61 (s, 3H), 2.34 (s, 6H). HRMS-ESI (+): Calc. for C15H10ClF6N6S: 455.0280; found: 
455.0275 [M+H]
+ 
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General synthetic procedure for 40a-k:  To a solution of 37b (1.30 mmol) in DMF (8 ml), was added 
triethylamine (2mmol), followed by addition of appropriate alkyl halides, RX (1.35 mmol) and stirred at 
40-50°C and monitored using TLC. Upon completion, the reaction mixture was cooled to ambient tem-
perature and the DMF removed in vacuo. The dried residue was dissolved in ethyl acetate (20 mL) and 
washed with water (15 ml  2) and brine (10 ml  2). The solvent was evaporated in vacuo to obtain 
crude product, which was purified using silica gel column chromatography. Yields: 70-80% 
4-((3-(3,5-Bis(trifluoromethyl)phenyl)-1-methyl-1H-1,2,4-triazol-5-yl)thio)-6-chloro-2(methylthio) 
pyrimidine (40a): Yield: 85%; 
1
H NMR (CDCl3): δ 8.60 (s, 2H), 7.93 (s, 1H), 6.91(s, 1H), 4.04 (s, 3H), 
2.31 (s, 3H); 
13
C NMR (CDCl3): δ 174.1, 167.0, 160.6, 160.4, 144.2, 132.4, 132.3, 132.0, 126.2, 124.5, 
123.0, 123.0, 121.8, 112.3, 36.9, 14.1. HRMS-ESI (+): Calc. for C16H10ClF6N5S2 [M+H]
+
: 486.0049; 
found: 486.0045.  
4-((3-(3, 5-Bis(trifluoromethyl) phenyl)-1-ethyl-1H-1, 2, 4-triazol-5-yl)thio)-6-chloro-2-(methylthio) 
pyrimidine (40b): Yield: 82%;  
1
H NMR (CDCl3):  δ 8.62 (s, 2H), 7.93 (s, 1H), 6.88 (s, 1H), 4.36 (q, 2H, 
J = 8.0 Hz), 2.32 (s, 3H), 1.57 (t, J = 8.0 Hz, 3H); 
13
C NMR (CDCl3): δ 174.0, 167.4, 160.6, 143.2, 132.4, 
132.3, 132.0, 126.3, 122.9, 122.9, 112.2, 45.3, 15.2, 14.1. HRMS-ESI (+): Calc. for C17H12ClF6N5S2 
[M+H]
+
: 500.0205; found: 500.0197.  
4-((3-(3,5-Bis(trifluoromethyl)phenyl)-1-isopropyl-1H-1,2,4-triazol-5-yl)thio)-6-chloro-2(methyl 
thio)pyrimidine (40c): Yield: 78%;  
1
H NMR (CDCl3):  δ 8.63 (s, 2H), 7.93 (s, 1H), 6.86 (s, 1H), 4.88 
(m, J = 8.0 Hz, 1H),  2.34 (s, 3H), 1.57 (d, J = 4.0 Hz, 6H); 
13
C NMR (CDCl3): δ 174.04, 167.68, 160.64, 
142.30, 132.70, 132.32, 131.98, 131.65, 126.28, 124.59, 122.87, 112.24, 112.20, 52.40, 29.70, 22.89, 
14.12. HRMS-ESI (+): Calc. for C18H14ClF6N5S2 [M+H]
+
: 514.0362;  found: 514.0358  
4-((3-(3, 5-Bis(trifluoromethyl)phenyl)-1-(cyclopropylmethyl)-1H-1,2,4-triazol-5-yl)thio)-6-chloro-2-
(methylthio)pyrimidine (40d): Yield: 72%; 
1
H NMR (CDCl3):  δ 8.62 (s, 2H), 7.94 (s, 1H), 6.86 (s, 1H), 
4.18 (d, J = 8.0 Hz, 2H), 2.33 (s, 3H), 0.66 (d, 2H), 0.46 (d, 2H);
13
C NMR (CDCl3):  δ 171.5, 162.4, 
159.4, 148.1, 132.6, 132., 132.2, 131.9, 131.6, 127.2, 126.0, 126.0, 124.5, 122.6, 122.6, 122.6, 121.8, 
119.1, 26.2, 12.4. HRMS-ESI (+): Calc. for C19H14ClF6N5S2 [M+H]
+
: 526.0362; found: 526.0358. 
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4-((3-(3,5-Bis(trifluoromethyl)phenyl)-1-(3,5-dimethoxybenzyl)-1H-1,2,4-triazol-5-yl)thio)-6-chloro-
2-(methylthio)pyrimidine (40e). Yield: 77%;  
1
H NMR (CDCl3): δ 8.64 (s, 2H), 7.95 (s, 1H), 6.56 (s, 
1H), 6.40 (s, 2H), 6.32 (s, 1H), 5.43 (s, 2H), 3.78 (s, 6H), 2.24 (s, 3H); 
13
C NMR (CDCl3):  δ 173.6, 
167.1, 161.0, 160.2, 143.9, 135.6, 132.7, 132.4, 132.3, 132.0, 131.7, 126.35, 124.5, 123.1, 121.8, 112.1, 
106.9, 106.5, 104.9, 99.5, 55.3, 54.2, 14.0. HRMS-ESI (+): Calc. for C24H18ClF6N5O2S2
 
[M+H]
+
: 
622.0573; found: 622.0571.  
4-((1-(4-Azidobenzyl)-3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)thio)-6-chloro-2-
(methylthio)pyrimidine (40f). Yield: 83%; 
1
H NMR (CDCl3): δ 8.62 (s, 2H), 7.94 (s, 1H), 7.31 (d, J = 
8.0 Hz, 2H), 6.95 (d, J = 8.0 Hz, 2H), 6.63 (s, 1H), 6.32 (s, 1H), 2.27 (s, 3H); 
13
C NMR (CDCl3):  δ 173.8, 
167.0, 160.7, 160.5, 143.88, 140.7, 132.4, 132.2, 132.0, 130.3, 129.8, 126.3, 123.1, 123.1, 119.3, 112.3, 
53.4, 14.1. HRMS-ESI (+): Calc. for C22H13ClF6N8S2 [M+H]
+
: 603.0376; found: 603.0362. 
General synthetic procedure for 42: To a solution of 32a (1.30 mmol) in CH3CN (8 ml), was added me-
thyl Iodide (1.8mmol) at 0 to -5°C and stirred for 4-5 h. Then, the reaction was stirred at room tempera-
ture for 2-3 h and monitored by TLC. Upon completion, the solvent was removed in vacuo. The dried res-
idue thus obtained was  dissolved in acetone (10 ml) and added triethylamine (2 mmol) followed by 4,6-
dichloro-2-(methylthio)pyrimidine (1.4 mmol) and stirred at room temperature. Upon completion, the 
reaction solvent was evaporated in vacuo and residue dissolved in ethyl acetate (20 mL) and washed with 
water (15 ml  2) and brine (10 ml  2). The solvent was evaporated in vacuo to obtain crude product, 
which was purified using silica gel column chromatography. Yields: 85% 
General synthetic procedure for 43a-b:  To a solution of 2,4,6 trichloropyrimidine (1.5 mmol) in ace-
tone (8 ml) at 0-4°C was added K2CO3 (2mmol), followed by slow addition of 32a-b. Then, the reaction 
was monitored by TLC and upon completion; the reaction solvent was removed in vacuo. The dried resi-
due thus obtained was dissolved in ethyl acetate (20 mL) and washed with water (15 ml  2) and brine (10 
ml  2). The solvent was evaporated in vacuo to obtain crude product, which was purified using silica gel 
column chromatography. Yields: 60%. 
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4-(3-(3,5-Bis(trifluoromethyl)phenyl)-5-(methylthio)-1H-1,2,4-triazol-1-yl)-6-chloro -2(methylthio) 
pyrimidine (42): Yield: 85%;  
 1
H NMR (CDCl3):  δ 8.64 (s, 2H), 7.97 (s, 1H), 7.66 (s, 1H), 2.83 (s, 3H), 
2.74 (s, 3H); 
13
C NMR (CDCl3): δ 174.1, 162.2, 160.4, 159.4, 156.5, 132.3, 132.0, 131.8, 126.8, 123.5, 
104.3, 16.4, 14.8. HRMS-ESI (+): Calc. for C16H10ClF6N5S2 [M+H]
+
: 486.0049; found: 486.0042.  
2.6 References 
1. (a) Falagas, M. E.; Karageorgopoulos, D. E., Pandrug Resistance (PDR), Extensive Drug 
Resistance (XDR), and Multidrug Resistance (MDR) among Gram-Negative Bacilli: Need for 
International Harmonization in Terminology. Clinical Infectious Diseases 2008, 46 (7), 1121-1122; (b) 
Falagas, M. E.; Koletsi, P. K.; Bliziotis, I. A., The diversity of definitions of multidrug-resistant (MDR) 
and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. Journal of Medical 
Microbiology 2006, 55 (12), 1619-1629. 
2. (a) Queenan, A. M.; Bush, K., Carbapenemases: the Versatile β-Lactamases. Clinical 
Microbiology Reviews 2007, 20 (3), 440-458; (b) Naas, T.; Nordmann, P.; Vedel, G.; Poyart, C., Plasmid-
Mediated Carbapenem-Hydrolyzing β-Lactamase KPC in a Klebsiella pneumoniae Isolate from France. 
Antimicrob Agents Ch 2005, 49 (10), 4423-4424; (c) Perez, F.; Endimiani, A.; Ray, A. J.; Decker, B. K.; 
Wallace, C. J.; Hujer, K. M.; Ecker, D. J.; Adams, M. D.; Toltzis, P.; Dul, M. J.; Windau, A.; 
Bajaksouzian, S.; Jacobs, M. R.; Salata, R. A.; Bonomo, R. A., Carbapenem-resistant Acinetobacter 
baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on 
dissemination. Journal of Antimicrobial Chemotherapy 2010, 65 (8), 1807-1818. 
3. (a) Levy, S. B.; Marshall, B., Antibacterial resistance worldwide: causes, challenges and 
responses. Nat Med 2004, 10 (12), S122-S129; (b) Taubes, G., The bacteria fight back. Science 2008, 321 
(5887), 356-61. 
4. Birmingham, M. C.; Rayner, C. R.; Meagher, A. K.; Flavin, S. M.; Batts, D. H.; Schentag, J. J., 
Linezolid for the Treatment of Multidrug-Resistant, Gram-Positive Infections: Experience from a 
Compassionate-Use Program. Clinical Infectious Diseases 2003, 36 (2), 159-168. 
5. Robbel, L.; Marahiel, M. A., Daptomycin, a Bacterial Lipopeptide Synthesized by a 
Nonribosomal Machinery. J Biol Chem 2010, 285 (36), 27501-27508. 
6. Wang, J.; Soisson, S. M.; Young, K.; Shoop, W.; Kodali, S.; Galgoci, A.; Painter, R.; 
Parthasarathy, G.; Tang, Y. S.; Cummings, R.; Ha, S.; Dorso, K.; Motyl, M.; Jayasuriya, H.; Ondeyka, J.; 
Herath, K.; Zhang, C.; Hernandez, L.; Allocco, J.; Basilio, Á.; Tormo, J. R.; Genilloud, O.; Vicente, F.; 
Pelaez, F.; Colwell, L.; Lee, S. H.; Michael, B.; Felcetto, T.; Gill, C.; Silver, L. L.; Hermes, J. D.; 
Bartizal, K.; Barrett, J.; Schmatz, D.; Becker, J. W.; Cully, D.; Singh, S. B., Platensimycin is a selective 
FabF inhibitor with potent antibiotic properties. Nature 2006, 441 (7091), 358-361. 
7. (a) Mori, H.; Ito, K., The Sec protein-translocation pathway. TRENDS in Microbiology 2001, 9, 
494-500; (b) Driessen, A. J.; Nouwen, N., Protein translocation across the bacterial cytoplasmic 
membrane. Annu Rev Biochem 2008, 77, 643-67; (c) Chen, Y.; Pan, X.; Tang, Y.; Quan, S.; Tai, P. C.; 
Sui, S. F., Full-length Escherichia coli SecA dimerizes in a closed conformation in solution as determined 
by cryo-electron microscopy. J Biol Chem 2008, 283 (43), 28783-7. 
8. (a) Papanikolau, Y.; Papadovasilaki, M.; Ravelli, R. B. G.; McCarthy, A. A.; Cusack, S.; 
Economou, A.; Petratos, K., Structure of dimeric SecA, the Escherichia coli preprotein translocase motor. 
J Mol Biol 2007, 366 (5), 1545-1557; (b) Sharma, V.; Arockiasamy, A.; Ronning, D. R.; Savva, C. G.; 
Holzenburg, A.; Braunstein, M.; Jacobs, W. R.; Sacchettini, J. C., Crystal structure of Mycobacterium 
tuberculosis SecA, a preprotein translocating ATPase. P Natl Acad Sci USA 2003, 100 (5), 2243-2248; (c) 
Vassylyev, D. G.; Mori, H.; Vassylyeva, M. N.; Tsukazaki, T.; Kimura, Y.; Tahirov, T. H.; Ito, K., 
Crystal structure of the translocation ATPase SecA from Thermus thermophilus reveals a parallel, head-
103 
 
to-head dimer. J Mol Biol 2006, 364 (3), 248-258; (d) Zimmer, J.; Li, W. K.; Rapoport, T. A., A novel 
dimer interface and conformational changes revealed by an X-ray structure of B-subtilis SecA. J Mol Biol 
2006, 364 (3), 259-265. 
9. (a) Gelis, I.; Bonvin, A. M. J. J.; Keramisanou, D.; Koukaki, M.; Gouridis, G.; Karamanou, S.; 
Economou, A.; Kalodimos, C. G., Structural basis for signal-sequence recognition by the translocase 
motor SecA as determined by NMR. Cell 2007, 131 (4), 756-769; (b) Gouridis, G.; Karamanou, S.; Gelis, 
I.; Kalodimos, C. G.; Economou, A., Signal peptides are allosteric activators of the protein translocase. 
Nature 2009, 462 (7271), 363-U132. 
10. (a) Wang, H. W.; Chen, Y.; Yang, H.; Chen, X.; Duan, M. X.; Tai, P. C.; Sui, S. F., Ring-like 
pore structures of SecA: implication for bacterial protein-conducting channels. Proc Natl Acad Sci U S A 
2003, 100 (7), 4221-6; (b) Chen, Y.; Tai, P. C.; Sui, S. F., The active ring-like structure of SecA revealed 
by electron crystallography: conformational change upon interaction with SecB. J Struct Biol 2007, 159 
(1), 149-53. 
11. (a) Bu, Z.; Wang, L.; Kendall, D. A., Nucleotide binding induces changes in the oligomeric state 
and conformation of Sec A in a lipid environment: a small-angle neutron-scattering study. J Mol Biol 
2003, 332 (1), 23-30; (b) Shilton, B.; Svergun, D. I.; Volkov, V. V.; Koch, M. H. J.; Cusack, S.; 
Economou, A., Escherichia coli SecA shape and dimensions. Febs Letters 1998, 436 (2), 277-282. 
12. Eser, M.; Ehrmann, M., SecA-dependent quality control of intracellular protein localization. 
Proc. Natl. Acad. Sci. U. S. A. 2003, 100 (23), 13231-13234. 
13. Akita, M.; Shinkai, A.; Matsuyama, S.-i.; Mizushima, S., SecA, an essential component of the 
secretory machinery of Escherichia coli, exists as homodimer. Biochem. Biophys. Res. Commun. 1991, 
174 (1), 211-216. 
14. Moran, U.; Phillips, R.; Milo, R., SnapShot: Key Numbers in Biology. Cell 2010, 141 (7), 1262-
1262.e1. 
15. Cabelli, R. J.; Dolan, K. M.; Qian, L. P.; Oliver, D. B., Characterization of membrane-associated 
and soluble states of SecA protein from wild-type and SecA51(TS) mutant strains of Escherichia coli. J. 
Biol. Chem. 1991, 266 (36), 24420-7. 
16. (a) Woodbury, R. L.; Hardy, S. J. S.; Randall, L. L., Complex behavior in solution of 
homodimeric SecA. Protein Sci. 2002, 11 (4), 875-882; (b) Driessen, A. J. M., SecA, the peripheral 
subunit of the Escherichia coli precursor protein translocase, is functional as a dimer. Biochemistry 1993, 
32 (48), 13190-13197. 
17. Kusters, I.; van den Bogaart, G.; Kedrov, A.; Krasnikov, V.; Fulyani, F.; Poolman, B.; Driessen, 
Arnold J. M., Quaternary Structure of SecA in Solution and Bound to SecYEG Probed at the Single 
Molecule Level. Structure 2011, 19 (3), 430-439. 
18. Kusters, I.; Driessen, A. M., SecA, a remarkable nanomachine. Cell. Mol. Life Sci. 2011, 68 (12), 
2053-2066. 
19. (a) Cordin, O.; Banroques, J.; Tanner, N. K.; Linder, P., The DEAD-box protein family of RNA 
helicases. Gene 2006, 367, 17-37; (b) Tanner, N. K.; Linder, P., DExD/H box RNA helicases: From 
generic motors to specific dissociation functions. Mol Cell 2001, 8 (2), 251-262. 
20. (a) Cooper, D. B.; Smith, V. F.; Crane, J. M.; Roth, H. C.; Lilly, A. A.; Randall, L. L., SecA, the 
motor of the secretion machine, binds diverse partners on one interactive surface. J Mol Biol 2008, 382 
(1), 74-87; (b) Papanikou, E.; Karamanou, S.; Baud, C.; Frank, M.; Sianidis, G.; Keramisanou, D.; 
Kalodimos, C. G.; Kuhn, A.; Economou, A., Identification of the preprotein binding domain of SecA. J 
Biol Chem 2005, 280 (52), 43209-43217. 
21. Papanikou, E.; Karamanou, S.; Economou, A., Bacterial protein secretion through the translocase 
nanomachine. Nat Rev Microbiol 2007, 5 (11), 839-51. 
22. Hunt, J. F.; Weinkauf, S.; Henry, L.; Fak, J. J.; McNicholas, P.; Oliver, D. B.; Deisenhofer, J., 
Nucleotide control of interdomain interactions in the conformational reaction cycle of SecA. Science 
2002, 297 (5589), 2018-2026. 
23. Zimmer, J.; Rapoport, T. A., Conformational Flexibility and Peptide Interaction of the 
Translocation ATPase SecA. J Mol Biol 2009, 394 (4), 606-612. 
104 
 
24. Zimmer, J.; Nam, Y.; Rapoport, T. A., Structure of a complex of the ATPase SecA and the 
protein-translocation channel. Nature 2008, 455 (7215), 936-943. 
25. Osborne, A. R.; Rapoport, T. A., Protein translocation is mediated by oligomers of the SecY 
complex with one SecY copy forming the channel. Cell 2007, 129 (1), 97-110. 
26. Nithianantham, S.; Shilton, B. H., Analysis of the Isolated SecA DEAD Motor Suggests a 
Mechanism for Chemical–Mechanical Coupling. J. Mol. Biol. 2008, 383 (2), 380-389. 
27. (a) Wang, H. W.; Chen, Y.; Yang, H.; Chen, X.; Duan, M. X.; Tai, P. C.; Sui, S. F., Ring-like 
pore structures of SecA: implication for bacterial protein-conducting channels. Proc. Natl. Acad. Sci. U. 
S. A. 2003, 100 (7), 4221-6; (b) Chen, Y.; Pan, X.; Tang, Y.; Quan, S.; Tai, P. C.; Sui, S. F., Full-length 
Escherichia coli SecA dimerizes in a closed conformation in solution as determined by cryo-electron 
microscopy. J. Biol. Chem. 2008, 283 (43), 28783-7; (c) Chen, Y.; Tai, P. C.; Sui, S. F., The active ring-
like structure of SecA revealed by electron crystallography: conformational change upon interaction with 
SecB. J. Struct. Biol. 2007, 159 (1), 149-53. 
28. Osborne, A. R.; Clemons, W. M.; Rapoport, T. A., A large conformational change of the 
translocation ATPase SecA. P Natl Acad Sci USA 2004, 101 (30), 10937-10942. 
29. Chimera is developed by the Resource for Biocomputing, Visualization, and Informatics at the 
University of California, San Francisco, with support from the National Institutes of Health (National 
Center for Research Resources grant 2P41RR001081, National Institute of General Medical Sciences 
grant 9P41GM103311). 
30. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; 
Ferrin, T. E., UCSF Chimera—A visualization system for exploratory research and analysis. J. Comput. 
Chem. 2004, 25 (13), 1605-1612. 
31. Wickner, W.; Schekman, R., Protein Translocation Across Biological Membranes. Science 2005, 
310 (5753), 1452-1456. 
32. (a) Rapoport, T. A., Protein translocation across the eukaryotic endoplasmic reticulum and 
bacterial plasma membranes. Nature 2007, 450 (7170), 663-669; (b) Segers, K.; Klaassen, H.; Economou, 
A.; Chaltin, P.; Anné, J., Development of a high-throughput screening assay for the discovery of small-
molecule SecA inhibitors. Anal Biochem 2011, 413 (2), 90-96; (c) Lycklama a Nijeholt, J. A.; Driessen, 
A. J. M., The bacterial Sec-translocase: structure and mechanism. Philosophical Transactions of the 
Royal Society B: Biological Sciences 2012, 367 (1592), 1016-1028. 
33. (a) Economou, A.; Wickner, W., Seca Promotes Preprotein Translocation by Undergoing Atp-
Driven Cycles of Membrane Insertion and Deinsertion. Cell 1994, 78 (5), 835-843; (b) Economou, A.; 
Pogliano, J. A.; Beckwith, J.; Oliver, D. B.; Wickner, W., SecA membrane cycling at SecYEG is driven 
by distinct ATP binding and hydrolysis events and is regulated by SecD and SecF. Cell 1995, 83 (7), 
1171-1181; (c) Jilaveanu, L. B.; Oliver, D. B., In Vivo Membrane Topology of Escherichia coli SecA 
ATPase Reveals Extensive Periplasmic Exposure of Multiple Functionally Important Domains Clustering 
on One Face of SecA. J. Biol. Chem. 2007, 282 (7), 4661-4668. 
34. Karamanou, S.; Gouridis, G.; Papanikou, E.; Sianidis, G.; Gelis, I.; Keramisanou, D.; Vrontou, 
E.; Kalodimos, C. G.; Economou, A., Preprotein-controlled catalysis in the helicase motor of SecA. 
EMBO J. 2007, 26 (12), 2904-14. 
35. Fak, J. J.; Itkin, A.; Ciobanu, D. D.; Lin, E. C.; Song, X. J.; Chou, Y. T.; Gierasch, L. M.; Hunt, J. 
F., Nucleotide exchange from the high-affinity ATP-binding site in SecA is the rate-limiting step in the 
ATPase cycle of the soluble enzyme and occurs through a specialized conformational state. Biochemistry-
Us 2004, 43 (23), 7307-7327. 
36. (a) Smith, P. A.; Powers, M. E.; Roberts, T. C.; Romesberg, F. E., In Vitro Activities of 
Arylomycin Natural-Product Antibiotics against Staphylococcus epidermidis and Other Coagulase-
Negative Staphylococci. Antimicrob Agents Ch 2011, 55 (3), 1130-1134; (b) Lill, R.; Dowhan, W.; 
Wickner, W., The ATPase activity of SecA is regulated by acidic phospholipids, SecY, and the leader and 
mature domains of precursor proteins. Cell 1990, 60 (2), 271-80. 
105 
 
37. Li, W.; Schulman, S.; Boyd, D.; Erlandson, K.; Beckwith, J.; Rapoport, T. A., The plug domain 
of the SecY protein stabilizes the closed state of the translocation channel and maintains a membrane seal. 
Mol Cell 2007, 26 (4), 511-21. 
38. (a) de Keyzer, J.; van der Sluis, E. O.; Spelbrink, R. E. J.; Nijstad, N.; de Kruijff, B.; Nouwen, N.; 
van der Does, C.; Driessen, A. J. M., Covalently Dimerized SecA Is Functional in Protein Translocation. 
J. Biol. Chem. 2005, 280 (42), 35255-35260; (b) Jilaveanu, L. B.; Oliver, D., SecA Dimer Cross-Linked 
at Its Subunit Interface Is Functional for Protein Translocation. J. Bacteriol. 2006, 188 (1), 335-338; (c) 
Jilaveanu, L. B.; Zito, C. R.; Oliver, D., Dimeric SecA is essential for protein translocation. Proc. Natl. 
Acad. Sci. U. S. A. 2005, 102 (21), 7511-7516. 
39. (a) Or, E.; Navon, A.; Rapoport, T., Dissociation of the dimeric SecA ATPase during protein 
translocation across the bacterial membrane. The EMBO Journal 2002, 21 (17), 4470-4479; (b) Or, E.; 
Boyd, D.; Gon, S.; Beckwith, J.; Rapoport, T., The Bacterial ATPase SecA Functions as a Monomer in 
Protein Translocation. J. Biol. Chem. 2005, 280 (10), 9097-9105. 
40. Duong, F., Binding, activation and dissociation of the dimeric SecA ATPase at the dimeric 
SecYEG translocase. EMBO J. 2003, 22 (17), 4375-4384. 
41. Tziatzios, C.; Schubert, D.; Lotz, M.; Gundogan, D.; Betz, H.; Schägger, H.; Haase, W.; Duong, 
F.; Collinson, I., The Bacterial Protein–Translocation Complex: SecYEG Dimers Associate with One or 
Two SecA Molecules. J. Mol. Biol. 2004, 340 (3), 513-524. 
42. (a) Fekkes, P.; vanderDoes, C.; Driessen, A. J. M., The molecular chaperone SecB is released 
from the carboxy-terminus of SecA during initiation of precursor protein translocation. Embo Journal 
1997, 16 (20), 6105-6113; (b) Randall, L. L.; Crane, J. M.; Liu, G.; Hardy, S. J. S., Sites of interaction 
between SecA and the chaperone SecB, two proteins involved in export. Protein Sci. 2004, 13 (4), 1124-
1133; (c) Mao, C.; Hardy, S. J. S.; Randall, L. L., Maximal Efficiency of Coupling between ATP 
Hydrolysis and Translocation of Polypeptides Mediated by SecB Requires Two Protomers of SecA. J. 
Bacteriol. 2009, 191 (3), 978-984; (d) Suo, Y.; Hardy, S. J. S.; Randall, L. L., Orientation of SecA and 
SecB in Complex, Derived from Disulfide Cross-Linking. J. Bacteriol. 2011, 193 (1), 190-196. 
43. (a) Engelman, D. M.; Steitz, T. A., The spontaneous insertion of proteins into and across 
membranes: The helical hairpin hypothesis. Cell 1981, 23 (2), 411-422; (b) Joly, J. C.; Wickner, W., The 
Seca and Secy Subunits of Translocase Are the Nearest Neighbors of a Translocating Preprotein, 
Shielding It from Phospholipids. Embo Journal 1993, 12 (1), 255-263; (c) Cannon, K. S.; Or, E.; 
Clemons, W. M.; Shibata, Y.; Rapoport, T. A., Disulfide bridge formation between SecY and a 
translocating polypeptide localizes the translocation pore to the center of SecY. The Journal of Cell 
Biology 2005, 169 (2), 219-225. 
44. (a) Tani, K.; Tokuda, H.; Mizushima, S., Translocation of ProOmpA possessing an 
intramolecular disulfide bridge into membrane vesicles of Escherichia coli. Effect of membrane 
energization. J. Biol. Chem. 1990, 265 (28), 17341-17347; (b) Shiozuka, K.; Tani, K.; Mizushima, S.; 
Tokuda, H., The proton motive force lowers the level of ATP required for the in vitro translocation of a 
secretory protein in Escherichia coli. J. Biol. Chem. 1990, 265 (31), 18843-7; (c) Nouwen, N.; de Kruijff, 
B.; Tommassen, J., prlA suppressors in Escherichia coli relieve the proton electrochemical gradient 
dependency of translocation of wild-type precursors. Proc. Natl. Acad. Sci. U. S. A. 1996, 93 (12), 5953-
5957; (d) Nishiyama, K.-i.; Fukuda, A.; Morita, K.; Tokuda, H., Membrane deinsertion of SecA 
underlying proton motive force-dependent stimulation of protein translocation. EMBO J. 1999, 18 (4), 
1049-1058; (e) Bessonneau, P.; Besson, V.; Collinson, I.; Duong, F., The SecYEG preprotein 
translocation channel is a conformationally dynamic and dimeric structure. EMBO J. 2002, 21 (5), 995-
1003. 
45. Benach, J.; Chou, Y.-T.; Fak, J. J.; Itkin, A.; Nicolae, D. D.; Smith, P. C.; Wittrock, G.; Floyd, D. 
L.; Golsaz, C. M.; Gierasch, L. M.; Hunt, J. F., Phospholipid-induced Monomerization and Signal-
peptide-induced Oligomerization of SecA. J. Biol. Chem. 2003, 278 (6), 3628-3638. 
46. (a) Schiebel, E.; Driessen, A. J.; Hartl, F. U.; Wickner, W., Delta mu H+ and ATP function at 
different steps of the catalytic cycle of preprotein translocase. Cell 1991, 64 (5), 927-39; (b) van der 
106 
 
Wolk, J. P. W.; de Wit, J. G.; Driessen, A. J. M., The catalytic cycle of the Escherichia coli SecA ATPase 
comprises two distinct preprotein translocation events. EMBO J. 1997, 16 (24), 7297-7304. 
47. Segers, K.; Anné, J., Traffic Jam at the Bacterial Sec Translocase: Targeting the SecA Nanomotor 
by Small-Molecule Inhibitors. Chemistry & biology 2011, 18 (6), 685-698.Licence number: 
3186070981147. 
48. Hsieh, Y. H.; Zhang, H.; Lin, B. R.; Cui, N.; Na, B.; Yang, H.; Jiang, C.; Sui, S. F.; Tai, P. C., 
SecA alone can promote protein translocation and Ion-channel activity:SecYEG increases efficiency and 
signal peptide specificity. J. Biol. Chem. 2012, 286, 44702-9. 
49. (a) Chen, X.; Brown, T.; Tai, P. C., Identification and characterization of protease-resistant SecA 
fragments: secA has two membrane-integral forms. J. Bacteriol. 1998, 180 (3), 527-37; (b) Chen, X.; Xu, 
H.; Tai, P. C., A significant fraction of functional SecA is permanently embedded in the membrane. SecA 
cycling on and off the membrane is not essential during protein translocation. J. Biol. Chem. 1996, 271 
(47), 29698-706; (c) Hu, H. J.; Holley, J.; He, J.; Harrison, R. W.; Yang, H.; Tai, P. C.; Pan, Y., To be or 
not to be: predicting soluble SecAs as membrane proteins. IEEE Trans. NanoBiosci. 2007, 6 (2), 168-79. 
50. Wang, H.; Na, B.; Yang, H.; Tai, P. C., Additional in vitro and in vivo evidence for SecA 
functioning as dimers in the membrane: dissociation into monomers is not essential for protein 
translocation in Escherichia coli. J. Bacteriol. 2008, 190 (4), 1413-8. 
51. (a) Tang, Y.; Pan, X.; Chen, Y.; Tai, P. C.; Sui, S. F., Dimeric SecA couples the preprotein 
translocation in an asymmetric manner. PLoS One 2011, 6 (1), e16498; (b) Tang, Y.; Pan, X.; Tai, P. C.; 
Sui, S., Electron microscopic visualization of asymmetric precursor translocation intermediates: SecA 
functions as a dimer. Sci China Life Sci 2010, 53 (9), 1049-56. 
52. (a) Yang, Y. B.; Lian, J.; Tai, P. C., Differential translocation of protein precursors across SecY-
deficient membranes of Escherichia coli: SecY is not obligatorily required for translocation of certain 
secretory proteins in vitro. J. Bacteriol. 1997, 179 (23), 7386-93; (b) Yang, Y. B.; Yu, N.; Tai, P. C., 
SecE-depleted membranes of Escherichia coli are active. SecE is not obligatorily required for the in vitro 
translocation of certain protein precursors. J. Biol. Chem. 1997, 272 (21), 13660-5. 
53. Chen, Y.; Pan, X.; Tang, Y.; Quan, S.; Tai, P. C.; Sui, S.-F., Full-length Escherichia coli SecA 
Dimerizes in a Closed Conformation in Solution as Determined by Cryo-electron Microscopy. J. Biol. 
Chem. 2008, 283 (43), 28783-28787. 
54. (a) Robson, A.; Gold, V. A. M.; Hodson, S.; Clarke, A. R.; Collinson, I., Energy transduction in 
protein transport and the ATP hydrolytic cycle of SecA. P Natl Acad Sci USA 2009, 106 (13), 5111-5116; 
(b) Sianidis, G.; Karamanou, S.; Vrontou, E.; Boulias, K.; Repanas, K.; Kyrpides, N.; Politou, A. S.; 
Economou, A., Cross-talk between catalytic and regulatory elements in a DEAD motor domain is 
essential for SecA function. Embo Journal 2001, 20 (5), 961-970; (c) Rao, S. C. V.; Bockstael, K.; Nath, 
S.; Engelborghs, Y.; Anne, J.; Geukens, N., Enzymatic investigation of the Staphylococcus aureus type I 
signal peptidase SpsB - implications for the search for novel antibiotics. Febs J 2009, 276 (12), 3222-
3234. 
55. Baud, C.; Karamanou, S.; Sianidis, G.; Vrontou, E.; Politou, A. S.; Economou, A., Allosteric 
communication between signal peptides and the SecA protein DEAD motor ATPase domain. J Biol Chem 
2002, 277 (16), 13724-13731. 
56. Keramisanou, D.; Biris, N.; Gelis, I.; Sianidis, G.; Karamanou, S.; Economou, A.; Kalodimos, C. 
G., Disorder-order folding transitions underlie catalysis in the helicase motor of SecA. Nat Struct Mol 
Biol 2006, 13 (7), 594-602. 
57. Ding, H. Y.; Mukerji, I.; Oliver, D., Nucleotide and phospholipid-dependent control of PPXD and 
C-domain association for SecA ATPase. Biochemistry-Us 2003, 42 (46), 13468-13475. 
58. de Keyzer, J.; van der Does, C.; Kloosterman, T. G.; Driessen, A. J. M., Direct demonstration of 
ATP-dependent release of SecA from a translocating preprotein by surface plasmon resonance. J Biol 
Chem 2003, 278 (32), 29581-29586. 
59. (a) Gouridis, G.; Karamanou, S.; Koukaki, M.; Economou, A., In vitro assays to analyze 
translocation of the model secretory preprotein alkaline phosphatase. Methods Mol Biol 2010, 619, 157-
72; (b) Lanzetta, P. A.; Alvarez, L. J.; Reinach, P. S.; Candia, O. A., An improved assay for nanomole 
107 
 
amounts of inorganic phosphate. Anal Biochem 1979, 100 (1), 95-7; (c) Mitchell, C.; Oliver, D., Two 
distinct ATP-binding domains are needed to promote protein export by Escherichia coli SecA ATPase. 
Molecular Microbiology 1993, 10 (3), 483-97. 
60. Huang, Y.-J.; Wang, H.; Gao, F.-B.; Li, M.; Yang, H.; Wang, B.; Tai, P. C., Fluorescein 
Analogues Inhibit SecA ATPase: The First Sub-micromolar Inhibitor of Bacterial Protein Translocation. 
Chemmedchem 2012, 7 (4), 571-577. 
61. Vrontou, E.; Karamanou, S.; Baud, C.; Sianidis, G.; Economou, A., Global co-ordination of 
protein translocation by the SecA IRA1 switch. J. Biol. Chem. 2004, 279 (21), 22490-7. 
62. Lin, B. R.; Gierasch, L. M.; Jiang, C.; Tai, P. C., Electrophysiological studies in Xenopus oocytes 
for the opening of Escherichia coli SecA-dependent protein-conducting channels. J. Membr. Biol. 2006, 
214 (2), 103-13. 
63. (a) Li, M.; Huang, Y.-J.; Tai, P. C.; Wang, B., Discovery of the first SecA inhibitors using 
structure-based virtual screening. Biochemical and Biophysical Research Communications 2008, 368 (4), 
839-845; (b) Chen, W.; Huang, Y.-j.; Gundala, S. R.; Yang, H.; Li, M.; Tai, P. C.; Wang, B., The first 
low μM SecA inhibitors. Bioorganic &amp; Medicinal Chemistry 2010, 18 (4), 1617-1625; (c) Jang, M.-
Y.; Jonghe, S. D.; Segers, K.; Anné, J.; Herdewijn, P., Synthesis of novel 5-amino-thiazolo[4,5-
d]pyrimidines as E. coli and S. aureus SecA inhibitors. Bioorganic & medicinal chemistry 2011, 19 (1), 
702-714; (d) Akula, N.; Zheng, H.; Han, F. Q.; Wang, N., Discovery of novel SecA inhibitors of 
Candidatus Liberibacter asiaticus by structure based design. Bioorganic & medicinal chemistry letters 
2011, 21 (14), 4183-4188; (e) Huang, Y.-J.; Wang, H.; Gao, F.-B.; Li, M.; Yang, H.; Wang, B.; Tai, P. C., 
Inside Back Cover: Fluorescein Analogues Inhibit SecA ATPase: The First Sub-micromolar Inhibitor of 
Bacterial Protein Translocation (ChemMedChem 4/2012). ChemMedChem 2012, 7 (4), 744-744. 
64. Loew, O., Ueber das Verhalten des Azoimids zu lebenden Organismen. Ber deut chem Ges 1891, 
24, 2947-2953. 
65. Oliver, D. B.; Cabelli, R. J.; Dolan, K. M.; Jarosik, G. P., Azide-resistant mutants of Escherichia 
coli alter the SecA protein, an azide-sensitive component of the protein export machinery. Proceedings of 
the National Academy of Sciences 1990, 87 (21), 8227-8231. 
66. Klein, M.; Hofmann, B.; Klose, M.; Freudl, R., Isolation and characterization of a Bacillus 
subtilis secA mutant allele conferring resistance to sodium azide. FEMS microbiology letters 1994, 124 
(3), 393-7. 
67. Eichler, J.; Wickner, W., The SecA Subunit of Escherichia coliPreprotein Translocase Is Exposed 
to the Periplasm. Journal of Bacteriology 1998, 180 (21), 5776-5779. 
68. Bowler, M. W.; Montgomery, M. G.; Leslie, A. G.; Walker, J. E., How azide inhibits ATP 
hydrolysis by the F-ATPases. Proc Natl Acad Sci U S A 2006, 103 (23), 8646-9. 
69. (a) Bowler, M. W.; Montgomery, M. G.; Leslie, A. G.; Walker, J. E., How azide inhibits ATP 
hydrolysis by the F-ATPases. Proc. Natl. Acad. Sci. U. S. A. 2006, 103 (23), 8646-9; (b) Yoshikawa, S.; 
Shinzawa-Itoh, K.; Nakashima, R.; Yaono, R.; Yamashita, E.; Inoue, N.; Yao, M.; Fei, M. J.; Libeu, C. 
P.; Mizushima, T.; Yamaguchi, H.; Tomizaki, T.; Tsukihara, T., Redox-coupled crystal structural changes 
in bovine heart cytochrome c oxidase. Science 1998, 280 (5370), 1723-9. 
70. Stoddard, B. L.; Ringe, D.; Petsko, G. A., The structure of iron superoxide dismutase from 
Pseudomonas ovalis complexed with the inhibitor azide. Protein Eng. 1990, 4 (2), 113-9. 
71. Yound, J. M.; Wang, J. H., The nature of binding of competitive inhibitors to alcohol 
dehydrogenases. J. Biol. Chem. 1971, 246 (9), 2815-21. 
72. Zaitsev, V. N.; Zaitseva, I.; Papiz, M.; Lindley, P. F., An X-ray crystallographic study of the 
binding sites of the azide inhibitor and organic substrates to ceruloplasmin, a multi-copper oxidase in the 
plasma. J. Biol. Inorg. Chem. 1999, 4 (5), 579-87. 
73. Alksne, L. E.; Burgio, P.; Hu, W.; Feld, B.; Singh, M. P.; Tuckman, M.; Petersen, P. J.; 
Labthavikul, P.; McGlynn, M.; Barbieri, L.; McDonald, L.; Bradford, P.; Dushin, R. G.; Rothstein, D.; 
Projan, S. J., Identification and Analysis of Bacterial Protein Secretion Inhibitors Utilizing a SecA-LacZ 
Reporter Fusion System. Antimicrob Agents Ch 2000, 44 (6), 1418-1427. 
108 
 
74. Sugie, Y.; al, e.; et al., ChemInform Abstract: CJ-21,058, a New SecA Inhibitor Isolated from a 
Fungus. ChemInform 2002, 33 (27), no-no. 
75. Parish, C. A.; Cruz, M. d. l.; Smith, S. K.;  ink, D.; Baxter,  .; Tucker-Samaras, S.; Collado,  .; 
Platas, G.; Bills, G.; D ez, M. T.; Vicente, F.; Pel ez, F.; Wilson, K., Antisense-Guided Isolation and 
Structure Elucidation of Pannomycin, a Substituted cis-Decalin from Geomyces pannorum. Journal of 
Natural Products 2008, 72 (1), 59-62. 
76. Chen, W.; Huang, Y.-j.; Gundala, S. R.; Yang, H.; Li, M.; Tai, P. C.; Wang, B., The first low μM 
SecA inhibitors. Bioorg. Med. Chem. 2010, 18 (4), 1617-1625. 
77. Huang, Y.-J.; Wang, H.; Gao, F.-B.; Li, M.; Yang, H.; Wang, B.; Tai, P. C., Fluorescein 
Analogues Inhibit SecA ATPase: The First Sub-micromolar Inhibitor of Bacterial Protein Translocation. 
ChemMedChem 2012, n/a-n/a. 
78. Siboo, I. R.; Chaffin, D. O.; Rubens, C. E.; Sullam, P. M., Characterization of the accessory Sec 
system of Staphylococcus aureus. J Bacteriol 2008, 190 (18), 6188-96. 
79. Nguyen-Mau, S. M.; Oh, S. Y.; Kern, V. J.; Missiakas, D. M.; Schneewind, O., Secretion genes 
as determinants of Bacillus anthracis chain length. J Bacteriol 2012, 194 (15), 3841-50. 
80. (a) Lin, B. R.; Gierasch, L. M.; Jiang, C.; Tai, P. C., Electrophysiological studies in Xenopus 
oocytes for the opening of Escherichia coli SecA-dependent protein-conducting channels. J. Membr. Biol. 
2006, 214 (2), 103-13; (b) Hsieh, Y. H.; Zhang, H.; Lin, B. R.; Cui, N.; Na, B.; Yang, H.; Jiang, C.; Sui, 
S. F.; Tai, P. C., SecA alone can promote protein translocation and ion channel activity: SecYEG 
increases efficiency and signal peptide specificity. J. Biol. Chem. 2011, 286 (52), 44702-9. 
81. (a) Chen, X.; Xu, H.; Tai, P. C., A significant fraction of functional SecA is permanently 
embedded in the membrane. SecA cycling on and off the membrane is not essential during protein 
translocation. J Biol Chem 1996, 271 (47), 29698-706; (b) Chen, X.; Brown, T.; Tai, P. C., Identification 
and characterization of protease-resistant SecA fragments: secA has two membrane-integral forms. J 
Bacteriol 1998, 180 (3), 527-37. 
82. Lin, B. R.; Gierasch, L. M.; Jiang, C.; Tai, P. C., Electrophysiological studies in Xenopus oocytes 
for the opening of Escherichia coli SecA-dependent protein-conducting channels. J Membr Biol 2006, 
214 (2), 103-13. 
83. Hsieh, Y. H.; Zhang, H.; Lin, B. R.; Cui, N.; Na, B.; Yang, H.; Jiang, C.; Sui, S. F.; Tai, P. C., 
SecA alone can promote protein translocation and Ion-channel activity:SecYEG increases efficiency and 
signal peptide specificity. J Biol Chem 2011. 
84. Agarwal, A.; Pearson, P. P.; Taylor, E. W.; Li, H. B.; Dahlgren, T.; Herslof, M.; Yang, Y.; 
Lambert, G.; Nelson, D. L., Three-dimensional quantitative structure-activity relationships of 5-HT 
receptor binding data for tetrahydropyridinylindole derivatives: a comparison of the Hansch and CoMFA 
methods. Journal of Medicinal Chemistry 1993, 36 (25), 4006-4014. 
85. Golbraikh, A.; Tropsha, A., Beware of q2! Journal of Molecular Graphics and Modelling 2002, 
20 (4), 269-276. 
86. Kaatz, G. W.; McAleese, F.; Seo, S. M., Multidrug resistance in Staphylococcus aureus due to 
overexpression of a novel multidrug and toxin extrusion (MATE) transport protein. Antimicrob Agents 
Chemother 2005, 49 (5), 1857-64. 
87. Price, C. T.; Kaatz, G. W.; Gustafson, J. E., The multidrug efflux pump NorA is not required for 
salicylate-induced reduction in drug accumulation by Staphylococcus aureus. Int J Antimicrob Agents 
2002, 20 (3), 206-13. 
88. Kaatz, G. W.; Moudgal, V. V.; Seo, S. M., Identification and characterization of a novel efflux-
related multidrug resistance phenotype in Staphylococcus aureus. J Antimicrob Chemother 2002, 50 (6), 
833-8. 
89. (a) Hsieh, Y. H.; Zhang, H.; Lin, B. R.; Cui, N.; Na, B.; Yang, H.; Jiang, C.; Sui, S. F.; Tai, P. C., 
SecA alone can promote protein translocation and ion channel activity: SecYEG increases efficiency and 
signal peptide specificity. J Biol Chem 2011, 286 (52), 44702-9; (b) Lin, B.-R.; Gierasch, L. M.; Jiang, 
C.; Tai, P. C., Electrophysiological studies in Xenopus oocytes for the opening of Escherichia coli SecA-
dependent protein-conducting channels. The Journal Of Membrane Biology 2006, 214 (2), 103-113. 
109 
 
90. (a) Furet, P.; Caravatti, G.; Guagnano, V.; Lang, M.; Meyer, T.; Schoepfer, J., Entry into a new 
class of protein kinase inhibitors by pseudo ring design. Bioorganic & Medicinal Chemistry Letters 2008, 
18 (3), 897-900; (b) Furet, P.; Bold, G.; Hofmann, F.; Manley, P.; Meyer, T.; Altmann, K.-H., 
Identification of a new chemical class of potent angiogenesis inhibitors based on conformational 
considerations and database searching. Bioorganic & Medicinal Chemistry Letters 2003, 13 (18), 2967-
2971; (c) Liechti, C.; Séquin, U.; Bold, G.; Furet, P.; Meyer, T.; Traxler, P., Salicylanilides as inhibitors 
of the protein tyrosine kinase epidermal growth factor receptor. European Journal of Medicinal 
Chemistry 2004, 39 (1), 11-26. 
91. Kuhn, B.; Mohr, P.; Stahl, M., Intramolecular Hydrogen Bonding in Medicinal Chemistry. 
Journal of Medicinal Chemistry 2010, 53 (6), 2601-2611. 
92. Ashwood, V. A.; Field, M. J.; Horwell, D. C.; Julien-Larose, C.; Lewthwaite, R. A.; McCleary, 
S.; Pritchard, M. C.; Raphy, J.; Singh, L., Utilization of an Intramolecular Hydrogen Bond To Increase 
the CNS Penetration of an NK1 Receptor Antagonist. Journal of Medicinal Chemistry 2001, 44 (14), 
2276-2285. 
93. Harter, W. G.; Albrect, H.; Brady, K.; Caprathe, B.; Dunbar, J.; Gilmore, J.; Hays, S.; Kostlan, C. 
R.; Lunney, B.; Walker, N., The design and synthesis of sulfonamides as caspase-1 inhibitors. Bioorganic 
& Medicinal Chemistry Letters 2004, 14 (3), 809-812. 
94. Nomura, M.; Kinoshita, S.; Satoh, H.; Maeda, T.; Murakami, K.; Tsunoda, M.; Miyachi, H.; 
Awano, K., (3-Substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents. 
Bioorganic & Medicinal Chemistry Letters 1999, 9 (4), 533-538. 
95. Van Zandt, M. C.; Sibley, E. O.; McCann, E. E.; Combs, K. J.; Flam, B.; Sawicki, D. R.; Sabetta, 
A.; Carrington, A.; Sredy, J.; Howard, E.; Mitschler, A.; Podjarny, A. D., Design and synthesis of highly 
potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid inhibitors of aldose reductase for treatment of 
chronic diabetic complications. Bioorganic & Medicinal Chemistry 2004, 12 (21), 5661-5675. 
96. Labby, K. J.; Xue, F.; Kraus, J. M.; Ji, H.; Mataka, J.; Li, H.; Martásek, P.; Roman, L. J.; Poulos, 
T. L.; Silverman, R. B., Intramolecular hydrogen bonding: A potential strategy for more bioavailable 
inhibitors of neuronal nitric oxide synthase. Bioorganic & Medicinal Chemistry 2012, 20 (7), 2435-2443. 
 
  
 
 
 
 
 
 
 
 
 
 
110 
 
 
 
 
 
 
APPENDICES 
Appendix A. HRMS, 
1
H and 
13
C Spectra of compounds in chapter 1: 
Data for 4-([1, 1'-biphenyl]-4-yl)-2-((4-azidobenzyl) thio)-6-oxo-1, 6-dihydropyrimidine-5-
carbonitrile (15a). 
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112 
 
 
Data for (4-(((6-cyano-5-oxo-4, 5-dihydro-[1, 1':4',1''-terphenyl]-3yl) thio) methyl) phenyl) boronic 
acid (15c). 
 
113 
 
 
 
Data for 4-(((6-cyano-5-oxo-4,5-dihydro-[1,1':4',1''-terphenyl]-3-yl)thio)methyl)benzoic acid (15d). 
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115 
 
 
Data for Methyl 4-(((4-([1, 1'-biphenyl]-4-yl)-5-cyano-6-oxo-1,6-dihydropyrimidin-2-
yl)thio)methyl)benzoate (15e). 
 
116 
 
 
Data for 4-([1, 1'-biphenyl]-4-yl)-6-oxo-2-(prop-2-yn-1-ylthio)-1,6-dihydropyrimidine-5-carbonitrile  
(15g). 
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118 
 
 
Data for 4-([1, 1'-biphenyl]-4-yl)-2-((2-(4-azidophenyl)-2-oxoethyl)thio)-6-oxo-1,6 dihydropyrimi-
dine-5-carbonitrile (15h). 
 
 
 
119 
 
 
Data for Ethyl 4-(((4-([1,1'-biphenyl]-4-yl)-5-cyano-6-oxo-1,6-dihydropyrimidin-2-
yl)thio)methyl)benzoate  (15i). 
 
120 
 
 
 
121 
 
 
Data for 4-([1,1'-biphenyl]-4-yl)-2-((3-azidobenzyl)thio)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile 
(15j). 
 
 
122 
 
Data for 2-(benzylthio)-4-(3'-hydroxy-[1,1'-biphenyl]-4-yl)-6-oxo-1,6-dihydropyrimidine-5-
carbonitrile (15l).  
 
 
123 
 
 
 
Data for methyl 4'-(2-((4-azidobenzyl)thio)-5-cyano-6-oxo-1,6-dihydropyrimidin-4-yl)-4,5-
dimethoxy-[1,1'-biphenyl]-2-carboxylate (15m).  
            
124 
 
 
 
125 
 
Data for Methyl 4'-(5-cyano-2-((4-(methoxycarbonyl)benzyl)thio)-6-oxo-1,6 dihydropyrimidin-4-
yl)-4,5-dimethoxy-[1,1'-biphenyl]-2-carboxylate (15n). 
 
126 
 
 
127 
 
Data for 4-(((4-([1,1'-biphenyl]-4-yl)-5-cyano-6-oxo-1,6-dihydropyrimidin-2-yl)thio)methyl)-N-(3-
(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)benzamide (15o). 
 
 
 
 
128 
 
 
 
 
129 
 
 
Data for Tert-butyl (1-(4-(((4-([1,1'-biphenyl]-4-yl)-5-cyano-6-oxo-1,6-dihydropyrimidin-2-
yl)thio)methyl)phenyl)-1-oxo-6,9,12-trioxa-2-azapentadecan-15-yl)carbamate (15p). 
 
 
 
 
 
 
 
130 
 
 
Data for 4-([1,1'-biphenyl]-4-yl)-2-((4-azidobenzyl)thio)-6-(hydroxyamino)pyrimidine-5-
carbonitrile (17a). 
 
 
131 
 
 
Data for 4-([1, 1'-biphenyl]-4-yl)-2-(benzylthio)-6-((2-hydroxyethyl)amino)pyrimidine-5-
carbonitrile (17b).  
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133 
 
 
Data for 4-([1,1'-biphenyl]-4-yl)-2-(benzylthio)-6-methoxypyrimidine-5-carbonitrile (17c).  
 
134 
 
          
Data for 4-([1,1'-biphenyl]-4-yl)-2-((4-azidobenzyl)thio)-6-(methylamino)pyrimidine-5-carbonitrile 
(17d).
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136 
 
Data for Tert-butyl (3-(2-(2-(3-((6-([1,1'-biphenyl]-4-yl)-2-((4-azidobenzyl)thio)-5 cyanopyrimidin-
4-yl) amino)propoxy)ethoxy)ethoxy)propyl)carbamate  (17e). 
 
137 
 
 
 
Data for Tert-butyl (3-(2-(2-(3-((6-([1,1'-biphenyl]-4-yl)-2-(benzylthio)-5-cyanopyrimidin-4-
yl)amino)propoxy)ethoxy)ethoxy)propyl)carbamate (17f). 
 
 
138 
 
 
Data for 4-([1,1'-biphenyl]-4-yl)-6-((3-(2-(2-(3aminopropoxy)ethoxy)ethoxy)propyl)amino)-2-
(benzylthio)-1,6-dihydropyrimidine-5-carbonitrile (17g)
139 
 
 
 
 
140 
 
 
Data for 4-([1,1'-biphenyl]-4-yl)-2-((4-azidobenzyl)thio)-6-((2-hydroxyethyl)amino)-1,6-
dihydropyrimidine-5-carbonitrile (17h). 
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142 
 
 
 
Data for 4-([1,1'-biphenyl]-4-yl)-2-((4-azidobenzyl)thio)-6-hydrazinyl-1,6 dihydropyrimidine-5-
carbonitrile (17i). 
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Data for 4-([1,1'-biphenyl]-4-yl)-2-((4-azidobenzyl)thio)-6-(prop-2-yn-1-ylamino) pyrimidine-5-
carbonitrile (17j).  
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145 
 
Data for 4-([1,1'-biphenyl]-4-yl)-6-oxo-2-((4-(4-phenyl-1H-1,2,3-triazol-1-yl)benzyl)thio)-1,6-
dihydropyrimidine-5-carbonitrile (18a).  
 
 
 
 
146 
 
Data for 4-([1,1'-biphenyl]-4-yl)-2-((4-(4-(4-aminophenyl)-1H-1,2,3-triazol-1yl)benzyl)thio)-6-oxo-
1,6-dihydropyrimidine-5-carbonitrile (18b).  
 
 
 
 
 
147 
 
Data for 1-(4-(((4-([1,1'-biphenyl]-4-yl)-5-cyano-6-oxo-1,6-dihydropyrimidin 2yl)thio 
methyl)phenyl)-1H-1,2,3-triazole-4-carboxylic acid  (18c). 
 
Data for (1-(4-(((4-([1,1'-biphenyl]-4-yl)-5-cyano-6-oxo-1,6-dihydropyrimidin-2-yl)thio )me-
thyl)phenyl)-1H-1,2,3-triazol-4-yl)methyl acetate (18d).      
148 
 
 
 
 
 
149 
 
Data for 3-(1-(4-(((4-([1,1'-biphenyl]-4-yl)-5-cyano-6-oxo-1,6-dihydropyrimidin-2-
yl)thio)methyl)phenyl)-1H-1,2,3-triazol-4-yl)propanoic acid  (18e). 
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151 
 
Data for 2-(1-(4-(((4-([1,1'-biphenyl]-4-yl)-5-cyano-6-oxo-1,6-dihydropyrimidin-2-
yl)thio)methyl)phenyl)-1H-1,2,3-triazol-4-yl)acetic acid (18f). 
 
 
 
 
 
 
152 
 
 
Data for 4-([1,1'-biphenyl]-4-yl)-2-((4-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)benzyl)thio)-6-oxo-
1,6-dihydropyrimidine-5-carbonitrile (18g). 
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154 
 
Data for 4-([1,1'-biphenyl]-4-yl)-2-((4-azidobenzyl)thio)-6-methoxypyrimidine-5-carbonitrile (19b). 
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Data for 4-([1,1'-biphenyl]-4-yl)-6-((4-azidobenzyl)oxy)-2-((4-azidobenzyl)thio)pyrimidine-5-
carbonitrile (19c). 
 
 
 
156 
 
 
157 
 
Data for 2-((4-azidobenzyl)thio)-4-(4-(benzyloxy)phenyl)-6-oxo-1,6-dihydropyrimidine-5-
carbonitrile (21a). 
 
 
 
158 
 
 
 
159 
 
Data for Methyl 4-(((4-(4-(benzyloxy)phenyl)-5-cyano-6-oxo-1,6-dihydropyrimidin-2-
yl)thio)methyl)benzoate (21b). 
 
 
 
160 
 
    
 
Data for 4-(4-(benzyloxy)phenyl)-2-((4-methoxybenzyl)thio)-6-oxo-1,6-dihydropyrimidine-5-
carbonitrile (21c).  
 
161 
 
 
162 
 
 
Data for 4-(4-(benzyloxy)phenyl)-2-((4-bromobenzyl)thio)-6-oxo-1,6-dihydropyrimidine-5-
carbonitrile (21d). 
 
163 
 
 
 
Data for 4-(4-(benzyloxy)phenyl)-2-((2-bromobenzyl)thio)-6-oxo-1,6-dihydropyrimidine-5-
carbonitrile (21e). 
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165 
 
Data for 4-(4-(benzyloxy)phenyl)-2-((cyclohexylmethyl)thio)-6-oxo-1,6-dihydropyrimidine-  5-
carbonitrile (21f).  
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167 
 
Data for 4-(4-(benzyloxy) phenyl)-2-((3, 5-dimethoxybenzyl) thio)-6-oxo-1,6  dihydropyrimidine-5-
carbonitrile (21g). 
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Data for 4-(4-(benzyloxy) phenyl)-2-((3,5-dimethylbenzyl)thio)- 6oxo1,6dihydropyrimidine-5-
carbonitrile (21h). 
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170 
 
Data for 2-((4-azidobenzyl)thio)-6-oxo-4-(4-phenoxyphenyl)-1,6-dihydropyrimidine-5-carbonitrile 
(21i). 
171 
 
Data for Methyl 4-(((5-cyano-6-oxo-4-(4-phenoxyphenyl)-1,6-dihydropyrimidin-2-
yl)thio)methyl)benzoate (21j). 
 
 
172 
 
 
173 
 
Data for 2-((4-methoxybenzyl)thio)-6-oxo-4-(4-phenoxyphenyl)-1,6-dihydropyrimidine-5-
carbonitrile (21k). 
174 
 
Data for 2-((4-azidobenzyl)thio)-6-oxo-4-(4-(phenylethynyl)phenyl)-1,6-dihydropyrimidine-5-
carbonitrile (21l).  
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176 
 
Data for methyl 4-(((5-cyano-6-oxo-4-(4-(phenylethynyl)phenyl)-1,6-dihydropyrimidin-2-
yl)thio)methyl)benzoate (21m).  
 
177 
 
 
178 
 
Data for 2-((4-methoxybenzyl)thio)-6-oxo-4-(4-(phenylethynyl)phenyl)-1,6  dihydropyrimidine-5-
carbonitrile (21n). 
 
 
179 
 
 
 
 
 
Data for 2-((3,5-dimethoxybenzyl)thio)-6-oxo-4-(4-(phenylethynyl)phenyl)-1,6-dihydropyrimidine-
5-carbonitrile (21o).  
180 
 
 
181 
 
 
 
182 
 
Data for 4-(((4-([1,1'-biphenyl]-4-yl)-5-cyano-6-oxo-1,6-dihydropyrimidin-2-yl)thio)methyl)-N-(15-
oxo-19-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-4,7,10-trioxa-14-
azanonadecyl)benzamide (24). 
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184 
 
 
185 
 
 
Appendix A. HRMS, 
1
H and 
13
C Spectra of compounds in chapter 2: 
Data for 4-((5-(3,5-bis(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-yl)thio)-6-chloro-2-(methylthio) 
pyrimidine (37b) …. . 
.
186 
 
 
187 
 
 
Data for   4-((5-(3, 5-bis(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-yl)thio)-2-chloro-6-(piperidin-1-
yl)pyrimidine (37c). 
 
 
188 
 
 
Data for 4-((3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)thio)-6-chloro-N cyclopen-
tylpyrimidin-2-amine (37d). 
 
189 
 
 
190 
 
Data for 4-((3-(3, 5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)thio)-6-chloro-N-(prop-2-yn-1-
yl)pyrimidin-2-amine (37e). 
 
 
191 
 
 
Data for 4-((5-(3,5-bis(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-yl)thio)-6-chloro-N cyclobutylpy-
rimidin-2-amine (37f). 
 
192 
 
 
 
Data for 4-(4-((5-(3,5-bis(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-yl)thio)-6-chloropyrimidin-2-
yl)morpholine (37g). 
 
193 
 
 
 
 
194 
 
Data for 4-((3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)thio)-6-chloro-2-(pyrrolidin-1-
yl)pyrimidine (37h).  
 
 
195 
 
 
Data for 4-((5-(3,5-bis(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-yl)thio)-6-chloro-N-(2 (trifluoro-
methyl)benzyl)pyrimidin-2-amine (37j). 
 
196 
 
 
  
 
 
Data for 4-((3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)thio)-6-chloro-2-((4-
methoxyphenyl)thio)pyrimidine (37k). 
197 
 
 
198 
 
 
 
Data for  4-((3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)thio)-6-chloro-N-(2-
methoxybenzyl)pyrimidin-2-amine (37l). 
199 
 
 
200 
 
 
 
Data for  4-((3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)thio)-6-chloro-N-
cyclohexylpyrimidin-2-amine (37m). 
 
 
 
201 
 
 
 
202 
 
Data for 4-((5-(3,5-bis(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-yl)thio)-6-chloro-2-(p-
tolylthio)pyrimidine (37n). 
 
 
203 
 
 
Data for 4-((3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)thio)-6-chloro-2-(pyrimidin-2-
ylthio)pyrimidine (37o).  
 
 
204 
 
 
 
205 
 
Data for  4-((5-(3,5-bis(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-yl)thio)-6-chloro-2-((1,4,5,6-
tetrahydropyrimidin-2-yl)thio)pyrimidine (37p). 
Data for 4-azido-6-((5-(3,5-bis(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-yl)thio)-2-
(methylthio)pyrimidine (38b). 
 
 
 
 
 
206 
 
Data for6-((5-(3,5-bis(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-yl)thio)-N,N-dimethyl-2-
(methylthio)pyrimidin-4-amine (38c).  
 
 
207 
 
 
 
Data for 6-((3-(3, 5-bis (trifluoromethyl) phenyl)-1H-1, 2, 4-triazol-5-yl) thio)-N-methyl-2-
(methylthio) pyrimidin-4-amine (38d).  
208 
 
 
 
209 
 
 
Data for 6-((3-(3, 5-bis (trifluoromethyl) phenyl)-1H-1, 2, 4-triazol-5-yl) thio)-N-isopropyl-2-
(methylthio) pyrimidin-4-amine (38e).  
 
210 
 
211 
 
Data for 6-((5-(3,5-bis(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-yl)thio)-N-cyclopropyl-2-
(methylthio)pyrimidin-4-amine  (38f). 
 
 
 
 
212 
 
 
 
Data for  4-((3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)thio)-2-(methylthio)-6-
(piperidin-1-yl)pyrimidine (38g).  
 
213 
 
 
 
 
 
214 
 
Data for 4-(6-((3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)thio)-2-
(methylthio)pyrimidin-4-yl)morpholine (38h). 
 
 
215 
 
 
 
Data for 4-((3-(3, 5-bis(trifluoromethyl)phenyl)-1-methyl-1H-1,2,4-triazol-5-yl)thio)-6-chloro-2-
(methylthio)pyrimidine (40a).  
  
 
216 
 
 
 
 
 
217 
 
Data for 4-((5-(3,5-bis(trifluoromethyl)phenyl)-4-ethyl-4H-1,2,4-triazol-3-yl)thio)-6-chloro-2-
(methylthio)pyrimidine (40b).  
  
 
 
218 
 
 
Data for 4-((5-(3,5-bis(trifluoromethyl)phenyl)-4-isopropyl-4H-1,2,4-triazol-3-yl)thio)-6-chloro-2-
(methylthio)pyrimidine (40c). 
 
 
219 
 
 
Data for 4-((5-(3,5-bis(trifluoromethyl)phenyl)-4-(cyclopropylmethyl)-4H-1,2,4-triazol-3-yl)thio)-6-
chloro-2-(methylthio)pyrimidine (40d). 
 
220 
 
 
 
Data for  4-((3-(3,5-bis(trifluoromethyl)phenyl)-1-(3,5-dimethoxybenzyl)-1H-1,2,4-triazol-5-yl)thio)-6-
chloro-2-(methylthio)pyrimidine (40e).  
 
 
221 
 
222 
 
 
Data for 4-((1- (4-azidobenzyl)-3-(3, 5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-5-yl)thio)-6-chloro-2-
(methylthio)pyrimidine (40f). 
 
223 
 
 
 
224 
 
Data for  4-(3-(3,5-bis(trifluoromethyl)phenyl)-5-(methylthio)-1H-1,2,4-triazol-1-yl)-6-chloro-2-
(methylthio)pyrimidine (42). 
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